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1 Chapter 1 
Introduction and Scope 
A variety of physiological functions in the body is mediated by oxygenated 
polyunsaturated fatty acids (PUFA) including regulation of blood pressure, 
endothelial function, blood coagulation and kidney function. These eicosanoids 
(in the case of formation from 20-carbon PUFA) and other oxylipins are formed 
endogenously by oxygenation of n6- and n3-PUFA in the arachidonic acid 
(ARA) cascade via three main enzymatic pathways or autoxidation resulting in a 
multitude of structurally distinct products [1, 2]. Enzymatic conversion of PUFA 
by cyclooxygenases (COX), lipoxygenases (LOX) or cytochrome P450 
monooxygenases (CYP) leads to the generation of regio- and stereospecifically 
oxygenated products, such as prostanoids, hydroxy-PUFA or epoxy-PUFA. In 
contrast, PUFA autoxidation underlies a radical mechanism and gives rise to a 
complex mixture of oxidative products with similar structure but diverse regio- 
and stereochemistry. 
Formation of oxylipins in the body is strictly controlled and a dysregulation of 
oxylipin formation contributes to the pathogenesis of diseases. Therefore, 
investigation of the oxylipin profile has gained increasing interest as valuable 
marker to assess the (patho)physiological state and may also provide 
information about the oxidative stress status of the organism. 
Under normal physiological conditions, PUFA which are predominantly 
esterified in phospholipids of plasma membranes or in blood lipoproteins, are 
released upon stimulation by lipases, e.g. phospholipase A2 or lipoprotein lipase 
[3, 4], to make them accessible for enzymatic conversion by COX, LOX or CYP 





endoperoxides (PGG, PGH) which are rapidly transformed to thromboxanes 
and prostanoids with varying ring structures depending on the presence of 
distinct prostanoid synthases [6]. Activity of LOX initially results – depending on 
the involved isoform (5-LOX, 12-LOX, 15-LOX) – in formation of stereo- and 
regioselective hydroperoxy-PUFA which can be reduced to respective hydroxy-
PUFA or further processed by sequential conversion with the same or different 
isoforms to dihydroxy- or trihydroxy-PUFA and other oxylipins including 
leukotrienes, lipoxins, resolvins, protectins and maresins [7-10]. Different CYP 
isoforms catalyze the formation of hydroxy-PUFA or cis-epoxy-PUFA (R,S- and 
S,R-enantiomers), respectively, whereby the latter are hydrolyzed by soluble 
epoxide hydrolase (sEH) forming the corresponding vicinal dihydroxy-PUFA [11, 
12]. While almost all PUFA-converting enzymes require free (i.e. non-esterified) 
PUFA substrates, 15-LOX (encoded by the gene ALOX15), e.g. present in 
distinct blood cells (eosinophils, reticulocytes, stimulated monocytes), is also 
able to oxygenate esterified PUFA, thus forming directly hydroxy-PUFA 
esterified in phospholipids or complex lipids [13-15]. Furthermore, following their 
acute formation several free oxylipins are also readily incorporated in 
membrane lipids thereby contributing to the esterified portion of oxylipins [16-
18].  
Besides enzymatic conversion, due to their pentadiene structure PUFA are 
prone to non-enzymatic autoxidation, which is particularly relevant during 
oxidative stress. In this free radical-mediated process oxidation of PUFA is 
initiated by abstraction of a bisallylic hydrogen radical, followed by addition of 
molecular oxygen, thus leading to racemic hydroperoxy-PUFA radicals which 
comprise multiple regioisomers. Further conversion during chain oxidation 
reactions yields a complex mixture of secondary oxidation products carrying 
hydro(pero)xy, epoxy, keto or cyclic functional groups within their structure [19]. 
One class of cyclic autoxidation products which is predominantly formed 
esterified in phospholipids comprises prostaglandin-like structures, so-called 
isoprostanes (IsoP), of which F-ring-IsoP, particularly the ARA derived 
15(R,S)-15-F2t-IsoP were evaluated as promising oxidative stress markers in 
vivo [20, 21]. 




In order to assess the physiological or pathophysiological role of oxylipins, their 
potential use as biomarkers for diseases and oxidative stress, or their 
modulation by the diet, powerful analytical techniques are required [22]. In the 
past years targeted LC-MS/MS methods have been increasingly applied for the 
selective and sensitive detection of oxylipins allowing parallel analysis of 
numerous oxylipins derived from different formation pathways [1]. Initially, most 
methods were focused on ARA derived eicosanoids or oxylipins from single 
pathways (COX, LOX, CYP). Based on the observation that the different 
formation branches are linked and a modulation of single enzyme activities 
results in a shift towards other pathways, it is now widely acknowledged that the 
overall physiological response is rather mediated by the whole profile than by 
the presence and concentration of individual oxylipins [1]. For this reason a 
comprehensive oxylipin profile covering oxylipins from all major biologically 
relevant n6- and n3-PUFA derived from all pathways needs to be determined. 
However, comprehensive methods analyzing both, enzymatically and non-
enzymatically formed oxylipins in parallel are limited. Regarding autoxidatively 
formed IsoP, existing LC-MS/MS methods are mainly focused on ARA derived 
products or IsoP from individual PUFA which limits their applicability with 
respect to the varying fatty acid composition of different tissues and specimen. 
Furthermore, with regard to the vast number of potentially formed isomers these 
methods are restricted in terms of their analyte coverage (Fig. 1.1). In 
chapter 2, an LC-ESI(-)-MS/MS method for the analysis of IsoP and isofuran 
(IsoF) isomers is described covering a wide range of these stable 
prostaglandin-like autoxidation products from all biologically relevant PUFA. 
Considering the multitude of potential isomers, a focus is set on the selection of 
specific fragments for selected reaction monitoring (SRM) of individual 
regioisomers and the chromatographic separation of diastereomers which have 
identical fragmentation behavior to allow their selective quantification. The 
combination of this method with a targeted oxylipin method for the analysis of 
enzymatically formed oxylipins forms the basis for the comprehensive 






Fig. 1.1: Comparison of the analyte coverage of current LC-MS/MS methods for the analysis of 
isoprostanes (IsoP) and isofurans (IsoF) derived from different PUFA [23-32]. 
A major concern in the analysis of oxylipins in biological samples is their 
susceptibility to ex vivo oxidation which may result from autoxidative processes 
as well as residual enzymatic activity in the samples. Thus, the endogenous 
oxylipin pattern may be altered between sample collection and analysis. 
Particularly samples from biobanks or clinical studies collected in the clinical 
routine are handled under conditions which are hard to control. These samples 
oftentimes originate from severely diseased patients and are particularly 
valuable to characterize the (patho)physiological role of oxylipins or to 
contribute to the discovery of new disease biomarkers. However, changes in the 
levels of distinct oxylipins due to pre-analytical variations may impair the validity 
and significance of the analyzed oxylipin profile and thus may contribute to 
misleading interpretation. Chapter 3 examines the impact of whole blood 
storage or transport within a large hospital prior to further processing on the 
oxylipin profile. As blood is the most commonly analyzed specimen in clinical 
studies, providing information about the systemic state of the donor, differences 
of oxylipins in plasma and serum are evaluated. Furthermore, accounting for the 































IsoP and IsoF derived from




within lipoproteins, the effects on the free as well as the total (i.e. sum of free 
and esterified) oxylipin profile are investigated. The studies allow gaining 
information about the reliability and applicability of clinical blood samples and 
the stability of oxylipins.  
An important class of oxylipins comprises epoxy-PUFA which act vasodilatory, 
anti-inflammatory and analgesic and are of high interest in the context of 
several diseases ranging from hypertension [33] and diabetes [34, 35] to cancer 
[36, 37]. In the body each of the double bonds of the PUFA can be transformed 
by the epoxygenase activity of CYP resulting in the generation of respective cis-
epoxy-PUFA (R,S- and S,R-enantiomers) regioisomers. Using LC-MS/MS the 
different epoxy-PUFA regioisomers are selectively analyzed based on their 
specific SRM transitions. When investigating biological samples, however, for 
each regioisomer a second peak is frequently detected eluting slightly later than 
the authentic cis-epoxy-PUFA standard and showing an identical product ion 
spectrum. During the analysis of red blood cells (RBC) a similar peak pattern 
was observed and characterization of the structure of these later eluting peaks 
identified them as the respective trans-epoxy-PUFA isomers (S,S- and R,R-
enantiomers) [38, 39]. Though they also have been shown to possess biological 
activity, particularly vasoregulatory properties (e.g. relaxing pre-constricted 
arteries, acting anti-aggregatory), these trans-epoxy-PUFA are rarely 
considered when epoxy-PUFA are investigated. Based on the observations that 
their levels increase after incubation of RBC with tert-butyl hydroperoxide [39], 
which is an inducer of oxidative stress, and that these peaks are also detected 
in aged PUFA stocks (Fig. 1.2), their formation is assumed to be related to 
autoxidative processes. In chapter 4 the formation of trans-epoxy-PUFA in the 
context of oxidative stress is thoroughly characterized in various models 
including several different cell lines as well as the in vivo model organism 
Caenorhabditis elegans and an in vivo model of murine renal ischemia 
reperfusion injury. The significance of their generation in response to oxidative 
stress and their potential suitability as alternative oxidative stress markers is 
further evaluated by their correlation with the levels of IsoP, which are 






Fig. 1.2: Chromatographic separation of ARA derived cis- and tentatively identified (*) trans-
epoxy-PUFA (EpETrE) regioisomers in an aged ARA stock solution stored at −80 °C. 
Besides formation via enzymatic and non-enzymatic pathways, the overall 
oxylipin pattern is considerably affected by the PUFA status. With regard to 
epoxy-PUFA, terminal n3-derived cis-epoxy-PUFA (17(18)-EpETE and 
19(20)-EpDPE) are suggested as appropriate indicators for the endogenous 
n3-PUFA status based on a preferred epoxygenation of the n3-double bond by 
CYP [40, 41]. Considering varying physiological activities and properties of 
respective products from different precursor PUFA, the analysis of a broad 
spectrum of oxylipins is essential when studying their physiological role. In 
chapter 5 the developed targeted LC-MS/MS method enabling the parallel 
analysis of enzymatically and non-enzymatically formed oxylipins from the 
major n6- and n3-PUFA is applied to study the effects of an anti-inflammatory 
treatment by dietary n3-PUFA supplementation in a murine model of oxidative 
stress and inflammation in the kidney. Renal ischemia reperfusion injury (IRI) 
resulting from temporal interruption of renal blood flow and subsequent 
reperfusion is linked to pro-oxidative processes and the release of pro-
inflammatory cytokines. n3-PUFA are associated with anti-inflammatory effects 
which are on the one hand attributed to their direct action by modifying the 
membrane composition, or by binding to transcription factors such as NF-κB or 
PPARγ hereby altering the transcription of pro-inflammatory or anti-


































substrates in the ARA cascade and give rise to oxylipins with less potency 
compared to ARA derived prostanoids or leukotrienes. Moreover, they also lead 
to the generation of oxylipins with anti-inflammatory properties or may even 
form so-called specialized pro-resolving mediators which are considered to be 
actively involved in inflammation resolution. In order to evaluate the role of 
n3-PUFA in renal IRI, changes in the PUFA and the oxylipin pattern are 
analyzed in parallel with renal function parameters as well as inflammatory 
markers. 
Overall, this thesis aims to contribute to a better understanding of the functional 
role of oxylipins by using a comprehensive oxylipin profile to provide information 
about oxidative stress and (patho)physiology as well as the nutritional n3-PUFA 
status. 
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2 Chapter 2 
Development of an LC-ESI(-)-MS/MS method for the 
simultaneous quantification of 35 isoprostanes and 
isofurans derived from the major n3- and n6-PUFAs* 
Misregulation of oxidative and antioxidative processes in the organism – 
oxidative stress – contributes to the pathogenesis of different diseases, e.g. 
inflammatory or neurodegenerative diseases. Oxidative stress leads to 
autoxidation of polyunsaturated fatty acids giving rise to prostaglandin-like 
isoprostanes (IsoP) and isofurans (IsoF). On the one hand they could serve as 
biomarker of oxidative stress and on the other hand may act as lipid mediators, 
similarly as the enzymatically formed oxylipins. In the present paper we describe 
the development of an LC-ESI(-)-MS/MS method allowing the parallel 
quantification of 27 IsoP and 8 IsoF derived from 6 different PUFA (ALA, ARA, 
EPA, AdA, n6-DPA, DHA) within 12 minutes. The chromatographic separation 
was carried out on an RP-C18 column (2.1 x 150 mm, 1.8 µm) yielding narrow 
peaks with an average width at half maximum of 3.3 to 4.2 sec. Detection was 
carried out on a triple quadrupole mass spectrometer operating in selected 
reaction monitoring mode allowing the selective detection of regioisomers. The 
limit of detection ranged between 0.1 and 1 nM allowing in combination with 
solid phase extraction the detection of IsoP and IsoF at subnanomolar 
concentrations in biological samples. The method was validated for human 
plasma showing high accuracy and precision. Application of the approach on the 
investigation of oxidative stress in cultured cells indicated a distinct pattern of 
IsoP and IsoF in response to reactive oxygen species which warrants further 
investigation. The described method is not only the most comprehensive 
approach for the simultaneous quantification of IsoP and IsoF, but it was also 
integrated in a targeted metabolomics method (Ostermann et al. (2015) Anal 
Bioanal Chem) allowing the quantification of in total 164 oxylipins formed 
enzymatically and non-enzymatically within 30.5 min. 
* Reprinted from Analytica Chimica Acta, Vol. 1037, Rund K. M., Ostermann A. I., Kutzner 
L., Galano J.-M., Oger C., Vigor C., Wecklein S., Seiwert N., Durand T., Schebb N. H., 
Development of an LC-ESI(-)-MS/MS method for the simultaneous quantification of 35 
isoprostanes and isofurans derived from the major n3- and n6-PUFAs, pp. 63-74, Copyright 
(2018), with permission from Elsevier. doi: 10.1016/j.aca.2017.11.002. 
Author contributions: KR designed research, performed experiments and wrote the manuscript; AO, 
LK performed experiments and wrote the manuscript; JMG, CO, CV, TD provided standard 
substances and contributed to manuscript writing; SW, NS performed experiments; NHS designed 






Oxidative stress results from misregulation of oxidative and antioxidative 
mechanisms in the organism and is characterized by increased formation of 
reactive oxygen and nitrogen species (RONS) [1-3]. These highly reactive 
molecules attack biomolecules, thereby e.g. modifying proteins as well as DNA 
and causing mutations [4]. Oxidative degradation of membrane lipids alters the 
function of membranes and gives rise to a multitude of reactive and stable 
products [5, 6]. Oxidative stress, and thus autoxidation, is associated with the 
pathophysiology of several diseases including inflammatory, cardiovascular, 
respiratory and neurodegenerative diseases. 
In order to evaluate oxidative stress in health and disease, several biomolecules 
affected by autoxidation (i.e. proteins, DNA, lipids), their degradation products 
(e.g. malondialdehyde (MDA)) or endogenous antioxidants (e.g. glutathione 
(GSH), glutathione disulfide (GSSG)) are used as common biomarkers [7]. 
In a multi-laboratory comparison of different oxidative stress markers the 
measurement of 15-F2t-IsoP, an isoprostane derived from arachidonic acid 
(C20:4 n6, ARA) was found to be promising for the evaluation of the oxidative 
stress status in vivo [8]. Isoprostanes (IsoP) are prostaglandin-like autoxidation 
products formed from free PUFA and under physiological conditions dominantly 
from PUFA esterified in phospholipids [9]. During non-enzymatic, free radical 
mediated autoxidation, PUFA are initially converted via radical abstraction of a 
bisallylic hydrogen and subsequent addition of molecular oxygen to 
hydroperoxy fatty acid radicals (Fig. 2.1). Depending on the position of the initial 
radical abstraction, different regioisomeric hydroperoxy radicals are formed. The 
primary formed hydroperoxy intermediates further undergo secondary reactions 
leading to a diverse product spectrum. For instance, a sequence of two 5-exo-
cyclization steps of the hydroperoxy radicals followed by addition of molecular 
oxygen and reduction of the side chain hydroperoxide leads to prostaglandin-H-
like bicyclic endoperoxide intermediates. These are under physiological 




conditions unstable and react in the presence of reducing agents like GSH to 
stable F-ring isoprostanes or – when reducing cellular agents are depleted – 
undergo isomerization to D- or E-ring isomers (Fig. 2.1) [10].  
 
Fig. 2.1: Simplified mechanism of isoprostane (IsoP) and isofuran (IsoF) formation from 
arachidonic acid bound in phospholipids (R) depending on O2 concentration. The bicyclic 
endoperoxide intermediate is under physiological conditions unstable and in the presence of 
reducing agents like GSH reduced to stable F-ring isoprostanes. When reducing cellular agents 
are depleted it undergoes isomerization to D- or E-ring isomers. Finally, the esterified oxylipins 

















































































From ARA, 4 regioisomeric F2-IsoP can be formed each comprising 8 racemic 
diastereomers leading to a total of 64 possible isomers. However, the 
regioisomers are formed at different rates with the terminal 5- and 15-F2-IsoP 
being more abundant compared to the 8- and 12-F2-IsoP isomers [11, 12]. Also, 
other PUFA can be converted by an analogous mechanism leading to 
F1-PhytoP from α-linolenic acid (C18:3 n3, ALA) and F3-IsoP from 
eicosapentaenoic acid (C20:5 n3, EPA). Adrenic acid (C22:4 n6, AdA) gives 
rise to F2-dihomo-IsoP, docosahexaenoic acid (C22:6 n3, DHA) and 
docosapentaenoic acid (C22:5 n6, n6-DPA) to F4-NeuroP and F3-NeuroPn6, 
respectively. 
The product spectrum during autoxidation is directed by the oxygen content: 
With increasing oxygen concentration (i.e. partial pressure) the levels of IsoP 
increase. However, above 21% no further increase of IsoP occurs while the 
formation of another class of cyclic PUFA derivatives, the tetrahydrofuran 
substituted isofurans (IsoF), is significantly elevated in vitro [13]. Based on two 
proposed formation mechanisms – the cyclic peroxide cleavage pathway and 
the epoxide hydrolysis pathway – 8 regioisomeric isofurans comprising 32 
stereoisomers are formed from ARA resulting in a total of 256 possible isomers 
[13]. Conversion of other PUFA by an analogous mechanism leads to PhytoF 
[14, 15], dihomo-IsoF and NeuroF from ALA, AdA and DHA, respectively. 
Moreover, depending on the tissue fatty acid composition a characteristic 
pattern of the formed isoprostanes results. For example, DHA and AdA are both 
found in the brain, however AdA is predominantly enriched in myelin which is 
part of the white matter, whereas DHA is enriched in neurons present in the 
grey matter [16]. Consequently, F2-dihomo-IsoP are associated with oxidative 
stress of the white matter, whereas F4-NeuroP are related to oxidative damage 
of the grey matter in vitro [17].  
The analysis of isoprostanes in biological matrices is challenging because of 
their low concentration and the multitude of possible isomers formed from 
different PUFA. Several methods using gas chromatography (GC) and liquid 




chromatography (LC) coupled to mass-spectrometry (MS) as well as 
immunoassays are described for the analysis [18-38]. Immunoassays like 
ELISA which only allow the analysis of single isomers are easy to handle and 
enable high sample throughput. However, due to the multitude of structurally 
similar isoprostanes, ELISAs are susceptible to cross-reactivity leading to an 
overestimation compared to LC-MS and GC-MS methods [37, 38]. In contrast, 
chromatographic methods coupled to MS allow the selective and sensitive 
parallel quantification of multiple isomers derived from a single as well as 
different PUFA. In addition to sample preparation steps, including extraction and 
purification, GC-MS requires derivatization of the analytes to volatile derivatives. 
Since this is more laborious, LC-MS has been predominantly used in the past 
years [26-34, 39, 40]. Most LC-MS methods cover only ARA derived F2-IsoP, 
especially the prominent 15-F2t-IsoP isomer [26-29, 32, 40] or are focused on 
IsoP derived from a single PUFA [31, 34, 39]. Only few methods have been 
described enabling the parallel quantification of IsoP derived from different 
PUFA [30, 33, 41]. 
However, keeping the tissue specific PUFA pattern in mind, the simultaneous 
analysis of a comprehensive set of IsoP and IsoF from all biologically relevant 
PUFA is crucial for the evaluation of oxidative stress in vivo independent of the 
origin of the analyzed biological specimen. Therefore, we developed in the 
present study a new, sensitive LC-ESI(-)-MS/MS method covering a 
comprehensive set of IsoP and IsoF from 6 biologically relevant PUFA that was 
integrated in an established method covering enzymatically formed oxylipins. 
The mass-spectrometric and chromatographic parameters were optimized and 
the method performance was thoroughly characterized. Finally, the method was 
applied on the investigation of the formation of IsoP and IsoF in response to 







The isoprostane standard 15-F2t-IsoP as well as the deuterated internal 
standards (IS) 2H4-15-F2t-IsoP (2H4-8-iso-PGF2α) and 2H11-5(R,S)-5-F2t-IsoP 
(2H11-(±)5-iPF2α-VI) were purchased from Cayman Chemicals (local distributor: 
Biomol, Hamburg, Germany). All other IsoP and IsoF standards, i.e. ARA 
derived 5-F2t-IsoP, 5-epi-5-F2t-IsoP, 2,3-dinor-15-F2t-IsoP, 15-epi-2,3-dinor-15-
F2t-IsoP, EPA derived 5-F3t-IsoP, 5-epi-5-F3t-IsoP, 8-F3t-IsoP, 8-epi-8-F3t-IsoP, 
DHA derived 4(R,S)-4-F4t-NeuroP, 10-F4t-NeuroP, 10-epi-10-F4t-NeuroP, 
14(R,S)-14-F4t-NeuroP, 4(R,S)-ST-Δ5-8-NeuroF, AdA derived 17(R,S)-17-F2t-
dihomo-IsoP, ent-7(R,S)-7-F2t-dihomo-IsoP, 17(R,S)-10-epi-SC-Δ15-11-dihomo-
IsoF, 7(R,S)-ST-Δ8-11-dihomo-IsoF, n6-DPA derived 4-F3t-NeuroPn6, 4-epi-4-
F3t-NeuroPn6, and ALA derived ent-9-F1t-PhytoP, ent-9-epi-9-F1t-PhytoP, ent-16-
F1t-PhytoP, ent-16-epi-16-F1t-PhytoP, 16-B1-PhytoP, 9-L1-PhytoP, ent-16(R,S)-
13-epi-ST-Δ14-9-PhytoF as well as the unlabeled odd-chain IS C19-17-epi-17-
F1t-PhytoP and C21-15-F2t-IsoP were synthesized, using our last strategy as 
described [14, 42, 43]. 4(R,S)-4-F4t-NeuroP, 14(R,S)-14-F4t-NeuroP, 4(R,S)-ST-
Δ5-8-NeuroF, 17(R,S)-17-F2t-dihomo-IsoP, ent-7(R,S)-7-F2t-dihomo-IsoP, 
17(R,S)-10-epi-SC-Δ15-11-dihomo-IsoF, 7(R,S)-ST-Δ8-11-dihomo-IsoF, ent-
16(R,S)-13-epi-ST-Δ14-9-PhytoF were only available as epimeric mixtures. 
LC-MS-grade methanol (MeOH), acetonitrile (ACN) and acetic acid were 
purchased from Fisher Scientific (Schwerte, Germany). n-Hexane (HPLC 
Grade) was obtained from Carl Roth (Karlsruhe, Germany). All other chemicals 
were purchased from Sigma Aldrich (Schnelldorf, Germany). Pooled human 
EDTA-plasma was generated by centrifugation (10 min, 4 °C, 20,000 × g) of 
EDTA-blood, followed by mixing plasma from six healthy male and female 
volunteers aged between 25 and 38 years and immediately stored at −80 °C 
until analysis. All volunteers gave their written informed consent and all 
procedures were conducted according to the guidelines laid down in the 




Declaration of Helsinki and approved by the ethic committee at the Medical 
Association of Lower Saxony (Hannover, Germany). 
2.2.2 Calibration and quantification of IsoP 
For calibration, stock solutions of the individual analytes (in MeOH) were mixed 
and diluted in glass volumetric flasks (5–100 mL) with MeOH at 10 
concentration levels (0.1, 0.25, 0.5, 1, 2, 5, 10, 20, 100 and 500 nM), each with 
20 nM of the four internal standards. Calibration curves were calculated using 
linear least square regression (weighting: 1/x2). Analyte quantification was 
carried out based on the analyte to corresponding IS (Tab. 2.1) area ratio using 
the obtained calibration curves. 
2.2.3 In vitro assay 
HCT-116 human colorectal carcinoma cells were grown in 10 cm dishes 
(5 × 106 cells/dish) and incubated after 24 h with 50 µM and 200 µM of t-BOOH 
(Sigma Aldrich, Schnelldorf, Germany) for 30 min, 1 h and 2 h. The cells were 
then detached using trypsin and harvested by centrifugation (5 min, 4 °C, 
300 × g). After a washing step in cold PBS, the cells were centrifuged again 
(5 min, 4 °C, 300 × g) and the supernatant was discarded. The remaining cell 
pellet was snap-frozen in liquid nitrogen and stored at −80 °C until analysis. The 
cytotoxicity of the used t-BOOH concentrations was assessed using the MTS 
assay, which is based on the reduction of the tetrazolium salt MTS 
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) by viable cells. To this end, HCT-116 cells were seeded at a 
density of 2 × 104 per well and grown overnight. Cells were then incubated with 






2.2.4 Sample extraction 
Human plasma was extracted using anion exchange Bond Elut Certify II SPE 
cartridges (200 mg, 3 mL, Agilent, Waldbronn, Germany) [45]. In brief, 10 µL of 
IS solution (containing 100 nM of 2H4-15-F2t-IsoP, 2H11-5(R,S)-5-F2t-IsoP, C19-
17-epi-17-F1t-PhytoP, C21-15-F2t-IsoP and 13 isotope labeled internal 
standards used in the targeted metabolomics method [45], appendix Tab. 8.1) 
and 10 µL of antioxidant solution (0.2 mg/mL BHT and EDTA, 100 µM 
indomethacin, 100 µM of the soluble epoxide hydrolase inhibitor trans-4-[4-(3-
adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (t-AUCB) [46] in 
MeOH/water (50/50, v/v)) were added to 500 µL freshly thawed human plasma. 
The proteins were precipitated by addition of 1400 µL ice cold MeOH and 
storage at −80 °C for at least 30 min. After centrifugation (10 min, 4 °C, 
20,000 × g) the supernatant was evaporated under a N2-stream to a volume 
less than 1 mL and diluted with 2 mL of 0.1 M disodium hydrogen phosphate 
buffer adjusted to pH 5.5 with acetic acid, thus yielding a MeOH content of 
< 17% (pH = 6). 
The SPE cartridge was preconditioned with one column volume of each, ethyl 
acetate/n-hexane (75/25, v/v) containing 1% acetic acid, MeOH, and 0.1 M 
disodium hydrogen phosphate adjusted to pH 6.0 with acetic acid in 
water/MeOH (95/5, v/v). After loading onto the preconditioned cartridge, the 
sample was washed with 3 mL water and 3 mL water/MeOH (50/50, v/v) and 
dried with excess pressure of N2 for 1 min. The analytes were eluted with 2 mL 
of 75/25 (v/v) ethyl acetate/n-hexane with 1% acetic acid in tubes containing 
6 μL of 30% glycerol in MeOH as trap solution for the analytes, and evaporated 
until only the glycerol plug remained using a vacuum concentrator (1 mbar, 
30 °C, 45–60 min; Christ, Osterode am Harz, Germany). The residue was 
resuspended in 50 µL MeOH containing 40 nM of 1-(1-(ethylsulfonyl)piperidin-4-
yl)-3-(4-(trifluoromethoxy)phenyl)urea as IS2 for the calculation of the extraction 
efficiency of the IS, centrifuged (10 min, 4 °C, 20,000 × g) and analyzed by 
LC-MS/MS. 




For the analysis of isoprostanes formed in cell incubations, 10 µL of the 
antioxidant solution, 50 µL water and 300 µL MeOH were added to the cell 
pellets which contained about 1 × 107 cells. After homogenization in a ball mill 
(MM 400, Retsch, Haan, Germany) using two 3 mm stainless steel beads 
(10 min, 25 Hz), 600 µL MTBE was added and the homogenate was vigorously 
mixed. For separation of the aqueous and the organic layers 300 µL 0.15 M 
ammonium acetate solution was added. Following mixing and centrifugation 
(5 min, 4 °C, 3500 × g), the upper organic layer was transferred to another tube 
and the aqueous phase was washed with 300 µL MTBE. The combined organic 
layers were evaporated using a vacuum concentrator (1 mbar, 30 °C, 90–
120 min). To the residue 10 µL IS solution (100 nM, see above), 500 µL 
water/MeOH (50/50, v/v) and 300 µL 10 M NaOH were added and lipids were 
hydrolyzed for 30 min at 60 °C. After hydrolysis, the sample was immediately 
cooled, neutralized using acetic acid (50%) and mixed with 1900 µL 0.1 M 
disodium hydrogen phosphate buffer (pH = 6). SPE was conducted as 
described above. 
2.2.5 Method characterization 
The method was characterized and validated regarding linearity, sensitivity (limit 
of detection (LOD) and lower limit of quantification (LLOQ)), extraction 
efficiency, intra- and interday accuracy and precision based on criteria of the 
guideline on bioanalytical method validation of the European Medicines Agency 
[47]. Linearity was assessed using standard solutions covering a concentration 
range from 0.1 to 500 nM. The LOD was determined as the concentration 
yielding a signal to noise ratio (S/N) ≥ 3. The concentration with a S/N ≥ 5 and 
an accuracy and precision within the calibration curve of ± 20% was defined as 
LLOQ and set as the lowest concentration of the calibration curve. 
The extraction efficiency at three different level of plasma volumes (200, 500 





to the sample prior extraction calculated using a calibration curve normalized to 
IS2 which is added in the last step of the analysis. 
Intraday accuracy and precision (relative standard deviation, RSD) were 
evaluated in plasma samples spiked at four concentration levels (3 nM, 10 nM, 
30 nM, 100 nM in vial) with IsoP and IsoF prior extraction. Four replicates of 
each level as well as unspiked plasma were analyzed. For interday accuracy 
and precision the samples were analyzed on 3 days. The accuracy was 
calculated by comparing the determined concentration with the added 
concentration. For IsoP isomers detected in unspiked plasma samples this 
concentration was substracted from the determined concentration following 
spiking. 
2.2.6 LC-ESI(-)-MS/MS analysis 
Samples (5 µL) were injected into the LC-MS system using a HTS xt-PAL 
autosampler (CTC Analytics, Switzerland, local distributor: Axel Semrau, 
Sprockhövel, Germany) equipped with a 100 μL syringe and a 20 μL sample 
loop. The sample rack was kept at 4 °C.  
Liquid chromatography was performed using a 1290 Infinity LC System (Agilent, 
Waldbronn, Germany) composed of a binary pump and a column oven. 
Separation of the analytes was carried out on a Zorbax Eclipse Plus C18 
reversed-phase column (2.1 x 150 mm, particle size 1.8 μm; Agilent, 
Waldbronn, Germany) at 40 °C equipped upstream with an inline filter (3 µm, 
1290 infinity II in-line filter, Agilent, Waldbronn, Germany) and a SecurityGuard 
Ultra C18 cartridge as precolumn (2.1 x 2 mm, Phenomenex, Aschaffenburg, 
Germany). The mobile phase consisted of 0.1% acetic acid as solvent A and 
800/150/1 (v/v/v) ACN/MeOH/acetic acid as solvent B. The chromatographic 
separation was achieved using the following binary gradient with a flow rate of 
0.3 mL/min: 0–1.0 min isocratic 25% B, 1.0–1.5 min linear from 25% B to 
30% B, 1.5–10.0 min linear from 35% B to 53% B, 10.0–19.5 min linear from 




53% B to 68% B, 19.5–24.5 min linear from 68% B to 95% B, 24.5–27.0 min 
isocratic 95% B, 27.0–27.10 min linear from 95% B to 25% B followed by 
reconditioning for 3.4 min. During the first 2 min and the last 6 min of each run 
the LC flow was directed to waste using the 2-position-6-port valve integrated in 
the MS. Detection was carried out on a 6500 QTRAP mass-spectrometer 
(Sciex, Darmstadt, Germany) following negative electrospray ionization (ESI(-)) 
with the following source settings: ion-spray voltage: −4500 V, curtain gas (N2): 
35 psi, nebulizer gas (gas 1, zero air): 60 psi generated with a zero air 
generator (UHP-300-ZA-S-E, Parker, Kaarst, Germany) and drying gas (gas 2, 
zero air): 60 psi at a temperature of 475 °C. The offset of the sprayer was 
0.250 cm for the vertical axis and 0.550 cm for the horizontal axis, the electrode 
protrusion was approx. 1 mm. 
The analytes were detected in scheduled selected reaction monitoring mode 
(SRM) using nitrogen as collision gas (set to “high”, 12 psi) with a detection 
window of ± 22.5 sec around the expected retention time and a cycle time of 
0.4 sec. The compound specific parameters were optimized for each analyte 
and are summarized in Tab. 2.1. The LC-MS analysis of isoprostanes and 
related analytes from other PUFA was combined with an established 
multimethod for oxylipins [45, 48, 49]. A list of all covered analytes and their 
mass spectrometric parameters can be found in the appendix (Tab. 8.2). For 
data acquisition and instrument control Analyst Software (version 1.6.2, Sciex) 
and for integration and quantification Multiquant (version 2.1.1, Sciex) was 
used. 
 Results and Discussion 
For selective and sensitive LC-MS analysis of the isoprostanes and related 
analytes the mass spectrometric parameters were optimized for each 
compound individually and the chromatographic conditions were adjusted in 





2.3.1 Mass spectrometric detection 
Isoprostanes are autoxidative derivatives of fatty acids containing a carboxylic 
moiety, thus ionization was carried out in ESI(-) mode leading to the formation 
of [M-H]- ions, whose dominating formation was confirmed in MS full scan 
experiments. For each compound the declustering potential (DP) was optimized 
in single ion monitoring (SIM) mode of the [M-H]- ion to achieve an effective 
transmission of the ionized analytes from the source to the entrance of the 
vacuum chamber with minimal in-source fragmentation. For selective detection 
of regioisomers specific fragment ions for selected reaction monitoring (SRM) 
were chosen from the product ion spectra (appendix Fig. 8.1) and the collision 
energy (CE) was optimized. The optimized MS parameters are shown in 
Tab. 2.1. The structure of F-IsoP is characterized by a prostanoid-like F-ring 
with two hydroxyl groups and one further hydroxyl group in one of the two side 
chains, either the α-chain (carboxy terminus) or the ω-chain (methyl terminus) 
(Fig. 2.1). Accordingly, for different regioisomers identical abundant fragments 
resulting from unspecific loss of H2O or CO2 as well as combinations of CO2 
and up to 3-fold H2O loss were observed (Fig. 2.2 A and B). Thus, for selective 
MS detection of different regioisomers the choice of specific fragment ions is 
crucial. Specific fragments result from backbone fragmentation and can be 
attributed to α-cleavage adjacent to the hydroxyl group in the side chain which 
is referred to as “α-hydroxy-β-ene-rearrangement”, a common fragmentation for 
unsaturated hydroxy-fatty acids [50]. For the investigated F-IsoP the observed 
α-fragments comprise the carboxy-terminus with or without subsequent loss of 
CO2 and/or H2O. Depending on the side chain where the hydroxyl group is 
located, the predominantly observed α-fragments can be assigned to distinct 
cleavage sites relative to the hydroxyl group: F-IsoP with the hydroxyl group in 
the α-chain, e.g. ent-9-F1t-PhytoP (Fig. 2.2 A), showed an α-fragmentation 
which could be attributed to the cleavage on the methyl side of the hydroxyl 
group leading to a specific fragment containing the carboxyl- and the hydroxyl-
moiety (m/z 170.9 for ent-9-F1t-PhytoP). By contrast, the dominantly observed 
fragments of F-IsoP with the hydroxyl group in the ω-chain, e.g. ent-16-F1t-




PhytoP (Fig. 2.2 B), could be assigned to the cleavage on the carboxyl side 
relative to the hydroxyl group and thus to a fragmentation segment carrying the 
carboxyl-moiety (m/z 269.1 for ent-16-F1t-PhytoP). Interestingly, the DHA 
derived 10(R,S)-10-F4t-NeuroP with the hydroxyl group in the α-chain and the 
14(R,S)-14-F4t-NeuroP with the hydroxyl group in the ω-chain are exceptions, 
showing a reverse fragmentation behavior compared to the observed pattern for 
the other F-IsoP described above, i.e. forming predominantly charged 
fragments which can be assigned to the reverse α-cleavage site relative to the 
hydroxyl group (appendix Fig. 8.1 D(ii) and (iii)). The selected fragment ions are 
consistent with the transitions used in other SRM methods for almost all F-IsoP 
with exception of 16(R,S)-16-F1t-PhytoP [31], 8(R,S)-8-F3t-IsoP [32, 33] and 
17(R,S)-17-F2t-dihomo-IsoP [30, 33, 43]. For those analytes different transitions 
compared to existing methods were selected which, however, could be ascribed 
to specific α-cleavages of the backbone of the molecule. 
 
Fig. 2.2: Collision-induced dissociation (CID) product ion spectra of [M-H]- ions of α-linolenic 
acid derived PhytoP and PhytoF. (A) ent-9-F1t-PhytoP (F-ring-PhytoP carrying the hydroxyl 
group in the α-chain) (B) ent-16-F1t-PhytoP (F-ring-PhytoP carrying the hydroxyl group in the 











































































































































The investigated cyclopentenone PhytoP with B- (Fig. 2.2 C) and L-ring 
structure (appendix, Fig. 8.1 A(iv)) only gave rise to few abundant fragment 
ions. Based on this fragmentation pattern no suggestion for the site of 
fragmentation could be made. For structural elucidation of the formed 
fragments, further studies, e.g. using isotopically labeled standards are 
necessary. Nevertheless, the selected transitions were specific for these 
PhytoP and have been reported previously for their quantification [31, 34]. 
The isofurans are structurally characterized by a furan-like 5-membered oxygen 
containing ring carrying a hydroxyl group and additionally two hydroxyl groups 
in the side chains located either in the same side chain as it is the case for 
enediol furans or in different side chains like in alkenyl furans (Fig. 2.1). For 
each of the investigated IsoF the fragmentation behavior is distinct: Compared 
to F-IsoP unspecific loss of H2O and CO2 is less pronounced and specific 
fragments resulting from backbone cleavage might be attributed either to 
fragmentation next to the furan ring (Fig. 2.2 D) or adjacent to one of the side 
chain hydroxyl groups (as e.g. for 7(R,S)-ST-∆8-11-dihomo-IsoF, appendix 
Fig. 8.1 E(iii)). However, 4(R,S)-ST-Δ5-8-NeuroF and 17(R,S)-10-epi-SC-Δ8-11-
dihomo-IsoF show a different fragmentation pattern (appendix Fig. 8.1 D(iv) and 
E(iv)) and suggestions for the structure of the fragments and fragmentation sites 
cannot be made based on the data. For 17(R,S)-10-epi-SC-Δ8-11-dihomo-IsoF 
the transition reported previously corresponding to the fragment with the highest 
abundance was selected [43]. Regarding 4(R,S)-ST-Δ5-8-NeuroF the fragment 
used in previous methods (m/z 123) [51] showed poor intensity, thus the 
fragment (m/z 187) with the highest abundance was selected (appendix 


























































Analyte Mass transition MS parameters1) IS tR 2) FWHM 3) LOD 4) Calibration range r 7) slope 8) 
 
       [min] [sec]  [pg  
on column] 
LLOQ 5) ULOQ 6)    
Q1 Q3 DP EP CE CXP    [nM] [nM]   
ent-16(R,S)-13-epi-ST-Δ14-9-PhytoF 1 *) 343.1 200.9 -80 -10 -33 -8 C19-17-epi-17-F1t-PhytoP 4.19 3.4 0.12 0.20 0.24 235 0.9993 0.91 
ent-16(R,S)-13-epi-ST-Δ14-9-PhytoF 2 *) 343.1 200.9 -80 -10 -33 -8 C19-17-epi-17-F1t-PhytoP 4.30 3.4 0.13 0.23 0.26 265 0.9995 1.02 
ent-16-epi-F1t-PhytoP 327.3 225.0 -70 -10 -34 -8 C19-17-epi-17-F1t-PhytoP 4.72 3.3 0.25 0.41 0.50 500 0.9983 0.78 
ent-16-F1t-PhytoP 327.3 225.0 -70 -10 -34 -8 C19-17-epi-17-F1t-PhytoP 4.89 3.4 0.25 0.41 0.50 500 0.9997 0.73 
ent-9-F1t-PhytoP 327.3 170.9 -40 -10 -31 -8 C19-17-epi-17-F1t-PhytoP 4.81 3.3 0.10 0.16 0.25 500 0.9991 1.44 
ent-9-epi-F1t-PhytoP 327.3 170.9 -40 -10 -31 -8 C19-17-epi-17-F1t-PhytoP 4.98 3.3 0.25 0.41 0.50 500 0.9990 1.12 
15(R,S)-2,3-dinor-15-F2t-IsoP 325.2 237.0 -40 -10 -18 -8 C19-17-epi-17-F1t-PhytoP 5.41 3.3 0.25 0.41 0.50 500 0.9995 1.79 
8-F3t-IsoP 351.1 155.0 -60 -10 -27 -8 C19-17-epi-17-F1t-PhytoP 6.15 3.6 0.50 0.88 1.0 500 0.9980 0.70 
8-epi-8-F3t-IsoP 351.1 155.0 -60 -10 -27 -8 C19-17-epi-17-F1t-PhytoP 6.51 3.3 0.50 0.88 1.0 500 0.9992 0.60 
5(R,S)-5-F3t-IsoP 351.2 114.9 -50 -10 -27 -8 C19-17-epi-17-F1t-PhytoP 6.53 3.4 1.0 1.8 2.0 500 0.9962 0.07 
15-F2t-IsoP (8-iso-PGF2α) 353.1 193.1 -70 -6 -33 -8 2H4-15-F2t-IsoP 7.56 3.7 0.25 0.44 0.50 500 0.9989 0.98 
10-F4t-NeuroP 377.2 153.0 -40 -10 -25 -8 2H4-15-F2t-IsoP 8.04 3.3 0.25 0.47 0.50 500 0.9989 1.81 
10-epi-10-F4t-NeuroP 377.2 153.0 -40 -10 -25 -8 2H4-15-F2t-IsoP 8.37 3.5 0.50 0.95 1.0 500 0.9990 0.88 
5(R,S)-5-F2t-IsoP 353.2 114.8 -60 -10 -26 -8 2H11-5(R,S)-5-F2t-IsoP 8.07 3.5 0.25 0.44 0.50 500 0.9959 0.52 
16-B1-PhytoP 307.3 235.0 -60 -10 -27 -8 2H11-5(R,S)-5-F2t-IsoP 8.26 3.7 0.10 0.15 0.25 500 0.9994 3.00 
9-L1-PhytoP 307.3 185.1 -60 -10 -27 -8 2H11-5(R,S)-5-F2t-IsoP 8.33 3.7 0.10 0.15 0.25 500 0.9986 3.07 
14(R,S)-14-F4t-NeuroP 377.2 205.1 -50 -10 -27 -8 C21-15-F2t-IsoP 8.62 6.5 10 19 20 500 0.9998 0.09 
4(R,S)-4-F4t-NeuroP 377.1 101.3 -60 -10 -26 -8 C21-15-F2t-IsoP 9.35 3.6 0.50 0.95 1.0 500 0.9982 0.23 
4(R,S)-ST-Δ5-8-NeuroF 393.3 187.2 -40 -10 -29 -8 C21-15-F2t-IsoP 9.59 4.2 20 39 40 500 0.9941 0.02 
17(R,S)-17-F2t-dihomo-IsoP 1 *) 381.3 263.2 -90 -10 -31 -8 C21-15-F2t-IsoP 9.78 3.6 0.63 1.2 1.3 314 0.9967 0.31 
17(R,S)-17-F2t-dihomo-IsoP 2 *) 381.3 263.2 -90 -10 -31 -8 C21-15-F2t-IsoP 9.95 3.2 0.37 0.71 0.75 186 0.9980 0.19 
7(R,S)-ST-Δ8-11-dihomo-IsoF 397.3 245.1 -50 -10 -31 -8 C21-15-F2t-IsoP 9.81 8.9 #) 1.0 2.0 2.0 500 0.9993 0.42 
ent-7(R,S)-7-F2t-dihomo-IsoP 381.3 143.0 -50 -10 -31 -8 C21-15-F2t-IsoP 9.86 5.7 0.25 0.48 0.50 500 0.9972 1.87 
4(R,S)-4-F3t-NeuroPn6 379.2 101.0 -50 -10 -29 -8 C21-15-F2t-IsoP 11.03 4.1 0.50 0.95 1.0 500 0.9971 0.59 
17(R,S)-10-epi-SC-Δ15-11-dihomo-IsoF 1 *) 397.1 221.0 -90 -10 -31 -8 C21-15-F2t-IsoP 11.26 3.7 0.52 1.0 1.0 260 0.9992 0.41 
17(R,S)-10-epi-SC-Δ15-11-dihomo-IsoF 2 *) 397.1 221.0 -90 -10 -31 -8 C21-15-F2t-IsoP 11.44 3.7 0.48 0.96 0.96 240 0.9982 0.38 
C19-17-epi-17-F1t-PhytoP 341.3 239.0 -70 -10 -35 -8 IS 6.02 3.3        
2H4-15-F2t-IsoP 357.2 196.8 -50 -6 -33 -8 IS 7.54 3.6        
2H11-5(R,S)-5-F2t-IsoP 364.3 115.2 -40 -10 -29 -10 IS 7.97 4.5        
C21-15-F2t-IsoP 367.2 193.1 -60 -10 -35 -8 IS 9.18 3.8             
1) The collision cell exit potential (CXP) was for all analytes -8 V. 2) Relative standard deviation of tR within one batch was ≤ 0.18% (< 0.01 min). 3) Full peak width at half maximum (FWHM) was 
determined as mean width of standards with the concentrations LLOQ–100 nM, for 14(R,S)-14-F4t-NeuroP and 4(R,S)-ST-Δ5-8-NeuroF concentrations LLOQ–500 nM were used; [#) for 7(R,S)-ST-
Δ8-11-dihomo-IsoF (incompletely separated) the FWHM was determined at the half maximal height of the smaller peak (see Fig. 2.3 B(V))]. 4) LOD was set to the lowest concentration yielding a 
signal to noise ratio ≥ 3. 5) LLOQ was set to the lowest calibration standard injected yielding a signal to noise ratio ≥ 5 and an accuracy in the calibration curve within ± 20%. 6) ULOQ 
concentration does not represent the end of the dynamic range, but is the highest calibration standard injected. 7) Calibration was performed as linear weighted least square regression using 1/x2 
weighting. 8) Slope of the calibration curve normalized for all analytes to 15-F2t-IsoP × 10. *) Isomers were provided as mixture of two diastereomers which were chromatographically separated; 1 





























































































































































































































































































































































































2.3.2 Chromatographic separation 
The chromatographic separation was optimized in order to obtain an efficient 
separation of the isobaric isomers in a reasonable time. The method covers 25 
F-ring IsoP comprising 12 diastereomeric (epimeric) pairs and one single 
stereoisomer derived from ALA, ARA, EPA, n6-DPA, DHA and AdA, one B- and 
one L-ring PhytoP and 4 epimeric pairs of IsoF derived from ALA, DHA and 
AdA. Using a C18 column with sub 2 µm particles and an optimized gradient of 
acidified water and ACN as well as MeOH, separation of the analytes could be 
achieved within 12 minutes (Fig. 2.3 A). The ALA derived PhytoF and F1t-
PhytoP elute first, followed by the polar β-oxidation metabolites 15(R,S)-2,3-
dinor-15-F2t-IsoP from ARA and the IsoP from EPA and ARA. B- and L-ring 
PhytoP and DHA derived F4t-NeuroP and NeuroF elute in the middle part of the 
chromatogram followed by AdA derived F2t-dihomo-IsoP and dihomo-IsoF as 
well as n6-DPA derived 4(R,S)-4-F3t-NeuroPn6 (Fig. 2.3). 
 
Fig. 2.3: (A) Chromatographic separation of (I) 27 isoprostanes and 8 isofurans derived from 6 
different PUFA. Shown are the SRM signals used for quantification following injection of a 
multianalyte standard (100 nM; except 14(R,S)-14-F4t-NeuroP, 4(R,S)-ST-∆5-8-NeuroF, ent-
7(R,S)-7-F2t-dihomo-IsoP, 17(R,S)-17-F2t-dihomo-IsoP each 500 nM). (II) For the quantification 























































































(II) Internal Standards (20 nM)
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Fig. 2.3: (B) Chromatographic separation efficiency of isoprostanoids covered by the method 
grouped by their precursor PUFA. Shown are the SRM signals used for quantification of 
(I) α-linolenic acid (C18:3 n3, ALA) derived ent-16(R,S)-13-epi-ST-∆14-9-PhytoF, ent-16-F1t-
PhytoP, ent-16-epi-16-F1t-PhytoP, ent-9-F1t-PhytoP, ent-9-epi-F1t-PhytoP, 16-B1-PhytoP, 9-L1-
PhytoP; (II) arachidonic acid (C20:4 n6, ARA) derived 15(R,S)-2,3-dinor-15-F2t-IsoP, 15-F2t-IsoP 
(= 8-iso-PGF2α), 5(R,S)-5-F2t-IsoP; (III) eicosapentaenoic acid (C20:5 n3, EPA) derived 8-F3t-
IsoP, 8-epi-8-F3t-IsoP, 5(R,S)-5-F3t-IsoP; (IV) docosahexaenoic acid (C22:6 n3, DHA) derived 
10-F4t-NeuroP, 10-epi-10-F4t-NeuroP, 14(R,S)-14-F4t-NeuroP, 4(R,S)-4-F4t-NeuroP, 4(R,S)-ST-
∆5-8-NeuroF; (V) adrenic acid (C22:4 n6, AdA) derived 7(R,S)-ST-∆8-11-dihomo-IsoF, ent-
7(R,S)-7-F2t-dihomo-IsoP, 17(R,S)-17-F2t-dihomo-IsoP, 17(R,S)-10-epi-SC-∆5-11-dihomo-IsoF; 
(VI) docosapentaenoic acid (C22:5 n6, n6-DPA) derived 4(R,S)-4-F3t-NeuroPn6. 
The initial gradient conditions were adjusted in order to achieve separation from 
the void volume (1.5 min), i.e. sufficient retention of the early eluting analytes, 
which is characterized by a retention factor k of at least 2. The first analytes 
(PhytoF) elute at 4.19 and 4.30 min (after more than two void volumes), which 
corresponds to a retention factor of k ≥ 1.8, showing a sufficient separation from 
the unretained void volume. The slope of the gradient was optimized in order to 
yield a high separation efficiency of most epimeric pairs. 
A short isocratic step (1 min) with 25% organic at the beginning of the gradient 


































(II) ARA derived F2t-IsoP



























































































































































(III) EPA derived F3t-IsoP

























narrow peaks over the whole separation time (exemplary shown in Fig. 2.4) 
characterized by a full width at half maximum (FWHM) of about 3.3–
4.2 seconds for almost all analytes (Tab. 2.1). Some epimeric pairs, e.g. 
14(R,S)-14-F4t-NeuroP and ent-7(R,S)-7-F2t-dihomo-IsoP (Tab. 2.1, Fig. 2.3 B), 
showed a broader FWHM due to incomplete separation of the epimers. 
 
Fig. 2.4: Chromatographic separation efficiency of selected epimeric pairs using a gradient 
starting with 25% organic (A) without and (B) with inclusion of a short isocratic step (1 min) at 
the beginning of the gradient. The resolution (R) is indicated for selected epimeric pairs. 
The chromatographic separation showed a high stability regarding retention 
time with an interbatch RSD of ≤ 0.25%, i.e. < 0.02 min (n = 360) or < 0.01 min 
within one batch (n = 50). 
The gradient allows an efficient separation of 7 critical epimeric pairs of IsoP 
and IsoF characterized by a resolution of R > 1.5. With exception of ent-
16(R,S)-13-epi-ST-∆14-9-PhytoF, which is the first eluting epimeric pair showing 
a resolution of R = 1.4, the resolution of the other separated epimers is R ≥ 1.7. 
However, 3 epimeric pairs (14(R,S)-14-F4t-NeuroP, ent-7(R,S)-7-F2t-dihomo-
IsoP and 7(R,S)-ST-∆8-11-dihomo-IsoF) show an incomplete separation and 6 
epimeric pairs coelute (Fig. 2.3 B). The use of a shallower gradient with an 
increase of 0.5% B/min instead of 2.7% B/min or isocratic separation (data not 
R = 1.8R = 1.4
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shown) only slightly improved the separation of the incompletely separated and 
coeluting stereoisomers while further prolonging the analysis time. Thus, only 
the use of a different column or mobile phase thereby changing the selectivity of 
the chromatographic system could solve this separation problem. However, we 
regarded these parameters as fixed during method development because the 
analytical procedure should be integrated in an existing method, already 
established in our laboratory, for the analysis of enzymatically formed oxylipins 
[45, 48, 49]. This combination enables to determine 129 oxylipins in addition to 
the covered IsoP and IsoF, thus allowing the detection of a total of 164 oxylipins 
formed enzymatically and via autoxidation together with 17 IS within 30.5 min. 
The mass spectrometric and chromatographic performance parameters for all 
analytes are summarized in the appendix Tab. 8.2. 
2.3.3 Method performance 
Quantification of the analytes was carried out based on the analyte to 
corresponding IS area ratio using the calibration curves. For the IsoP and IsoF 
two deuterated IsoP (2H11-5(R,S)-5-F2t-IsoP and 2H4-15-F2t-IsoP) and two odd-
chain unlabeled IsoP (C19-17-epi-17-F1t-PhytoP and C21-15-F2t-IsoP) that are 
eluted over the analytical time (Fig. 2.3 A) were used as IS. For 5(R,S)-5-F2t-
IsoP and 15-F2t-IsoP their respective isotopologs were used as IS. For the other 
analytes the assignment of the IS was based on retention time (Tab. 2.1). 
Characterization of the method performance was oriented on the guideline on 
bioanalytical method validation of the European Medicines Agency [47]. The 
sensitivity of the method was assessed by determining the LOD and the LLOQ 
based on the signal to noise ratio (Tab. 2.1). The concentration leading to an 
S/N ≥ 3 was defined as LOD (exemplary shown for 2,3-dinor-15-F2t-IsoP, 
Fig. 2.5). Almost all analytes showed a comparable LOD ranging from 0.15–
2 pg on column. However, 14(R,S)-14-F4t-NeuroP and 4(R,S)-ST-Δ5-8-NeuroF 
showed a considerably higher LOD with 19 pg and 39 pg on column, 





SIM mode (data not shown), these higher LOD could either be explained by 
different ionization behavior of the compounds or by impure standard stock 
solutions of these two compounds. Similar to the LOD, the LLOQ (i.e. the 
concentration with a S/N ≥ 5 and an accuracy of 80–120% within the calibration 
curve) ranged from 0.25 to 2 nM for almost all IsoP and IsoF except 14(R,S)-14-
F4t-NeuroP and 4(R,S)-ST-Δ5-8-NeuroF. 
 
Fig. 2.5: Determination of the limit of detection (LOD) and lower limit of quantification (LLOQ) 
for 2,3-dinor-15-F2t-IsoP based on the signal to noise ratio (S/N). Starting from (A) blank 
(MeOH), successive standards (B), (C), (D) with increasing concentration of the analyte were 
injected. (C) The concentration yielding a S/N ≥ 3 was set as LOD. (D) The concentration with a 
S/N ≥ 5 and an accuracy within the calibration curve of ± 20% was defined as LLOQ. 
The sensitivity was also reflected by the slope of the calibration curves. 
Comparing the slopes of all covered IsoP and IsoF normalized to the same IS 
revealed that 14(R,S)-14-F4t-NeuroP and 4(R,S)-ST-Δ5-8-NeuroF showed 
remarkably lower slopes compared to the other analytes (factor 10 and 50 
lower, respectively, compared to the mean of normalized slopes) which is 
consistent with the observed higher LLOQ and LOD (Tab. 2.1). Interestingly this 
higher LLOQ for 14(R,S)-14-F4t-NeuroP was also observed previously [33]. 
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S/N ≥ 5  LLOQD




low slope. Compared to other IsoP, a slightly higher LLOQ for 5(R,S)-5-F3t-IsoP 
was also reported previously [33]. 
The obtained LOD and LLOQ are in a similar range as reported previously for 
other oxylipins [45], and in comparison with previous reports for isoprostanes 
the obtained sensitivity was comparable or slightly better [30, 33]. Noteworthy, 
two methods which were focused only on F2t-IsoP [40] and PhytoP and PhytoF 
[34] reported LLOQs one to two orders of magnitude lower despite using a 
comparable triple quadrupole mass spectrometer. This may be in part explained 
by the high injection volume of 50 µL as well as the use of a micro-HPLC 
instrumentation [34, 40]. In our method, using a higher injection volume led to 
peak splitting and inacceptable peak shape (Fig. 2.6). This is caused by the 
high elution power of the methanol which is used to reconstitute the samples 
after SPE. Using a more polar solvent leads to an insufficient solution of less 
polar hydroxy- and epoxy-fatty acids which are also covered by our method and 
thus the amount of sample injected cannot be further increased. Nevertheless, 
our approach is still one of the three most sensitive methods described so far 
for the detection of IsoP. Moreover, it is the most comprehensive approach for 
the simultaneous quantification of prostanoid-like autoxidation products and 
covers more analytes than all previous methods. 
 
Fig. 2.6: Peak shape of 15-F2t-IsoP (10 nM in methanol) with increasing injection volume. 





Matching between method sensitivity and expected concentration in biological 
samples one should take into account that the baseline levels of IsoP and IsoF 
are very low, e.g. the commonly analyzed 15(R,S)-15-F2t-IsoP is in the range of 
40–170 pg/mL human plasma of healthy subjects (total, i.e. free and esterified 
level) [52], corresponding to 0.1–0.5 nM. Sufficient sample preparation including 
a pre-concentration step as carried out in the presented method by an 
optimized SPE procedure is therefore needed to determine these compounds in 
biological samples. 
For quantification, calibration curves at 10 concentration levels covering a 
concentration range from 0.1–500 nM for each analyte were prepared. With 
linear least square regression based on 1/x2 weighting correlation coefficients 
≥ 0.994 were achieved for all analytes indicating linearity for the covered 
concentration range (Tab. 2.1). The highest calibration level was set as upper 
limit of quantification (ULOQ), however does not represent the end of the linear 
detector response. Taking the low physiological concentration of IsoP and IsoF 
into account the calibration of higher concentrations as carried out in other 
methods [30-33] was for the intended application not necessary. 
2.3.4 Extraction efficiency 
The extraction efficiency from biological samples was characterized based on 
the recovery of IS spiked to the sample prior extraction. For the evaluation of 
the extraction efficiency of the used sample preparation procedure different 
volumes (200 µL, 500 µL, 1000 µL) of plasma from healthy volunteers were 
extracted by SPE. As shown in Fig. 2.7, recoveries in the range of 80–100% for 
all IS regardless of the used plasma volume indicate a sufficient extraction for 
quantitative determination. 





Fig. 2.7: Recovery of internal standards added to 200 µL, 500 µL and 1000 µL human plasma 
at the beginning of sample preparation followed by protein precipitation with MeOH and solid 
phase extraction. Shown are mean ± SD (n = 4).  
Regarding all IsoP and IsoF covered by the method, no IsoF and only ARA 
derived F2t-IsoP were detected in the analyzed human plasma from healthy 
subjects. The most abundant regioisomer was 5(R,S)-5-F2t-IsoP with 
comparable concentration for all investigated volumes (128 ± 13 pM, 
138 ± 6 pM and 132 ± 6 pM for 200 µL, 500 µL and 1000 µL, respectively) 
indicating a good accuracy and precision regardless of the amount of 
sample/matrix injected. For 15-F2t-IsoP, which is the most studied regioisomer, 
lower levels were detected (48 ± 1 pM and 38 ± 1 pM for 500 µL and 1000 µL, 
respectively). This is consistent with previous findings reporting concentrations 
for 15(R,S)-15-F2t-IsoP in the range of 16–48 pg/mL (45–135 pM) [19] and 3–




























2.3.5 Intra- and interday accuracy and precision 
Intra- and interday accuracy and precision were characterized oriented on the 
guideline on bioanalytical method validation of the European Medicines Agency. 
In order to evaluate the accuracy and precision of the analytical procedure, 
human plasma samples spiked at four concentration levels prior extraction were 
analyzed in four replicates. The intraday accuracy ranged for all analytes from 
77 to 121% indicating low interference of plasma matrix and good extraction 
efficiency of the analytes using the presented SPE procedure. Intraday 
precision calculated as RSD was < 15% for almost all analytes at all spiking 
levels with few exceptions being, however, below 22% (Tab. 2.2). Interday 
precision was better, below 11% for 10, 30 and 100 nM spiking levels, thus 
indicating a stable method which allows the analysis of large sample batches. 
However, at the low concentration level (3 nM), which is close to LLOQ, RSDs 
showed a trend towards higher values, but were still < 22% for almost all 
analytes, except 7(R,S)-ST-∆8-11-dihomo-IsoF (LLOQ of 2 nM, RSD = 32%, 
Tab. 2.2). 
Tab. 2.2: Intra- and interday accuracy (acc.) as well as precision (prec.) of the extraction of all 
IsoP and IsoF comprised by the method from human plasma (500 µL). For the determination of 
accuracy and precision, IsoP and IsoF were spiked in four concentration levels to the plasma 
samples (3, 10, 30, 100 nM) at the beginning of the sample preparation. Accuracy was 
determined from the calculated concentration following SPE in comparison to the spiking 
standard solution and precision was calculated as relative standard deviation of the sample sets 
(n = 4 for intra- and n = 3 for interday). *) For IsoP and IsoF which were available as isomeric 
mixtures, the spiking level correspond to the sum concentration of both isomers in the mixture 






  acc.[%] prec.[%] acc.[%] prec.[%] 
ALA ent-9-F1t-PhytoP 3 103 6 111 4 
  10 96 4 98 6 
  30 96 3 96 2 
   100 99 7 93 1 
 ent-9-epi-9-F1t-PhytoP 3 98 8 109 2 
  10 93 2 85 7 
  30 93 4 91 4 
   100 94 3 87 2 
 ent-16-epi-16-F1t-PhytoP 3 112 6 115 9 
  10 99 2 100 4 
  30 98 3 102 2 
   100 100 6 96 5 









  acc.[%] prec.[%] acc.[%] prec.[%] 
 ent-16-F1t-PhytoP 3 121 4 125 2 
  10 99 2 99 4 
  30 96 4 101 3 
   100 100 6 96 8 
 9-L1-PhytoP 3 99 13 93 1 
  10 98 10 91 3 
  30 103 18 124 1 
   100 95 6 94 5 
 16-B1-PhytoP 
  
3 101 13 127 8 
 10 102 10 100 3 
 30 108 16 133 1 
 100 100 5 99 1 
 ent-16(R,S)-13-epi-ST-Δ14-9- 
PhytoF 1 *) 
1.4 89 9 94 4 
 4.7 89 6 88 3 
  14 91 2 92 1 
   47 93 6 86 1 
 ent-16(R,S)-13-epi-ST-Δ14-9- 
PhytoF 2 *) 
1.6 104 6 100 4 
 5.3 91 2 92 4 
  16 94 4 97 2 
  53 97 7 93 5 
ARA 5(R,S)-5-F2t-IsoP 3 91 4 91 4 
  10 84 6 81 3 
  30 82 3 78 4 
   100 87 8 83 3 
 15-F2t-IsoP (8-iso-PGF2α) 3 102 4 108 7 
  10 94 1 94 3 
  30 101 6 93 2 
   100 97 7 95 0 
 15(R,S)-2,3-dinor-15-F2t-IsoP 3 88 4 101 7 
  10 89 7 93 2 
  30 87 7 80 2 
    100 96 7 90 3 
EPA 5(R,S)-5-F3t-IsoP 3 110 11 150 2 
  10 104 3 102 7 
  30 96 6 92 2 
   100 103 5 89 0 
 8-F3t-IsoP 3 103 5 97 3 
  10 97 3 94 4 
  30 96 4 94 3 
   100 99 8 93 3 
 8-epi-8-F3t-IsoP 3 98 5 107 1 
  10 91 3 96 3 
  30 88 4 86 2 
    100 95 5 91 4 
DHA 4(R,S)-4-F4t-NeuroP 3 92 16 114 5 
  10 83 7 98 3 
  30 85 16 74 9 
   100 95 15 84 3 
 10-F4t-NeuroP 3 113 4 124 3 
  10 109 2 112 3 
  30 119 8 108 2 










  acc.[%] prec.[%] acc.[%] prec.[%] 
 10-epi-10-F4t-NeuroP 3 105 9 118 12 
  10 99 5 100 2 
  30 106 10 87 3 
   100 102 10 97 4 
 14(R,S)-14-F4t-NeuroP 3 < LLOQ < LLOQ 
  10 < LLOQ < LLOQ 
  30 103 5 100 12 
   100 101 7 97 17 
 4(R,S)-ST-Δ5-8-NeuroF 3 < LLOQ < LLOQ 
  10 < LLOQ < LLOQ 
  30 < LLOQ < LLOQ 
   100 93 22 78 6 
AdA ent-7(R,S)-7-F2t-dihomo-IsoP 3 95 12 105 3 
  10 80 7 103 4 
  30 92 9 91 6 
   100 96 13 90 8 
 17(R,S)-17-F2t-dihomo-IsoP 1 *) 1.9 100 10 119 19 
  6.3 100 7 116 2 
  19 98 4 100 6 
   63 102 12 94 6 
 17(R,S)-17-F2t-dihomo-IsoP 2 *) 1.1 106 14 65 15 
  3.7 77 5 97 21 
  11 85 15 77 8 
   37 97 14 89 7 
 7(R,S)-ST-Δ8-11-dihomo-IsoF 3 93 13 92 32 
  10 97 10 104 11 
  30 99 9 101 2 
   100 100 12 96 7 
 17(R,S)-10-epi-SC-Δ15-11- 
dihomo-IsoF 1 *) 
  
1.6 109 7 90 15 
 5.2 93 7 103 2 
 16 107 9 122 8 
 52 105 8 97 9 
 17(R,S)-10-epi-SC-Δ15-11- 
dihomo-IsoF 2 *) 
  
1.4 96 6 96 13 
 4.8 96 6 108 1 
 14 103 11 124 10 
  48 101 9 97 10 
n6-DPA 4(R,S)-4-F3t-NeuroPn6 3 93 11 105 22 
  10 77 13 94 1 
  30 78 22 63 9 
    100 84 17 79 11 
 
2.3.6 Formation of IsoP in cell culture 
The developed method was applied to investigate the formation of IsoP and 
IsoF in HCT-116 cells during oxidative stress caused by t-BOOH. First, the 
viability of HCT-116 cells treated with increasing doses of t-BOOH for 2 h was 




determined with the MTS assay, revealing no effects at a dose of 50 µM and a 
moderate reduction of the viability to 84% in cells incubated with 200 µM 
t-BOOH (appendix Fig. 8.6 A). Following incubation a large number of IsoP 
were detected in the cells, i.e. 5(R,S)-5-F2t-IsoP, 15-F2t-IsoP, ent-7(R,S)-7-F2t-
dihomo-IsoP, 17(R,S)-17-F2t-dihomo-IsoP 2, 5(R,S)-5-F3t-IsoP, 4(R,S)-4-F4t-
NeuroP, 10-F4t-NeuroP, 10-epi-10-F4t-IsoP (Tab. 2.3, Fig. 2.8). In control 
incubations the levels of the detected IsoP were low or below the LLOQ 
(Tab. 2.3, Fig. 2.8), with EPA derived 5(R,S)-5-F3t-IsoP being most abundant. 
Tab. 2.3: Total (i.e. free and esterified) concentrations of IsoP in HCT-116 cells following 
incubation with 50 µM and 200 µM t-butyl hydroperoxide for 30 min, 1 h and 2 h. Shown are the 






control 50 µM 200 µM 
 Mean ± SD Mean ± SD Mean ± SD 
ARA 5(R,S)-5-F2t-IsoP 30 min 12 ± 3 47 ± 5 123 ± 16 
  1h 11 ± 2 47 ± 8 165 ± 19 
  2 h 15 ± 7 43 ± 13 232 ± 115 
 15-F2t-IsoP (8-iso-PGF2α)  30 min < 5.0 
 15 ± 2 34 ± 3 
 1h < 5.0  14 ± 2 44 ± 2 
 2 h < 5.0  12 ± 3 54 ± 25 
EPA 5(R,S)-5-F3t-IsoP 30 min 40 ± 11 167 ± 39 424 ± 17 
  1h 39 ± 4 155 ± 30 625 ± 113 
  2 h 44 ± 19 133 ± 46 737 ± 300 
DHA 4(R,S)-4-F4t-NeuroP 30 min 5.4 ± 0.6 26 ± 5 69 ± 6 
  1h 5.9 ± 1.4 24 ± 5 89 ± 13 
  2 h 6.7 ± 2.2 22 ± 3 105 ± 48 
 10-F4t-NeuroP 30 min < 2.5  < 2.5  5.8 ± 0.6 
  1h < 2.5  < 2.5  7.1 ± 0.8 
  2 h < 2.5  < 2.5  8.9 ± 4.2 
 10-epi-10-F4t-NeuroP 30 min < 5.0  5.9 ± 0.4 13 ± 2 
  1h < 5.0  5.4 ± 0.7 16 ± 2 
  2 h < 5.0  5.7 ± 0.9 20 ± 9 
AdA ent-7(R,S)-7-F2t-dihomo-IsoP 30 min < 2.5  3.8 ± 0.2 8.6 ± 1.0 
  1h < 2.5  3.6 ± 0.6 14 ± 3 
  2 h < 2.5  3.7 ± 0.9 18 ± 10 
 17(R,S)-17-F2t-dihomo-IsoP 2 30 min < 3.7  < 3.7  4.0 ± 0.4 
  1h < 3.7  < 3.7  4.7 ± 1.4 







Fig. 2.8: Application of the method on the analysis of HTC-116 cells. IsoP were quantified 
following incubation with 50 µM and 200 µM t-butyl hydroperoxide for 30 min, 1 h and 2 h. 
Shown are representative IsoP derived from (A) ARA, (B) EPA, (C) AdA, (D) DHA. All results 
are shown as mean ± SD (n = 3) and the grey dashed line indicates the lower limit of 
quantification (LLOQ). 
Regarding distribution of the different IsoP, a dominant formation of 
regioisomers carrying the side chain hydroxyl group in proximity to the carboxy 
terminus was observed for the IsoP formed from all different PUFA: 5(R,S)-5-
F2t-IsoP, 5(R,S)-5-F3t-IsoP, ent-7(R,S)-7-F2t-dihomo-IsoP and 4(R,S)-4-F4t-
NeuroP. At high concentrations of t-BOOH also other regiosomers were formed 
and the IsoP concentration increased dose dependently with the t-BOOH 
concentration. IsoP levels after 30 min with 200 µM were generally higher than 
after 2 h of incubation with 50 µM t-BOOH. Moreover, with 200 µM t-BOOH, 
even if not statistically significant, a trend towards higher levels of IsoP with 
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increasing incubation time was observed while in incubations with 50 µM 
t-BOOH similar concentrations of IsoP were found for the different time points. 
This may indicate a cellular defense mechanism against ROS and thus IsoP 
levels do not further increase. It is also remarkable that with higher t-BOOH 
concentration the regioisomers with the side chain hydroxyl group in proximity 
to the carboxy terminus were stronger elevated than other regiosomers 
(Tab. 2.3, Fig. 2.8), which may indicate not only differences in formation but 
also in the metabolism rates of the different regioisomers. This becomes 
particularly evident for the ARA derived IsoP. Here, 3–4-fold higher levels of 
5(R,S)-5-F2t-IsoP were found compared to 15-F2t-IsoP while in livers of CCl4 
exposed rats a ratio of 1.5:1 was found [12]. However, it should be noted that 
these differences might also indicate species specific formation and metabolism 
rates of different regioisomers. The metabolism of the F2-IsoP, particularly 15-
F2t-IsoP has been well described [54, 55]. By contrast, the metabolism of the 
NeuroP is yet not well understood, except an earlier investigation reported by 
Lawson et al. who showed that 7-F4t-NeuroP is readily beta-oxidized to 5-F3t-
IsoP (an isoprostanoid metabolite from EPA oxidation) and excreted [56] 
whereas certain NeuroP like 4-F4t-NeuroP are probably more stable due to the 
presence of the side chain hydroxyl group at C4, which can limit access of the 
enzymes involved in beta-oxidation as it is the case for 5-hydroxy eicosanoids 
[57]. 
These results indicate that either the cellular formation is cell specific or the 
products are metabolized at different rates. The cellular formation of IsoP in 
response to oxidative stress and especially the resulting IsoP pattern warrants 
further investigation. In particular, application of different cell types and cell 
lines, e.g. deficient in different ROS defense mechanisms, should be used to 
understand the intracellular formation and the metabolic fate of IsoP. This 
investigation will allow gaining more insights into the role of IsoP in biology and 
help to identify specific biomarkers for distinct physiological states. With the 
developed method described herein, we provide the ideal tool to 
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3 Chapter 3 
Clinical blood sampling for oxylipin analysis –  
Effect of storage and pneumatic tube transport of blood 
on free and total oxylipin profile in human plasma and 
serum* 
Quantitative analysis of oxylipins is of increasing interest in clinical studies. 
Most commonly blood samples are analyzed to investigate (patho)physiological 
changes in the oxylipin pattern. However, storage after sampling and transport 
of blood might induce artificial changes in the apparent oxylipin profile due to 
ex-vivo formation/degradation by autoxidation or enzymatic activity. 
In the present study we investigated the stability of free (i.e. non-esterified) and 
total oxylipins in EDTA-plasma and serum generated under clinical conditions 
assessing the influence of delays in blood processing and automated 
transportation: 
Free cytochrome P450 monooxygenase and 5-lipoxygenase (LOX) formed 
oxylipins as well as autoxidation products were marginally affected by storage of 
whole blood up to 4 h at 4 °C, while total (i.e. sum of free and esterified) levels of 
these oxylipins were stable up to 24 h and following transport. Cyclooxygenase 
(COX) products (TxB2, 12-HHT) and 12-LOX derived hydroxy-fatty acids were 
prone for storage and transport induced changes due to platelet activation. Total 
oxylipin patterns were generally more stable than the concentration of free 
oxylipins. In serum, coagulation induced higher levels of COX and 12-LOX 
products showing a high inter-individual variability. 
Overall, our results indicate that total EDTA-plasma oxylipins are the most stable 
blood oxylipin marker for clinical samples. Here, storage of blood before further 
processing is acceptable for a period up to 24 hours at 4 °C. However, levels of 
platelet derived oxylipins should be interpreted with caution regarding potential 
ex-vivo formation. 
* Preprint. Adapted from Analyst, 145, Rund K. M., Nolte F., Doricic J., Greite R., Schott S., 
Lichtinghagen R., Gueler F., Schebb N. H., Clinical blood sampling for oxylipin analysis – 
Effect of storage and pneumatic tube transport of blood on free and total oxylipin profile in 
human plasma and serum, pp. 2378-2388, (2020) – Published by The Royal Society of 
Chemistry. doi: 10.1039/C9AN01880H.  
This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 
Unported License (https://creativecommons.org/licenses/by-nc/3.0/). 
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Oxygenated polyunsaturated fatty acids (PUFA), i.e. eicosanoids and other 
oxylipins, are highly potent endogenous mediators of physiological and 
pathophysiological processes including regulation of endothelial function, blood 
pressure, thrombosis and inflammation [1-4]. 
Oxylipins are formed endogenously by conversion of PUFA within the 
arachidonic acid (ARA, C20:4 n6) cascade via three major enzymatic pathways 
as well as non-enzymatic autoxidation leading to a multitude of oxygenated 
products from different PUFA precursors: (I) Conversion by cyclooxygenases 
(COX) results in formation of prostanoids and thromboxanes; (II) lipoxygenases 
(LOX) convert PUFA to regio- and stereoselective hydroperoxy-PUFA which 
can be reduced to hydroxy-PUFA or further converted to leukotrienes or 
multiple hydroxylated PUFA; and (III) action of cytochrome P450 
monooxygenases (CYP) leads to formation of hydroxylated PUFA and epoxy-
PUFA whereby the latter can be further hydrolyzed to vicinal dihydroxy-PUFA 
by soluble epoxide hydrolases [1, 5, 6]. Besides regio- and stereoselective 
conversion by these enzymes, non-enzymatic radical mediated autoxidation 
gives rise to structurally similar oxygenated products with diverse regio- and 
stereochemistry such as isoprostanoids (IsoP), hydroxy-PUFA and epoxy-PUFA 
which also possess biological activity [7-10]. 
Dysregulation of oxylipin formation is implicated among others in 
cardiovascular, immune or metabolic diseases [11, 12] and several 
pharmaceuticals act by modulating the oxylipin profile (e.g. non-steroidal anti-
inflammatory drugs, anti-thrombotic drugs, the asthma drug zileuton) [13-15]. 
Considering the multitude and diversity of oxylipins as well as the different 
pathways involved in oxylipin formation the overall physiological effect might 
result rather from the general profile than from the levels of a single oxylipin [16, 
17]. Therefore, comprehensive and reliable quantification of the oxylipin pattern 
may be valuable to evaluate the disease state or monitor the action of drugs.  




For clinical diagnostics blood specimen, i.e. plasma or serum, are the most 
widely used biofluids reflecting the systemic condition of the donor. In blood, 
oxylipins occur in their free form, are associated with proteins, such as albumin 
[18, 19], however the major part (> 90%) – particularly hydroxy- and epoxy-
PUFA as well as isoprostanoids – is esterified in cellular lipids (i.e. in blood 
cells) and in lipoproteins [20-22].  
Endogenous factors, such as sex [23], age [24], physical exercise [25, 26], 
health status [27], intake of drugs [13, 15, 28] or diet [17, 29] as well as variation 
in expression or genetic polymorphisms in enzymes [30-33] impact the oxylipin 
profile of an individuum. Moreover exogenous, pre-analytical factors relevant 
during collection, processing and storage of samples until analysis affect the 
oxylipin pattern [5], thus complicating its reliable interpretation.  
In hospitals clinical blood samples are usually collected on a ward or in the 
emergency unit and are afterwards transported from the phlebotomy site to the 
clinical chemistry laboratory via transport systems such as pneumatic tube 
system transport (PTS) where centrifugation and generation of plasma or serum 
takes place.  
The oxylipin pattern and its information about the physiological status of the 
patient strongly depends upon the choice for serum or plasma during blood 
withdrawal. During serum generation the blood coagulation cascade is triggered 
which includes activation of platelets resulting in a massive increase of platelet 
derived oxylipins such as 12-LOX metabolites and thromboxanes [34, 35]. For 
plasma different anticoagulants during blood collection, such as EDTA, heparin 
or citrate are used. The type of anticoagulant affects the formation of oxylipins, 
particularly hydroxy-PUFA and platelet derived oxylipins (12-LOX and COX 
derived products) [34, 36]. Therefore, blood sampling, i.e. choice of the blood 
specimen, has to be carefully considered in clinical studies with respect to the 





Following blood withdrawal, temperature and transitory storage time as well as 
transport to the clinical chemistry laboratory such as pneumatic tube system 
transport (PTS), are relevant pre-analytical factors which are hard to control in a 
clinical setting. Few studies investigated the influence of duration and 
temperature during whole blood storage prior to further processing and revealed 
changes for some free, i.e. non-esterified oxylipins in the generated plasma 
especially after longer times (> 30 min) at elevated temperatures (room 
temperature, RT) [16, 34]. However, no data about the influence of typical 
sample handling in the clinic on the oxylipin pattern exists. This is especially 
necessary to evaluate the suitability and reliability of the oxylipin pattern in 
blood samples from clinical studies, as well as in samples collected from 
patients in emergency or intensive care units or from biobanks. Moreover, this 
data is an essential prerequisite to deduce the physiological role of a changed 
oxylipin pattern in clinical studies as well as its suitability as biomarker for 
disease.  
In the present study we therefore investigated the impact of storage of blood 
samples after collection for different periods of time at 4 °C as well as the 
transfer from the ward to the clinical chemistry laboratory within a large hospital 
using PTS until the removal of cells (plasma or serum generation). For all 
conditions, levels of both, free and total oxylipins, i.e. after alkaline hydrolysis, 
were determined in EDTA-plasma and serum to evaluate if free or total oxylipins 
are more stable in plasma or serum. In order to deduce pathway specific effects 
a comprehensive set of oxylipins covering representative analytes derived from 
ARA, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) from 
COX, LOX, CYP as well as non-enzymatic conversion was analyzed. 






Oxylipin and deuterated oxylipin standards were purchased from Cayman 
Chemicals (local distributor: Biomol, Hamburg, Germany). LC-MS-grade 
methanol (MeOH), LC-MS-grade acetonitrile (ACN), LC-MS-grade isopropanol, 
and LC-MS-grade acetic acid were obtained from Fisher Scientific (Schwerte, 
Germany). Sodium acetate trihydrate, sodium hydrogen phosphate and 
n-hexane (HPLC grade) were obtained from Carl Roth (Karlsruhe, Germany) 
and potassium hydroxide (KOH, 85%) from Gruessing GmbH (Filsum, 
Germany). 2-(1-thienyl)ethyl 3,4-dihydroxybenzylidenecyanoacetate (2-TEDC) 
was obtained from Santa Cruz. Ethyl acetate, phenyl methyl sulfonyl fluoride 
(PMSF) and all other chemicals were purchased from Sigma Aldrich 
(Schnelldorf, Germany). 
3.2.2 Blood sampling and pre-analytical procedures 
Venous blood samples were collected from 6 individual volunteers (4 females 
and 2 males, 23–56 years) by venipuncture in EDTA-monovettes (Sarstedt, 
Nümbrecht, Germany) and serum monovettes (Sarstedt, Nümbrecht Germany). 
Blood was collected at 10 am and no dietary restrictions were given. Each 
individual had breakfast before the blood sampling.  
From each individual plasma and serum samples were generated by 
centrifugation (20 min, 4 °C, 5000 rpm, Thermo Scientific, Heraeus, Multifuge 
3SR+) at 4 time points as described below: immediate, after 4 hours at 4 °C, 
after 24 hours at 4 °C and after pneumatic tube system transport (PTS) from the 
hospital ward to the clinical chemistry laboratory. For basal levels (t0) one 
plasma and serum monovette from each individual was centrifuged about 
15 min after blood sampling. The supernatant, i.e. plasma or serum, was 





influence of storage on oxylipins, blood samples were maintained for about 
30 min at room temperature reflecting the time blood sampling takes on a 
hospital ward. Afterwards monovettes from each individual were stored at 4 °C 
in the fridge for 4 hours or 24 hours until further processing to generate plasma 
or serum as described above. After 30 min of storage at room temperature an 
additional monovette was transferred by the PTS to the clinical chemistry 
laboratory where plasma and serum were generated in an analogous manner. 
All procedures were conducted according to the guidelines laid down in the 
Declaration of Helsinki and approved by the ethic committee of the Hannover 
Medical School (MHH ethical approval 6895) and all volunteers gave their 
written informed consent. 
3.2.3 Extraction and quantification of oxylipins  
Free oxylipins as well as total, i.e. free and esterified oxylipins were extracted 
from individual plasma and serum samples using anion exchange Bond Elut 
Certify II SPE cartridges (200 mg, 3 mL, Agilent, Waldbronn, Germany) as 
described with modifications [37].  
Analysis of free oxylipins was carried out as described [38]. In brief, to 500 µL 
plasma or serum 10 µL antioxidant solution (0.2 mg/mL BHT and EDTA, 
100 µM of the cyclooxygenase inhibitor indomethacin, 100 µM of the soluble 
epoxide hydrolase inhibitor trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyl-
oxy]-benzoic acid (t-AUCB) in MeOH/water (50/50, v/v)), 10 µL of 250 mM 
protease inhibitor PMSF in isopropanol, 10 µL of 100 µM LOX inhibitor 2-TEDC 
in MeOH and 10 µL of an internal standard (IS) solution (containing 100 nM of 
⁠2H⁠4-6-keto-PGF⁠1α, 2H⁠4-15-F⁠2t-IsoP, ⁠2H⁠11-5(R,S)-5-F⁠2t-IsoP, ⁠2H⁠4-PGE ⁠2, ⁠2H⁠4-PGD⁠2, 
⁠2H⁠4-TxB ⁠2, ⁠2H⁠4-LTB ⁠4, 2H⁠4-9,10-DiHOME, ⁠2H⁠11-14,15-DiHETrE, 2H⁠4-9-HODE, ⁠2H⁠8-
5-HETE, ⁠2H⁠8-12-HETE, ⁠2H⁠6-20-HETE, 2H⁠4-9(10)-EpOME, ⁠2H⁠11-14(15)-EpETrE) 
were added. Samples were diluted with 1 mL 1 M sodium acetate (pH 6.0, 
water/MeOH 95/5, v/v) and loaded on the preconditioned SPE cartridge. 




Total, i.e. free and esterified oxylipins were extracted from 100 µL plasma or 
serum as described with slight modifications [39]. After addition of 10 µL 
antioxidant solution and 10 µL IS solution, 400 µL isopropanol was added and 
samples were stored for 30 min at −80 °C for protein precipitation. After 
centrifugation the supernatant was hydrolyzed (300 µL 1.5 M KOH (75/25, 
MeOH/water, v/v), immediately neutralized with acetic acid, diluted with 2 mL 
sodium phosphate buffer (pH 5.5) and extracted by SPE. 
The extracts were analyzed in scheduled selected reaction monitoring mode 
following negative electrospray ionization by LC-MS/MS (QTRAP, Sciex, 
Darmstadt, Germany) [37, 40]. In parallel to the samples aliquots of pooled 
human quality control plasma (QC) were extracted using the same sample 
preparation procedure for free (n = 6) and total oxylipins (n = 7), respectively.  
3.2.4 Data analysis 
Oxylipins were quantified based on the analyte to corresponding IS area ratio 
using external calibration with linear least square regression (1/x2 weighting) as 
described [37].  
In order to evaluate the influence of storage or transport of blood on oxylipin 
levels in plasma and serum %differences vs t0 (immediate sample processing) 
were calculated for each time point (tx) for each individual using the following 
formula: 100 × (conctx - conct0) / conct0. The relevance of change in the analyte 
concentration was evaluated by comparison with the acceptable change limit 
(ACL) calculated using ACL = 2.77 × RSDQC according to DIN ISO 5725-6 [41]. 
The factor 2.77 is based on 1.96 × √2, where 1.96 is used to cover the 95% 
confidence interval for bi-directional changes and √2 is used as the difference 
of two values is compared (at tx and t0). The relative standard deviation (RSD) 
was based on the RSD of quality control plasma samples (n = 6–7) analyzed in 





Data evaluation was carried out using GraphPad Prism version 6.01 for 
Windows (GraphPad Software, La Jolla California USA, www.graphpad.com). 
 Results 
Oxylipins were analyzed by LC-MS/MS in plasma and serum of 6 individuals 
generated at four time points after blood collection in EDTA- and serum-tubes, 
respectively: i) immediately; after storage at 4 °C for ii) 4 hours or iii) 24 hours; 
or iv) after transfer via the pneumatic tube transport system (PTS) to the clinical 
chemistry laboratory. At all conditions oxylipins were determined as free 
mediators (Fig. 3.1, appendix Fig. 8.2, Fig. 8.3) as well as after alkaline 
hydrolysis comprising both free and esterified oxylipins (Fig. 3.2, appendix 
Fig. 8.4, Fig. 8.5). For the major formation pathways of the arachidonic acid 
cascade (COX, 5-LOX, 12-LOX, 15-LOX, CYP and non-enzymatic) selected 
ARA derived oxylipins (Fig. 3.1, Fig. 3.2) were evaluated together with their 
EPA derived and DHA derived counterparts (appendix Fig. 8.2, Fig. 8.3, 
Fig. 8.4, Fig. 8.5) to investigate pathway specific effects in the changes. 
3.3.1 Levels of oxylipins in plasma and serum after immediate 
processing 
Comparing free oxylipins levels in plasma and serum after immediate 
processing (Fig. 3.1, appendix Fig. 8.2, Fig. 8.3) revealed 2–3 orders of 
magnitude higher concentrations of COX-derived PGE2, TxB2 and 12-HHT in 
serum compared to plasma (21–125-; 128–948-; 68–500-fold, respectively). 
Similarly, also 12-LOX derived 12-HETE, 12-HEPE and 14-HDHA were 
massively increased (13–103-; 2–73-; 2–47-fold, respectively) in serum, while 
15-LOX derived 15-HETE, 15-HEPE and 17-HDHA were elevated to a lesser 
extent (1–26-; 1–6-; 1–6-fold, respectively) and 5-LOX derived 5-HETE, 
5-HEPE and 4-HDHA and 7-HDHA were unchanged or only slightly elevated 
(1–5-; 1–2-; 1–2-fold, respectively) in serum. In contrast, concentrations of CYP 




derived epoxy- and dihydroxy-PUFA were almost similar in plasma and serum 
consistent for ARA, EPA and DHA derived products. Levels of non-
enzymatically formed ARA derived 5(R,S)-5-F2t-IsoP were comparable in 
plasma and serum.  
Regarding concentrations after immediate processing following alkaline 
hydrolysis (Fig. 3.2, appendix Fig. 8.4, Fig. 8.5), levels of total oxylipins showed 
the same trend as their free counterparts when comparing plasma and serum: 
Levels of epoxy- and dihydroxy-PUFA, as well as 5(R,S)-5-F2t-IsoP were 
comparable in plasma and serum. Serum levels of total 12-HHT were elevated 
to a similar extent (51–441-fold) compared to free 12-HHT. For hydroxy-PUFA 
differences between plasma and serum were moderate: Levels of 12-LOX 
derived 12-HETE, 12-HEPE, 14-HDHA were clearly elevated (5–50-; 2–14-; 2–
16-fold, respectively) while 15-LOX derived 15-HETE, 15-HEPE, 17-HDHA (1–
3-; 1–2-; 1–3-fold, respectively) were same or only slightly higher in serum, and 
levels of 5-LOX derived 5-HETE, 5-HEPE and 4-HDHA and 7-HDHA were 
similar in plasma and serum after hydrolysis.  
Comparing levels of free and total oxylipins revealed similar concentrations for 
dihydroxy-PUFA while levels of hydroxy-PUFA, epoxy-PUFA and 5(R,S)-5-F2t-
IsoP were massively higher after hydrolysis. 
3.3.2 Analytical variability of oxylipins in plasma and serum 
Stability of oxylipins in the differently stored and transported blood samples 
before processing to plasma and serum was evaluated based on changes in the 
apparent oxylipin levels in comparison to immediate processing and the 
“acceptable change limit” (ACL). The ACL covers the analytical variance 
including sample preparation and is based on the relative standard deviation of 
quality control plasma samples analyzed in parallel with the samples with 
similar concentrations (Tab. 3.1). For free oxylipins the ACL was below 35% for 





LLOQ (48% and 58%, respectively), and for 12-LOX products (42–51%). 
Similarly, for total oxylipins the ACL was below 40% for most analytes, except 
for epoxy-PUFA (48–60%) and DHA derived hydroxy-PUFA (43–49%).  
Tab. 3.1: Levels of representative free and total oxylipins quantified in quality control plasma 
analyzed in parallel with the samples (n = 6–7), their lower limit of quantification, their relative 
standard deviation (RSD) and the acceptable change limit (ACL) calculated using 
ACL = 2.77 × RSDQC. 
  free oxylipins total, i.e. free and esterified oxylipins 
Analyte LLOQ Mean ± SD 
RSD 
[%] ACL LLOQ Mean ± SD 
RSD 
[%] ACL 
PGE2 0.025 0.03 ± 0.004 17 48  *    
TxB2 0.125 0.52 ± 0.06 12 32  *    
12-HHT 0.05 0.53 ± 0.07 14 39 0.25 1.25 ± 0.13 9 26 
12-HETE 0.050 5.63 ± 0.89 16 44 0.25 8.48 ± 0.90 11 30 
12-HEPE 0.063 1.51 ± 0.28 18 51 0.313 1.14 ± 0.10 9 25 
14-HDHA 0.10 3.63 ± 0.55 15 42 0.5 2.98 ± 0.53 18 49 
15-HETE 0.125 1.14 ± 0.10 8 23 0.625 10.42 ± 1.50 14 40 
15-HEPE 0.125 0.20 ± 0.03 14 39 0.625 1.05 ± 0.15 14 39 
17-HDHA 0.20 0.89 ± 0.12 13 36 1 4.54 ± 0.75 17 46 
5-HETE 0.05 0.86 ± 0.09 11 29 0.25 17.77 ± 1.55 9 24 
5-HEPE 0.05 0.26 ± 0.03 13 36 0.25 2.69 ± 0.16 6 16 
4-HDHA 0.025 0.35 ± 0.03 7 21 0.125 3.62 ± 0.45 12 34 
7-HDHA 0.10 0.11 ± 0.02 21 58 0.5 2.47 ± 0.39 16 43 
14(15)-EpETrE 0.05 0.10 ± 0.01 9 24 0.25 54.46 ± 11.78 22 60 
17(18)-EpETE 0.10 < LLOQ   0.5 5.11 ± 0.88 17 48 
19(20)-EpDPE 0.05 0.31 ± 0.03 9 26 0.25 11.60 ± 2.06 18 49 
14,15-DiHETrE 0.01 0.64 ± 0.04 6 16 0.05 1.53 ± 0.16 11 29 
17,18-DiHETE 0.025 0.55 ± 0.06 11 31 0.125 0.80 ± 0.07 9 25 
19,20-DiHDPE 0.05 3.09 ± 0.17 5 15 0.25 3.77 ± 0.16 4 12 
5(R,S)-5-F2t-IsoP 0.05 0.11 ± 0.01 10 28 0.25 0.47 ± 0.05 11 31 
11-HETE 0.05 0.31 ± 0.02 7 20 0.25 6.42 ± 0.74 11 32 
9-HETE 0.25 < LLOQ   1.25 6.37 ± 0.77 12 34 
18-HEPE 0.10 0.42 ± 0.02 4 10 0.5 1.30 ± 0.15 12 33 
* PGE2 and TxB2 are degraded during alkaline hydrolysis 
 
 




3.3.3 Stability of free oxylipins in plasma and serum 
Regarding changes of free oxylipins in plasma after storage or PTS of blood 
samples, levels of 5(R,S)-5-F2t-IsoP, terminal dihydroxy-PUFA and epoxy-PUFA 
as well as 5-LOX products were almost stable at all investigated conditions with 
slight deviations for 5-LOX products in samples from a single individuum and for 
epoxy-PUFA in samples stored 24 h at 4 °C before processing. Changes of 
PGE2, TxB2 and 12-HHT were within the ACL for most samples after 4 h 
storage at 4 °C, while in samples stored for 24 h levels were clearly increased 
and after PTS further elevated with high inter-individual variance. 12-LOX 
metabolites showed a similar pattern with massive increases after PTS. With 
respect to 15-LOX metabolites, changes of 15-HETE and 17-HDHA were within 
the ACL in 4 h stored samples, clearly higher in 24 h stored samples, but only 
slightly elevated in PTS samples, while interestingly changes of 15-HEPE were 
within the ACL at all investigated conditions. 
In serum overall storage/transport-induced changes of free oxylipins were more 
pronounced. PGE2, TxB2 and 12-HHT showed a similar pattern in all stored and 
transported samples with high inter-individual variance being within the ACL for 
samples from 2–3 individuals, but massively higher for 2–4 individuals. For 
12-LOX and 15-LOX metabolites changes were higher compared to plasma, 
though similar in 4 h and 24 h stored samples, but massively higher in PTS 
samples with high inter-individual variance. 5-LOX metabolites were almost 
stable in 4 h stored samples, but exceeded the ACL in 24 h stored and PTS 
samples. While dihydroxy-PUFA were stable in all conditions, changes of 
epoxy-PUFA and 5(R,S)-5-F2t-IsoP were within the ACL in almost all samples 








Fig. 3.1: ARA derived free oxylipins in (A) plasma and (B) serum. Shown are individual 
concentrations (n = 6) of selected oxylipins from major formation pathways at t0 (immediate 
processing) and %difference vs t0 after 4 hours and 24 hours at 4 °C or after pneumatic tube 
transport (PTS) prior to centrifugation to generate plasma or serum. The different symbols 
represent samples from different individual human subjects. The grey lines indicate the 
acceptable change limits calculated based on relative standard deviation of quality control 
plasma (summarized in Tab. 3.1). Figure is continued on page 58. 
 
































































































































































































































































































































































Fig. 3.2: ARA derived total (i.e. sum of free and esterified) oxylipins in (A) plasma and (B) serum. 
Shown are individual concentrations (n = 6) of selected oxylipins from major formation pathways 
at t0 (immediate processing) and %difference vs t0 after 4 hours and 24 hours at 4 °C or after 
pneumatic tube transport (PTS) prior to centrifugation to generate plasma or serum. The 
different symbols represent samples from different individual human subjects. The grey lines 
indicate the acceptable change limits calculated based on relative standard devivation of quality 
control plasma (summarized in Tab. 3.1). Figure is continued on page 59. 
 























































































































































































































Fig. 3.1: Continued from page 56. ARA derived free oxylipins in (A) plasma and (B) serum. 






















































































































































































































































































































































































































































































































































































3.3.4 Stability of total oxylipins in plasma and serum 
Similar to free oxylipins, storage/transport-induced lower changes of total 
oxylipins in plasma compared to serum. However, the overall impact of sample 
handling was less pronounced for total levels compared to free oxylipins. In 
plasma and serum for all conditions changes of total 5-LOX metabolites, 
dihydroxy-PUFA, epoxy-PUFA as well as 5(R,S)-5-F2t-IsoP were within the 
respective ACL for almost all individual samples. 15-LOX-metabolites were 
stable in plasma of 4 h and 24 h stored blood samples, while in PTS samples 
slight increases were observed being most pronounced for DHA derived 
17-HDHA. Deviations in serum were higher, slightly exceeding the ACL in 4 h 
and 24 h stored samples, while being massively elevated in PTS samples, with 
high inter-individual variance. The strongest influence of pre-processing 
handling was observed for 12-LOX metabolites, being more pronounced in 
serum than in plasma. While 12-LOX metabolites in plasma were stable in 4 h 
stored samples and slightly elevated in 24 h stored samples, in serum they 
were clearly increased, already exceeding the ACL in almost all 4 h and 24 h 
stored samples. Changes in PTS samples were considerably higher than the 
ACL for plasma and serum, being however massively higher in serum with 
higher inter-individual variance. For total 12-HHT the extent and pattern of 
changes was similar to free 12-HHT.  
 Discussion 
Targeted oxylipin metabolomics of clinical samples is increasingly becoming 
valuable in the evaluation of the disease state or for the discovery of disease 
biomarkers [5]. However, blood sampling in clinical routine is often 
accompanied with uncontrolled transitory time intervals during collection and 
processing until further analysis and standardized handling of samples is hard 
to attain in the clinical setting. Efficient transport systems are established in 
large hospitals, such as pneumatic tube system transport (PTS), to achieve fast 
sample delivery to the clinical chemistry laboratory. The influence of these “real 




life” blood sample handling has been previously described for hemolysis and 
clinical chemistry parameters [42, 43], however no information is available on its 
impact on the oxylipin pattern. Because of the oxidation-prone structure of 
oxylipins as well as the residual enzymatic activity in blood samples related to 
PUFA converting enzymes in blood cells, artificial formation and degradation of 
oxylipins during the pre-analytical workflow including collection, transport, 
processing, storage and preparation of samples cannot be excluded and may 
impact reliable interpretation of the analyzed oxylipin pattern. Therefore, we 
evaluated in the present study the effect of storage of whole blood samples at 
4 °C for 4 h and 24 h as well as of the transport via the PTS prior to 
centrifugation on the levels of a comprehensive set of free and total oxylipins in 
EDTA-plasma and serum covering oxylipins from all major formation pathways. 
Serum generation is associated with massive increase of free and total 
platelet derived oxylipins 
In direct comparison of free oxylipin levels in directly processed plasma and 
serum we observed a massive increase of COX and 12-LOX derived products 
by 1–3 orders of magnitude in serum. Levels of 15-LOX products were also 
elevated however to a lesser extent, while 5-LOX derived metabolites were only 
slightly higher in serum, and CYP derived epoxy- and dihydroxy-PUFA were 
almost similar in plasma and serum. This is consistent with previous studies 
observing massive higher levels of free TxB2, 12-HHT and 12-HETE in serum 
compared to plasma [34, 35, 44]. The observed increase in these eicosanoids is 
attributable to the intrinsic activation of the clotting cascade triggered by the 
contact of the contact system factor FXII which circulates in the blood with the 
negatively charged surfaces in the vacutainer used to generate serum during 
blood collection [45]. Activation of this protease cascade ultimately leads to the 
activation of platelets and their main PUFA converting enzymes COX-1 and 
12-LOX and subsequently to the formation of TxA2, 12-HHT (via COX-1) and 
12-HETE (12-LOX) during coagulation [46, 47]. The observed increase in 
15-HETE could also – besides synthesis via 12/15-LOX which is under 





activated platelets via COX-1 which have been shown to produce 15-HETE 
(predominantly the S-enantiomer) and 11-HETE [49]. Consistently, 11-HETE 
showed a similar pattern (Fig. 3.3). The slight elevation of 5-HETE levels in 
serum is also consistent with previous reports [34, 35] and the prevailing 
proportion of 5(S)-HETE [35] suggests contribution of enzymatic formation via 
5-LOX expressed in various leukocytes [50] which have been implicated in the 
regulation of thrombosis [51].  
 
Fig. 3.3: ARA derived 11-HETE and 9-HETE in (A+C) plasma and (B+D) serum. Shown are 
individual concentration (n = 6) of (A+B) free or (C+D) total (comprising free and esterified) 
mediators at t0 (immediate processing) and %difference vs t0 after storage for 4 hours and 
24 hours at 4 °C and after pneumatic tube transport prior to centrifugation to generate plasma or 
serum. The different symbols represent samples from different individual human subjects. The 
grey lines indicate acceptable change limits calculated based on relative standard deviation of 




A Free oxylipins in plasma B Free oxylipins in serum
C Total oxylipins in plasma D Total oxylipins in serum




Respective hydroxy-PUFA derived from EPA and DHA, showed the same 
pattern as their ARA derived counterparts supporting the contribution of these 
enzymatic pathways to their formation during serum generation (appendix 
Fig. 8.2, Fig. 8.3, Fig. 8.4, Fig. 8.5). However, these metabolites were elevated 
to a lesser extent reflecting the low levels of EPA and DHA in blood competing 
with ARA for their enzymatic conversion, as human 12/15-LOX and 12-LOX 
enzymes have been shown to prefer DHA and EPA over ARA [52]. The 
observation that levels of non-enzymatically formed 5(R,S)-5-F2t-IsoP were 
almost similar in plasma and serum suggests that autoxidative processes do not 
play a major role in freshly prepared serum. Similar only marginal alterations 
were seen for 9-HETE (Fig. 3.3), which is discussed as autoxidation product. 
The major portion of hydroxy- and epoxy-PUFA, as well as 5(R,S)-5-F2t-IsoP 
was found esterified in plasma and serum, because massive higher 
concentrations were observed after alkaline hydrolysis, consistent with earlier 
reports [20-22]. Dihydroxy-PUFA were only present non-esterified with same 
apparent concentration for free and total oxylipins. Since under alkaline 
conditions thromboxanes as well as β-hydroxy-keto-prostanoids, e.g. PGE2 and 
PGD2, are degraded [53], we used formation of 12-HHT as a surrogate for COX 
activity [46]. The levels of 12-HHT were similar with and without hydrolysis and 
massively increased in serum. Thus, also the total oxylipin pattern based on 
12-HHT, reflects increased COX activity due to platelet activation during serum 
generation. 
Serum generation was also accompanied by an increase in total hydroxy-PUFA 
levels which was however less pronounced compared to the respective free 
hydroxy-PUFA. Even though it has been shown that eosinophilic 12/15-LOX 
directly form esterified 15-HETE in phospholipids [48], and platelet 12-LOX 
derived hydroxy-PUFA are readily esterified contributing to the esterified pool 
[54], only a minor increase of 12- and 15-HETE (and respective EPA and DHA 





Esterified oxylipins in the cell free fraction of blood (i.e. serum and plasma) is 
thus hardly influenced by the activation of the coagulation cascade. 
Plasma oxylipin profile is more stable than serum and total oxylipins are 
more stable than free oxylipins 
The extended transitory storage of whole blood prior to further processing to 
plasma or serum can cause formation and degradation of several oxylipins due 
to prolonged ex vivo contact with blood cells, i.e. erythrocytes, leukocytes or 
platelets, exhibiting enzymatic activity versus PUFA and oxylipins. In order to 
evaluate the impact of the transitory storage or PTS transport we used the ACL 
based on the methodological RSD obtained from quality control plasma 
samples analyzed in parallel [41] which was in a similar range as previously 
reported for both, free [34, 55] and total oxylipins [39].  
Free oxylipins in plasma from whole blood stored at 4 °C for 4 h remained 
almost stable with exception of samples from a few individuals showing higher 
deviations for 12-LOX and COX-1 derived products. After 24 h at 4 °C besides 
considerable increase in platelet-derived oxylipins also 15-LOX products were 
clearly increased. Though these results are consistent with a previous study 
reporting that free oxylipins in EDTA-whole blood are stable up to 2 h at 4 °C 
[34], another study showed a clear decrease of some prostanoids (PGE2, 
PGF2α), hydroxy-PUFA (11- and 15-HETE) and epoxy-PUFA (14(15)- and 
11(12)-EpETrE) in EDTA-whole blood already after 1 h on ice [16].  
In contrast to plasma, free oxylipins in serum of stored clotted whole blood were 
largely unstable. Especially platelet-derived (COX and 12-LOX) as well as 
15-LOX products showed a strong increase with high inter-individual variance 
similar for 4 h and 24 h at 4 °C. 5-LOX derived products were stronger elevated 
after longer storage (24 h vs 4 h). Consistently, La Frano et al reported that a 
“freezing delay” of clotted whole blood dramatically elevated hydroxy-PUFA 
attributed to ongoing enzymatic processes in cooled whole blood [56]. 




Apparent total oxylipin patterns were considerably more stable towards 
transitory storage of whole blood. However, the observed changes revealed a 
similar pattern as for free oxylipins: Total plasma oxylipins were stable for 4 h at 
4 °C and showed only elevation of platelet derived oxylipins after 24 h. In serum 
similarly to free oxylipins platelet derived oxylipins were massively increased 
after 4 h and 24 h, however increase in 15-LOX products was less pronounced 
and absent for 5-LOX products. These results suggest that transitory storage at 
4 °C without removal of the blood cells or/and the blood clot led to enzymatic 
activity resulting from ex-vivo activation of platelets. This leads to considerable 
artificial ex-vivo formation of COX and 12-LOX products. While in plasma this 
can be ascribed to continuing enzymatic conversion related to the duration of 
storage, the high inter-individual variances in platelet-derived metabolites in 
serum which are similar at 4 h and 24 h indicate that these changes result 
rather from individual differences in the platelets and enzymatic activity of the 
blood coagulation cascade. One should note, that under all conditions the levels 
of free as well as total oxylipins of CYP derived dihydroxy-PUFA were stable 
and free levels of epoxy-PUFA showed only slight increases after 24 h. 
Moreover, the almost unchanged 5(R,S)-5-F2t-IsoP and 9-HETE levels indicate 
that only minor autoxidation takes place during the delay in sample processing.  
Non-controlled blood transport amplifies formation of platelet derived 
(COX-1, 12-LOX) oxylipins 
Automated pneumatic tube transport of blood caused in all samples a massive 
increase in 12-LOX and COX products with high inter-individual variances. 
While 15-LOX metabolites were only slightly and 5-LOX products barely 
affected in plasma, in serum PTS transport also led to a clear elevation of these 
hydroxy-PUFA. Again, these changes were more pronounced for free oxylipins. 
Consistent with previous studies observing decreased clotting time after PTS 
transport [57, 58] these observations suggest that during PTS transport 
platelets might be activated, e.g. due to shear stress or hemolysis induced by 
physical forces (shaking, rapid acceleration). Even though the used PTS has 





PTS might have varying effects, the observed increase in platelet derived COX 
and 12-LOX metabolites after PTS are likely attributable to enhanced platelet 
activation during PTS. 
 Conclusion 
In the present study we investigated the impact of transitory storage as well as 
PTS transport of whole blood samples on the pattern of free and total oxylipins 
in plasma and serum with the aim to evaluate if free or total oxylipins are more 
stable in plasma or serum after whole blood handling in a clinical setting. Based 
on parallel analysis of oxylipins derived from ARA, EPA and DHA from all major 
formation pathways including COX, LOX, CYP as well as non-enzymatic 
conversion we could show: 1.) Free oxylipins in plasma are stable up to 4 h at 
4 °C and prolonged storage as well as sample transport led to increased levels 
of COX and 12-LOX products. 2.) The total oxylipin pattern in plasma and 
serum is less affected by transitory storage and transport. 3.) Blood coagulation, 
i.e. serum generation, leads to massively higher levels of free and total COX 
and 12-LOX derived oxylipins due to ex-vivo platelet activation. 4.) Serum 
samples showed higher storage and transport induced variability and inter-
individual differences were more pronounced. Thus, with respect to clinical 
studies – where blood sampling cannot be tightly controlled – total plasma 
oxylipins seem to be the best analytical marker for the blood oxylipin pattern. 
While great caution with respect to artifact formation in interpretation of 12-LOX 
and COX metabolites is required, total levels of 5-LOX, CYP as well as the 
autoxidation product 5(R,S)-5-F2t-IsoP are almost stable with respect to blood 
handling conditions. 
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4 Chapter 4 
Formation of trans-epoxy fatty acids correlates with 
formation of isoprostanes and could serve as 
biomarker of oxidative stress* 
In mammals, epoxy-polyunsaturated fatty acids (epoxy-PUFA) are enzymatically 
formed from naturally occurring all-cis PUFA by cytochrome P450 
monooxygenases leading to the generation of cis-epoxy-PUFA (mixture of R,S- 
and S,R-enantiomers). In addition, also non-enzymatic chemical peroxidation 
gives rise to epoxy-PUFA leading to both, cis- and trans-epoxy-PUFA (mixture of 
R,R- and S,S-enantiomers). Here, we investigated for the first time trans-epoxy-
PUFA and the trans/cis-epoxy-PUFA ratio as potential new biomarker of lipid 
peroxidation. Their formation was analyzed in correlation with the formation of 
isoprostanes (IsoP), which are commonly used as biomarkers of oxidative 
stress. Five oxidative stress models were investigated including incubations of 
three human cell lines as well as the in vivo model Caenorhabditis elegans with 
tert-butyl hydroperoxide (t-BOOH) and analysis of murine kidney tissue after 
renal ischemia reperfusion injury (IRI). A comprehensive set of IsoP and epoxy-
PUFA derived from biologically relevant PUFA (ARA, EPA and DHA) was 
simultaneously quantified by LC-ESI(-)-MS/MS. Following renal IRI only a 
moderate increase in the kidney levels of IsoP and no relevant change in the 
trans/cis-epoxy-PUFA ratio was observed. In all investigated cell lines (HCT-116, 
HepG2 and Caki-2) as well as C. elegans a dose dependent increase of both, IsoP 
and the trans/cis-epoxy-PUFA ratio in response to the applied t-BOOH was 
observed. The different cell lines showed a distinct time dependent pattern 
consistent for both classes of autoxidatively formed oxylipins. Clear and highly 
significant correlations of the trans/cis-epoxy-PUFA ratios with the IsoP levels 
were found in all investigated cell lines and C. elegans. Based on this, we 
suggest the trans/cis-epoxy-PUFA ratio as potential new biomarker of oxidative 
stress, which warrants further investigation. 
* Reprinted from Prostaglandins & Other Lipid Mediators, Vol. 144, Rund K. M., Heylmann 
D., Seiwert N., Wecklein S., Oger C., Galano J.-M., Durand T., Chen R., Gueler F., Fahrer 
J., Bornhorst J., Schebb N. H., Formation of trans-epoxy fatty acids correlates with 
formation of isoprostanes and could serve as biomarker of oxidative stress, 106334, 
Copyright (2019), with permission from Elsevier. doi: 10.1016/j.prostaglandins.2019.04.004. 
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Oxidative stress, i.e. the imbalance of antioxidative and oxidative mechanisms 
is associated with the pathophysiology of several diseases. It is characterized 
by an impairment of redox signaling and control in the organism, ambivalently 
caused and/or resulting by the disease state [1]. Various diseases are linked to 
oxidative stress including inflammatory, cardiovascular, respiratory and 
neurological diseases [2]. 
Elevated levels of reactive oxygen and nitrogen species (RONS) formed in the 
course of oxidative stress oxidatively modify biomolecules including lipids, 
proteins, DNA, thereby altering their biological properties and function. 
Polyunsaturated fatty acids (PUFA) which are essential constituents in 
membrane phospholipids are susceptible to free radical mediated autoxidation 
[3]. During this lipid peroxidation radical abstraction of a bisallylic hydrogen and 
subsequent addition of molecular oxygen results initially in conversion of PUFA 
to hydroperoxy fatty acid radicals which are further converted in chain oxidation 
reactions giving rise to a multitude of reactive and stable secondary oxidation 
products which inter alia bear hydro(pero)xy, epoxy and cyclic moieties [4]. 
Several of these products arising during non-enzymatic autoxidation are 
structurally similar to products formed by enzymatic conversion. However, 
enzymatic conversion of PUFA by cyclooxygenase (COX) results in regio- and 
stereospecific formation of prostaglandins (PG), whereas non-enzymatic lipid 
peroxidation leads to a complex mixture of regio- and stereoisomeric 
prostaglandin-like products, referred to as isoprostanes (IsoP), comprising in 
the case of arachidonic acid (ARA, C20:4 n6) 64 different F2-IsoP isomers [5, 
6]. While only free, i.e. non-esterified PUFA are enzymatically converted by 
COX, IsoP are formed from PUFA esterified in phospholipids and are released 
upon stimuli [7]. PG, like PGE2, are known to be potent mediators of 
inflammation and for selected IsoP  also biological activity have been shown, 
e.g. 15-F2t-IsoP acting as renal vasoconstrictor [8]. ARA derived F2-IsoP, 
especially 15-F2t-IsoP (8-iso-PGF2α), were assessed to be valuable for the 




evaluation of oxidative stress in vivo and the latter is commonly used as 
biomarker in diseases and environmental exposures implicated with oxidative 
stress [9-11]. However, in recent years the validity of the sole measurement of 
15-F2t-IsoP as biomarker of oxidative stress is regarded controversial as it 
besides non-enzymatic autoxidation may also arise from enzymatic conversion 
by COX [12, 13]. To account for the contribution of both pathways to the 
detected 15-F2t-IsoP level, determination of the 15-F2t-IsoP/PGF2α ratio may be 
used to differentiate between non-enzymatic and enzymatic formation and 
enable accurately evaluating the underlying oxidative stress [14, 15]. Moreover, 
the parallel analysis of different IsoP isomers from individual as well as multiple 
biological relevant PUFA – as carried out in the present study – allows drawing 
comprehensive conclusions on the oxidative stress status independent from the 
origin of the analyzed specimen. 
In addition to IsoP a multitude of autoxidative PUFA products is generated 
during lipid peroxidation. This includes products with epoxy moieties resulting 
from hydroperoxides via intramolecular homolytic substitution of the peroxide 
bond by an adjacent carbon radical [4]. Epoxy-PUFA are well characterized 
highly potent lipid mediators which possess important biological properties, e.g. 
acting anti-inflammatory and vasodilatory [16] and are present in body fluids 
and tissues (e.g. plasma, red blood cells, liver, kidney, lung, heart) [17, 18]. In 
mammals they are generated from enzymatic conversion of the naturally 
occurring all-cis PUFA by cytochrome P450 monooxygenases (CYP) leading to 
regioisomeric cis-epoxy-PUFA (R,S- and S,R-enantiomers, Fig. 4.1) for each of 
the double bonds with distinct stereo- and regioselectivity depending on the 
respective involved CYP isoform [19, 20]. Similarly to COX only the free, non-
esterified PUFA are enzymatically converted by CYP, whereas in contrast to 
PG, epoxy-PUFA are mainly incorporated in lipids [21], e.g. predominantly the 








Fig. 4.1: Stereochemistry of epoxy-PUFA. Each of the four double bonds can be epoxygenated 
resulting in the formation of four regioisomeric epoxy-PUFA from ARA each comprising two 
diastereoisomers, i.e. cis- and trans-epoxy-PUFA isomers with two enantiomers (with S,R and 
R,S or S,S and R,R configuration, respectively). 
Apart from the CYP derived cis-epoxy-PUFA also trans-epoxy-PUFA (S,S- and 
R,R-enantiomers, Fig. 4.1) have been detected in red blood cells (RBC) [23] 
and heart tissue from untreated healthy animals [24]. Exposure of RBC with the 
oxidative stress causing agent tert-butyl hydroperoxide (t-BOOH) led to an 
increase of ARA derived epoxy-PUFA compared to control [25, 26]. Regarding 
stereochemistry in response to t-BOOH treatment both diastereomers (i.e. cis 
and trans) increased in RBC, though a greater increase of trans-epoxy-ARA 
was observed [26]. A favored formation of trans- over cis-epoxy-ARA was also 
observed after exposing ARA to radical starter in benzene and liposomes [24]. 
However, so far no information about the time course of trans-epoxy-PUFA 
formation in biological settings and its correlation to the extent of oxidative 
stress is available.  
In the present study we examined the formation of IsoP and epoxy-PUFA 
following oxidative stress to investigate the potential use of trans-epoxy-PUFA 
and the trans/cis-epoxy-PUFA ratio as marker of oxidative stress. For this 
purpose, we extended an established LC-ESI(-)-MS/MS method covering 
enzymatically and non-enzymatically formed oxylipins to enable the separation 
and parallel quantification of cis- and trans-epoxy-PUFA. The concentration and 
time dependent generation of the oxidative lipid metabolites was examined in 
three cell lines from different human tissues and the model organism 






















t-BOOH, and in murine kidney tissue after renal ischemia reperfusion injury 
(IRI). The parallel assessment of both, IsoP – known biomarker of oxidative 
stress – and epoxy-PUFA allowed us to demonstrate the applicability of the 
trans/cis-epoxy-PUFA ratio as oxidative stress marker. 
 Experimental 
4.2.1 Chemicals 
Standards of regioisomeric cis-epoxy-PUFA (mixture of R,S- and S,R-
enantiomers), isoprostane 15-F2t-IsoP and the deuterated internal standards 
(IS) 2H4-15-F2t-IsoP (2H4-8-iso-PGF2α), 2H11-5(R,S)-5-F2t-IsoP (2H11-(±)5-iPF2α-
VI), 2H4-9(10)-EpOME, 2H11-14(15)-EpETrE were purchased from Cayman 
Chemicals (local distributor: Biomol, Hamburg, Germany). Other IsoP and IsoF 
standards from the biologically relevant PUFA α-linolenic acid (18:3 n3, ALA), 
ARA, eicosapentaenoic acid (20:5 n3, EPA), adrenic acid (22:4 n6, AdA), 
docosapentaenoic acid (22:5 n6, n6-DPA), docosahexaenoic acid (22:6 n3, 
DHA) [27] were synthesized according to our chemical strategies already 
described in the literature [28-32]. LC-MS-grade methanol (MeOH), LC-MS-
grade acetonitrile (ACN), LC-MS-grade isopropanol and LC-MS-grade acetic 
acid were purchased from Fisher Scientific (Schwerte, Germany). Disodium 
hydrogen phosphate dihydrate and n-hexane (HPLC Grade) were obtained from 
Carl Roth (Karlsruhe, Germany). Potassium hydroxide (85%) was obtained from 
Gruessing GmbH (Filsum, Germany). All other chemicals were purchased from 
Sigma Aldrich (Schnelldorf, Germany). 
4.2.2 Cell culture assay 
HCT-116 human colorectal carcinoma cells, Caki-2 human kidney carcinoma 
cells and HepG2 human liver carcinoma cells were grown in 10 cm dishes and 





Germany) for 30 min, 1 h and 2 h. The cells were harvested using trypsin as 
described and the cell pellets were stored at −80 °C until analysis [27]. Cell 
pellets typically contained 5 × 106 (HCT-116), 4 × 106 (Caki-2) and 20 × 106 
(HepG2) cells. Cytotoxicity was assessed by the MTS assay 
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) as described [27, 33]. The used t-BOOH concentration showed no 
relevant effect on cell viability (> 84%) (appendix Fig. 8.6, [27]). 
4.2.3 C. elegans treatment 
The N2 Bristol strain, provided by the Caenorhabditis Genetics Center (CGC; 
University of Minnesota), was propagated at 20 °C on Nematode Growth 
Medium (NGM) plates spotted with the Escherichia coli strain OP50-1 [34]. Age-
synchronized L4 stage worms were obtained by treating worms with an alkaline 
bleach solution (1% NaClO and 0.25 M NaOH) and growing the hatched 
L1 larvae on OP50-1-seeded NGM plates for approximately 48 h. Treatment 
was performed using 12,000 L4 stage worms. Therefore, the nematodes were 
exposed to 0 mM (control) and 2.5 mM t-BOOH for 60 min, or 6.5 mM t-BOOH 
for 15, 30, 45 or 60 min in 85 mM NaCl containing 0.01% Tween (6.5 mM 
represents the lethal dose 50% (LD50) following 1 h exposure (data not 
shown)). Worms were then pelleted by centrifugation at 1600 rpm for 2 min and 
washed four times in 85 mM NaCl containing 0.01% Tween. The remaining 
nematode pellet was snap-frozen in liquid nitrogen and stored at −80 °C until 
analysis. 
4.2.4 Renal ischemia reperfusion injury in mice 
C57BL/6Jham-ztm male mice (12–13 weeks of age) were purchased from the 
institute of laboratory animal science (Hannover Medical School, Germany). 
Animals were cared for in accordance with the institution’s guidelines for 
experimental animal welfare and with the guidelines of the American 
Physiological Society. The animal protection committee of the local authorities 




(Lower Saxony State Department for Food Safety and Animal Welfare, LAVES) 
approved all experiments (approval 33.14-42502-04-14/1657). Mice were 
housed under conventional conditions with a 12 h light/dark cycle and had free 
access to food (Altromin 1324 standard mouse diet) and domestic quality 
drinking water ad libitum. 
Surgery to induce renal IRI was done in general isoflurane anesthesia (5% 
induction, 2% maintenance) in combination with iv analgetic treatment with 
butorphanol. IRI was induced by transient unilateral renal pedicle clamping for 
35 min using a non-traumatic vascular clamp [35]. Mice were sacrificed 2 h, 4 h 
and 24 h after reperfusion by deep general anesthesia and total body perfusion 
with ice cold PBS. Kidneys were collected, immediately shock frozen and stored 
at −80 °C until oxylipin analysis. 
4.2.5 Quantification of oxylipins 
For the analysis of total, i.e. free and esterified oxylipins formed under different 
treatment conditions cell pellets (comprising 5 × 106 HCT-116, 4 × 106 Caki-2 or 
20 × 106 HepG2 cells) and nematode pellets as well as kidney tissue samples 
(25 ± 3 mg) were extracted following alkaline hydrolysis using anion exchange 
Bond Elut Certify II SPE cartridges (Agilent, Waldbronn, Germany) as described 
[27, 36]. 
In brief, to cell pellets (HCT-116, HepG2, Caki-2), C. elegans pellets and kidney 
tissue samples 10 µL of IS solution (100 nM of 2H4-15-F2t-IsoP, 2H11-5(R,S)-5-
F2t-IsoP, C19-17-epi-17-F1t-PhytoP, C21-15-F2t-IsoP, 2H4-6-keto-PGF1α, 2H4-
PGE2, 2H4-PGD2, 2H4-TxB2, 2H4-LTB4, 2H4-9-HODE, 2H8-5-HETE, 2H8-12-HETE, 
2H6-20-HETE, 2H11-14,15-DiHETrE, 2H11-14(15)-EpETrE, 2H4-9(10)-EpOME and 
2H4-9,10-DiHOME), 10 µL of antioxidant solution (0.2 mg/mL BHT and EDTA, 
100 µM indomethacin, 100 µM of the soluble epoxide hydrolase inhibitor trans-
4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (t-AUCB) [37] in 





homogenized after addition of 400 µL isopropanol with a vibration ball mill (MM 
400, Retsch, Haan, Germany) using two stainless steel beads (3 mm, 10 min, 
25 Hz). After hydrolysis (300 µL 1.5 M KOH (25/75, H2O/MeOH, v/v) for 30 min 
at 60 °C) the samples were immediately cooled, neutralized using acetic acid 
(50%) and mixed with 2000 µL 0.1 M disodium hydrogen phosphate buffer 
(pH = 6.0) followed by SPE. After sample loading, the cartridges were washed 
with one column volume of each water and MeOH/water (50/50, v/v) and dried. 
The analytes were eluted with 2 mL of 75/25 (v/v) ethylacetate/n-hexane with 
1% acetic acid, evaporated and the residue was resuspended in 50 µL MeOH 
(containing 40 nM of 1-(1-(ethylsulfonyl)piperidin-4-yl)-3-(4-(trifluoromethoxy)-
phenyl)urea as IS2 for the calculation of the extraction efficiency of the IS). After 
centrifugation (10 min, 4 °C, 20,000 × g) the samples were analyzed by RP-LC-
MS/MS (6500 QTRAP, Sciex, Darmstadt, Germany) in scheduled selected 
reaction monitoring mode following negative electrospray ionization as 
described [27]. 
4.2.6 Data analysis 
Oxylipin concentrations were quantified using external calibration with authentic 
standards (linear fitting with 1/x2 weighting) based on the analyte to 
corresponding IS area ratio as described [27]. For each epoxy-fatty acid 
regioisomer both cis- and trans-epoxy-PUFA isomers were quantified using the 
calibration curve of corresponding cis-epoxy-PUFA (identified with authentic 
standards). Based on that, the trans/cis-epoxy-PUFA ratios were calculated. For 
7(8)-EpDPE and 5(6)-EpETE due to absence of accurate quantitative standards 
only the trans/cis-epoxy-PUFA ratio could be determined. Trans-epoxy-PUFA 
isomers eluting 0.14–0.3 min after their corresponding cis-isomers (Fig. 4.2) 
were identified based on retention time and identical MS-fragmentation pattern 
as described [23, 24, 26].  
Data evaluation and statistical analyses were performed as indicated using 
GraphPad Prism version 6.01 for Windows (GraphPad Software, La Jolla 
California USA, www.graphpad.com). 





Fig. 4.2: Chromatographic separation of epoxy-PUFA regioisomers. (A) ARA derived EpETrE in 
HCT-116 cells following incubation with 200 µM t-BOOH for 2 h. (B) EPA derived EpETE in 
C. elegans following incubation with 6.5 mM t-BOOH for 1 h and (C) DHA derived EpDPE in 
kidney tissue after unilateral IRI for 35 min and 2 h after reperfusion. Shown are mass 



























































































































































































In the present study using a comprehensive LC-MS/MS method total, i.e. free 
and esterified, levels of IsoP as well as cis- and trans-epoxy-PUFA derived from 
different precursor PUFA were simultaneously quantified in cell pellets and 
C. elegans incubated with oxidative stress generating t-BOOH, and in murine 
kidney tissue after renal ischemia reperfusion injury. 
4.3.1 Formation of IsoP 
IsoP in cells following treatment with t-BOOH 
In cell pellets from colorectal (HCT-116), renal (Caki-2) and hepatic (HepG2) 
origin 6 IsoP regioisomers derived from 4 precursor PUFA (ARA, EPA, DHA, 
AdA) were quantified. Regarding detected isomers the regioisomers carrying 
the hydroxyl group in proximity to the carboxy function, i.e. ARA derived 5(R,S)-
5-F2t-IsoP, EPA derived 5(R,S)-5-F3t-IsoP, DHA derived 4(R,S)-4-F4t-NeuroP 
and AdA derived ent-7(R,S)-7-F2t-dihomo-IsoP showed higher concentration 
than other regioisomers from the same PUFA or were the only regioisomers 
detected as it is the case for AdA derived F2t-dihomo-IsoP. Under basal 
conditions in HCT-116 cells only 5(R,S)-5-F2t-IsoP, 5(R,S)-5-F3t-IsoP and 
4(R,S)-4-F4t-NeuroP were detected, while in Caki-2 and HepG2 cells 
additionally other regioisomers (15-F2t-IsoP and 10(R,S)-10-F4t-NeuroP) were 
found. Interestingly, basal levels of detected IsoP in Caki-2 cells were 2–7-fold 
higher than in HepG2 and 6–20-fold higher than in HCT-116 cells. In all cell 
lines incubation with t-BOOH led to an increase in IsoP formation, however the 
dose and time dependent pattern showed considerable differences between the 
cell types, though being similar for all regioisomers within the individual cell 
types (Fig. 4.3). 
Fig. 4.3 (right, page 83): Total levels of representative (A) IsoP and (B) epoxy-PUFA derived 
from ARA, EPA and DHA following incubation of (I) HCT-116, (II) HepG2 and (III) Caki-2 cells 
with 50 µM and 200 µM tert-butyl hydroperoxide (t-BOOH) for 0.5 h, 1 h and 2 h. Shown are 
mean ± SD (HCT-116: n = 4, HepG2: n = 3, Caki-2: n = 4). For epoxy-PUFA the trans/cis-
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In HCT-116 cells a dose dependent increase of IsoP levels was observed 
leading to 3–5-fold and 10–17-fold higher IsoP concentrations compared to 
control with 50 µM and 200 µM t-BOOH, respectively (Fig. 4.3 (I) A). While with 
50 µM t-BOOH no effect of the incubation time (0.5 h – 2 h) was observed, 
200 µM t-BOOH induced a trend towards higher IsoP levels with longer 
incubation time. In HepG2 cells only 200 µM of t-BOOH led to an increase of 
IsoP levels compared to control (Fig. 4.3 (II) A). Interestingly, with longer 
incubation time a decrease in IsoP concentrations was observed leading at 2 h 
to almost same concentrations as with 50 µM t-BOOH. In Caki-2 cells only 
incubation with 200 µM t-BOOH led to a slight increase of IsoP concentrations, 
however here no time dependent change of IsoP levels was observed 
(Fig. 4.3 (III) A). 
IsoP in C. elegans following treatment with t-BOOH 
In nematode pellets of wildtype N2 C. elegans only EPA derived 5(R,S)-5-F3t-
IsoP were detected in the control group. Incubation with t-BOOH led to an 
increase and additional formation of EPA derived 8(R,S)-8-F3t-IsoP as well as 
ARA derived 15-F2t-IsoP and 5(R,S)-5-F2t-IsoP. A dose dependent increase in 
IsoP levels was observed with the applied t-BOOH concentration leading to 4–
6-fold higher IsoP levels for 6.5 mM compared to 2.5 mM t-BOOH after 60 min 
incubation (Fig. 4.4 (I) A). Also, longer incubation time led to a gradual increase 
resulting in 4–6-fold higher IsoP levels for 60 min compared to 15 min 
incubation with 6.5 mM t-BOOH (Fig. 4.4 (II) A). 
 
 
Fig. 4.4 (right, page 85): Total levels of (A) IsoP and (B) epoxy-PUFA derived from ARA and 
EPA in C. elegans incubated for (I) 60 min with 2.5 mM and 6.5 mM t-BOOH and for (II) 15, 30, 
45 and 60 min with 6.5 mM t-BOOH. Shown are mean ± SD (n = 2–6). In case the levels do not 
exceed the lower limit of quantification (LLOQ) in one treatment group, the LLOQ is indicated as 
a dashed line. For epoxy-PUFA the trans/cis-epoxy-PUFA-ratio (trans/cis) is indicated above the 
corresponding bars. Statistical differences between control and the treatment groups were 
evaluated by one-way ANOVA followed by Tukey post-test. For dose dependent formation of 
5(R,S)-5-F2t-IsoP unpaired t-test was used. For time dependent formation only differences 
between control and treatment groups are shown, results for differences between all treatments 

























































































































































































































(A) IsoP (B) epoxy-PUFA
(I) Dose dependent formation after 60 min (II) Time dependent formation at 6.5 mM t-BOOH
(A) IsoP (B) epoxy-PUFA
6.5 mM t-BOOH 2.5control
cis-epoxy-PUFA
IsoP / trans-epoxy-PUFA
control 2.5 6.5 mM t-BOOH 45 60 min t-BOOH 30 15 control
60 min t-BOOH 45 30 15 
cis-epoxy-PUFA
IsoP / trans-epoxy-PUFA control















IsoP in murine kidneys after ischemia reperfusion injury 
In murine kidney tissue ARA derived 5(R,S)-5-F2t-IsoP and 15-F2t-IsoP and 
DHA derived 4(R,S)-4-F4t-NeuroP and 10(R,S)-10-F4t-NeuroP were detected 
with higher levels of the regioisomers carrying the hydroxyl group in proximity to 
the carboxy function. While in IRI tissue 2 h after reperfusion higher levels of 
ARA derived IsoP were observed compared to unclamped contralateral kidney 
tissue, DHA derived NeuroP remain almost unchanged. 4 h after reperfusion 
higher levels for both, ARA and DHA derived IsoP were observed in IRI tissue 
compared to unclamped control. Interestingly, 24 h after unilateral IRI lower 
levels of DHA derived NeuroP were observed in the IRI kidney compared to the 
contralateral unclamped kidney, while levels of ARA derived IsoP were similar 
in the IRI and unclamped kidney (Fig. 4.5 A). 
4.3.2 Formation of epoxy-PUFA 
Epoxy-PUFA in cells following treatment with t-BOOH 
In cell pellets from colorectal (HCT-116), renal (Caki-2) and hepatic (HepG2) 
origin for all epoxy-PUFA derived from ARA (i.e. EpETrE), EPA (i.e. EpETE) 
and DHA (i.e. EpDPE) cis- and trans-isomers could be determined. However as 
a result of chromatographic interference in HCT-116 cells cis-19(20)-EpDPE 
and in HepG2 cells cis-8(9)-EpETE were not evaluable. 
In control incubations the trans/cis-epoxy-PUFA ratios of the respective 
regioisomers were similar between the different cell types, however differed 
between the individual regioisomers. While for most regioisomers levels of cis-
isomers were higher than of trans-isomers, for regioisomers carrying the epoxy 
moiety in the middle or front part of the carbon chain (i.e. 8(9)-EpETrE, 
11(12)-EpETrE, 5(6)-EpETE, 7(8)-EpDPE and 10(11)-EpDPE) the ratios of 
trans/cis-isomers were approximately equal (0.7–1.4) or higher as for 
5(6)-EpETrE (trans/cis-ratio > 1.5).  




Incubation with t-BOOH led in all cell lines to an increase of trans-epoxy-PUFA 
levels, while levels of respective cis-isomers remained almost constant, 
resulting in an increase of the trans/cis-epoxy-PUFA ratios. However, dose and 
time dependent formation of trans-epoxy-PUFA differed between the 
investigated cell lines with the individual regioisomers showing the same pattern 
within the particular cell types irrespective of the precursor PUFA (Fig. 4.3). In 
HCT-116 cells with 50 µM t-BOOH trans-epoxy-PUFA remained almost 
constant, whereas 200 µM t-BOOH led to 1.7–6.6-fold higher levels of trans-
isomers compared to control. Regarding incubation time, only with 200 µM 
t-BOOH a trend towards higher levels of trans-epoxy-PUFA with longer 
incubation was observed, leading to a 1.7–2.7-fold increase of the trans/cis-
ratios for 1 h and 2 h compared to 0.5 h incubation (Fig. 4.3 (I) B). In HepG2 
cells 50 µM t-BOOH led only to a slight increase of the trans/cis-ratios (1.5–1.8-
fold), while with 200 µM t-BOOH trans/cis-ratios were 2.0–5.2-fold higher 
compared to control. Similar to HCT-116 cells with 50 µM t-BOOH cis- and 
trans-isomer levels remained almost unchanged with longer incubation time. In 
contrast, with 200 µM t-BOOH levels of trans-epoxy-PUFA increased after 0.5 h 
and remain similar after 1 h, however after 2 h of incubation a trend towards 
lower levels of cis- and trans-epoxy-PUFA was observed (Fig. 4.3 (II) B). In 
Caki-2 cells only with 200 µM t-BOOH a slight trend towards higher levels of 
trans-epoxy-PUFA was observed, however neither 50 µM nor 200 µM t-BOOH 
led to a time dependent change of epoxy-PUFA levels (Fig. 4.3 (III) B). 
Epoxy-PUFA in C. elegans following treatment with t-BOOH 
In non-exposed wildtype N2 C. elegans cis- and trans-isomers of all analyzed 
epoxy-PUFA regioisomers derived from ARA and EPA were detected. Levels of 
EPA derived epoxy-PUFA were markedly higher than ARA derived epoxy-
PUFA. Interestingly, levels of the terminal regioisomers, i.e. 14(15)-EpETrE and 
17(18)-EpETE, were different compared to the other regioisomers. While levels 
of all ARA derived regioisomers were in the same range, 17(18)-EpETE showed 
2.7–5.2-fold higher basal levels than the other EPA derived regioisomers. 





PUFA levels. With 2.5 mM t-BOOH for 60 min both, cis- and trans-isomers 
showed a slight but similar trend towards higher levels compared to control 
resulting in unchanged trans/cis-ratios. Further increasing the applied t-BOOH 
concentration to 6.5 mM led to a favored formation of trans- over cis-isomers, 
leading to a 2.3–2.9-fold increase in trans/cis-ratios compared to control 
(Fig. 4.4 (I) B). A similar pattern was also observed regarding incubation time 
with 6.5 mM t-BOOH. While after 15 min cis- and trans-isomers increased only 
slightly though to a similar extent, longer incubation (30–60 min) resulted in a 
favored formation of trans- over cis-isomers. Consequentially trans/cis-ratios 
increased gradually with longer incubation time resulting in 1.7–2.4-fold higher 
trans/cis-ratios for 60 min compared to 15 min incubation (Fig. 4.4 (II) B). 
Epoxy-PUFA in murine kidney after ischemia reperfusion injury 
In murine kidney tissue only for ARA and DHA derived epoxy-PUFA 
regioisomers cis- and trans-isomers were detected. For both precursor PUFA 
basal levels of individual epoxy-PUFA regioisomers showed a distinct 
distribution of trans- and cis-isomers depending on the position of the epoxy-
moiety relative to the carboxy-function: the closer the epoxy-moiety to the 
carboxy terminus the higher the observed trans/cis-ratio (appendix Fig. 8.7). 
Following unilateral IRI, 2 h after reperfusion levels of epoxy-PUFA remained 
almost unchanged, while 4 h after reperfusion both cis- and trans-epoxy-PUFA 
showed a slight increase compared to unclamped kidney resulting in almost 
unchanged trans/cis-ratios. 24 h after reperfusion levels of ARA derived epoxy-
PUFA were similar in IRI and unclamped kidney tissue. While in contrast for 
DHA derived epoxy-PUFA a decrease of cis-isomers was observed in IRI 
compared to unclamped kidney tissue with almost unchanged trans-epoxy-
PUFA levels. Interestingly, this decrease was more pronounced for terminal 
isomers, i.e. 19(20)- and 16(17)-EpDPE compared to 13(14)- and 10(11)-
EpDPE (Fig. 4.5 B, appendix Fig. 8.7). 





Fig. 4.5: Total levels of (A) IsoP and (B) epoxy-PUFA derived from ARA and DHA in murine 
kidney tissue following unilateral IRI for 35 min. Shown are mean ± SEM (n = 6) in the 
unclamped and IRI kidneys 2 h, 4 h and 24 h after reperfusion. For epoxy-PUFA the trans/cis-
epoxy-PUFA-ratio (trans/cis-ratio) is indicated above the corresponding bars. Statistical 
differences between the unclamped and IRI kidneys were evaluated by paired t-test for 5(R,S)-
5-F2t-IsoP, 4(R,S)-4-F4t-NeuroP and the trans/cis-epoxy-PUFA ratios (* p < 0.05, ** p < 0.01, 
*** p < 0.001). 
4.3.3 Correlation of IsoP  
In cell lines as well as in C. elegans following incubation with t-BOOH a clear 
correlation between IsoP formation and the trans/cis-epoxy-PUFA ratio was 
found (Fig. 4.6, Tab. 4.1). Pearson correlations between the levels of IsoP 
regioisomers carrying the hydroxyl group in proximity to the carboxy-function 
and the ratio of trans/cis-epoxy-PUFA regioisomers from the corresponding 
PUFA were determined (Tab. 4.1): ARA derived 5(R,S)-5-F2t-IsoP was 
correlated with EpETrE regioisomers, EPA derived 5(R,S)-5-F3t-IsoP with 
EpETE regioisomers and DHA derived 4(R,S)-4-F4t-NeuroP with EpDPE 
regioisomers. For all epoxy-PUFA regioisomers positive and highly significant 
correlations with IsoP levels were obtained in the three cell lines and C. elegans 
(Fig. 4.6, Tab. 4.1). As no significant increase in the trans/cis-ratio was found in 
unclamped clampedIsoP / trans-epoxy-PUFA: unclampedcis-epoxy-PUFA: clamped
(A) IsoP (B) epoxy-PUFA



































































0.6 | 0.5 0. 7 | 0.6 0. 3 | 0.5trans/cis-ratio


























murine renal IRI (Fig. 4.5, appendix Fig. 8.7) consequently no correlation of 
IsoP levels and trans/cis-epoxy-PUFA ratios resulted. 
 
Fig. 4.6: Correlation between the trans/cis-ratio of individual epoxy-PUFA regioisomers (i.e. for 
ARA 11(12)-EpETrE, for EPA 11(12)-EpETE, for DHA 10(11)-EpDPE) and the most abundant 
IsoP isomer derived from the same precursor PUFA (i.e. for ARA 5(R,S)-5-F2t-IsoP, for EPA 
5(R,S)-5-F3t-IsoP, for DHA 4(R,S)-4-F4t-NeuroP). Shown are pearson correlation coefficients r 
and respective p-values for ARA, EPA and DHA derived oxidative metabolites in (A) HCT-116, 























































































































































































































r = 0.8851, p < 0.0001 r = 0.9104, p < 0.0001 r = 0.8846, p < 0.0001
r = 0.6760, p = 0.0001 r = 0.6915, p < 0.0001 r = 0.6651, p = 0.0002
r = 0.8298, p < 0.0001 r = 0.9008, p < 0.0001 r = 0.8876, p < 0.0001
r = 0.9526, p < 0.0001 r = 0.9261, p < 0.0001




Tab. 4.1: Pearson correlations between the trans/cis-ratio of individual epoxy-PUFA 
regioisomers and the most abundant IsoP isomer derived from the same precursor PUFA (i.e. 
for ARA 5(R,S)-5-F2t-IsoP, for EPA 5(R,S)-5-F3t-IsoP, for DHA 4(R,S)-4-F4t-NeuroP). Shown are 
pearson correlation coefficients r for ARA, EPA and DHA derived oxidative metabolites in 
HCT-116, HepG2 and Caki-2 cells, as well as in C. elegans incubated with t-BOOH, and the 
respective p-values. * not evaluable due to chromatographic interference. 
ARA derived 5(R,S)-5-F2t-IsoP 
EpETrE HCT-116 HepG2 Caki-2 C. elegans 
14(15)- 
r = 0.9231  
p < 0.0001 
r = 0.7177 
p < 0.0001 
r = 0.8764 
p < 0.0001 
r = 0.9121 
p < 0.0001 
11(12)- 
r = 0.8851 
p < 0.0001 
r = 0.6760 
p = 0.0001 
r = 0.8298 
p < 0.0001 
r = 0.9526 
p < 0.0001 
8(9)- 
r = 0.9085 
p < 0.0001 
r = 0.6261 
p = 0.0005 
r = 0.848 
p < 0.0001 
r = 0.9150 
p < 0.0001 
5(6)- 
r = 0.8952 
p < 0.0001 
r = 0.6906 
p < 0.0001 
r = 0.7978 
p < 0.0001 
r = 0.8950 
p < 0.0001 
EPA derived 5(R,S)-5-F3t-IsoP 
EpETE HCT-116  HepG2 Caki-2 C. elegans  
17(18)- 
r = 0.8207 
p < 0.0001 
r = 0.8231 
p < 0.0001 
r = 0.7832 
p < 0.0001 
r = 0.9379 
p < 0.0001 
14(15)- 
r = 0.8610 
p < 0.0001 
r = 0.7929 
p < 0.0001 
r = 0.8303 
p < 0.0001 
r = 0.9015 
p < 0.0001 
11(12)- 
r = 0.9104 
p < 0.0001 
r = 0.6915 
p < 0.0001 
r = 0.9008 
p < 0.0001 
r = 0.9261 
p < 0.0001 
8(9)- 
r = 0.8649 
p < 0.0001 
* 
r = 0.7839 
p < 0.0001 
r = 0.9535 
p < 0.0001 
5(6)- 
r = 0.8335 
p < 0.0001 
r = 0.6162 
p =0.0006 
r = 0.8749 
p < 0.0001 
r = 0.9675 
p < 0.0001 
DHA derived 4(R,S)-4-F4t-NeuroP 
EpDPE HCT-116  HepG2 Caki-2  
19(20)- * 
r = 0.7461 
p < 0.0001 
r = 0.7327 
p < 0.0001 
 
16(17)- 
r = 0.8621 
p < 0.0001 
r = 0.6950 
p < 0.0001 
r = 0.8899 
p < 0.0001 
 
13(14)- 
r = 0.8342 
p < 0.0001 
r = 0.7489 
p < 0.0001 
r = 0.8942 
p < 0.0001 
 
10(11)- 
r = 0.8846 
p < 0.0001 
r = 0.6651 
p = 0.0002 
r = 0.8876 
p < 0.0001 
 
7(8)- 
r = 0.9006 
p <0.0001 
r = 0.5821 
p = 0.0014 
r = 0.9042 








In the present study total levels of IsoP and cis- and trans-epoxy-PUFA were 
simultaneously quantified. Based on that, the correlation between these 
autoxidatively formed oxylipins during oxidative stress was evaluated in three 
models: (i) t-BOOH induced stress in three cultured cell lines and in (ii) 
C. elegans and (iii) following ischemic reperfusion injury in the kidney in mice. 
ARA derived F2-IsoP are well established marker of oxidative damage formed 
during lipid peroxidation in vivo. Particularly 15-F2t-IsoP (8-iso-PGF2α) is 
commonly used as biomarker in diseases and environmental exposures related 
to oxidative stress [8, 9, 11]. In line we found a strong increase of IsoP in 
response to t-BOOH in all cell lines as well as in C. elegans (Fig. 4.3, Fig. 4.4). 
The modulation of IsoP was markedly different between the cell lines regarding 
both, dose and time dependency: While in HCT-116 cells already 50 µM 
t-BOOH led to an increase in IsoP levels, in HepG2 and Caki-2 cells a trend 
towards higher IsoP levels was only observed in incubations with 200 µM 
t-BOOH (Fig. 4.3). This could result from different intracellular RONS 
detoxifying mechanisms between the cell types, breaking down t-BOOH 
generated radicals and preventing oxidative damage. It seems that only if a 
threshold in intracellular ROS burden is reached, an increased IsoP formation 
results. For HCT-116 cells this level seems to be reached at t-BOOH 
concentrations above 50 µM, while for Caki-2 cells only at a high concentration 
of 200 µM t-BOOH IsoP levels are elevated. A threshold of oxidative stress 
inducing noxae for the formation of IsoP depending on the concentration of 
oxidative stress inducer was also observed previously in HepG2 cells treated 
with the redoxcycler paraquat [38]. Here only incubation with concentrations 
equal or above 100 µM led to an increase in IsoP formation compared to 
control.  
Noteworthy, with high concentration of t-BOOH (200 µM) for all detected 
regioisomers, IsoP levels showed a distinct time dependent pattern in the 
different cell lines. In HCT-116 cells a trend towards higher IsoP levels with 




longer incubation time was observed (Fig. 4.3 (I)). Consistently, a similar time 
dependent increase of IsoP was previously reported for copper induced 
peroxidation of ARA and EPA containing phospholipids or of cell lysates [38, 
39]. In contrast, in HepG2 cells levels of IsoP showed a decreasing trend with 
longer incubation and remained unaffected by the incubation time in Caki-2 
cells (Fig. 4.3). A decrease in total IsoP levels as observed in HepG2 cells 
might result from metabolic degradation of the formed oxylipins. As formation of 
IsoP occurs in situ on phospholipids [7] hydrolysis of IsoP containing 
phospholipids by phospholipase A2 seems likely to be involved in the observed 
decrease of total IsoP levels. Indeed, the intracellular type II platelet-factor-
acetyl hydrolase exhibiting negligible phospholipase activity against long-chain-
PUFA containing membrane phospholipids [40, 41] hydrolyses F2-IsoP 
containing phospholipids [42] and was shown to translocate from the cytosol to 
the membrane upon oxidative stress stimulus [43]. Furthermore, a time course 
similar to the one observed in HepG2 cells was also observed following CCl4 
induced peroxidation in the rat [7]. Here, total IsoP levels in the liver increased 
rapidly after CCl4 was applied with a peak after 2 h, followed by a decrease over 
time leading to almost restored levels after 24 h. Correspondingly, plasma level 
of free IsoP arising from release of esterified IsoP showed a similar, however 
delayed time course, further supporting the hypothesis of phospholipase 
contribution. 
Among the multitude of different IsoP regio- and stereoisomers that can be 
formed during lipid peroxidation (e.g. for ARA a total of 64 different F2-isomers) 
[5], we observed a favored formation of selected regioisomers in all investigated 
cell lines, C. elegans as well as kidney tissue. Regarding IsoP isomers covered 
in our analysis, regioisomers carrying the side chain hydroxyl group in proximity 
to the carboxy group, i.e. ARA derived 5(R,S)-5-F2t-IsoP, EPA derived 5(R,S)-5-
F3t-IsoP, DHA derived 4(R,S)-4-F4t-NeuroP and AdA derived ent-7(R,S)-7-F2t-
dihomo-IsoP, were observed in higher abundance than its regioisomers. This is 
consistent with previous studies where a preferred formation of particular 





IsoP, for EPA the 5- and 18-F3t-IsoP [44] and for DHA the 4- and 20-F4t-NeuroP 
[45] regioisomers were observed in greater abundance. This may be explained 
by further oxidative conversion of the precursors involved in the formation of 
other IsoP regioisomers during autoxidation. One could also expect, that the 
regioisomers bearing the hydroxyl-group at C4 or C5 position are also more 
stable towards β-oxidation which could contribute to higher levels of these 
regioisomers, as has been previously observed for other 5-hydroxy eicosanoids 
(e.g. leukotrienes) [46, 47]. 
Remarkably, in all cell lines, levels of these regioisomers were in a similar range 
for ARA, EPA and DHA derived IsoP (Fig. 4.3), while in C. elegans 
concentration of EPA derived 5(R,S)-5-F3t-IsoP was considerably higher than 
the corresponding ARA derived regioisomer (Fig. 4.4). As PUFA serve as 
substrates for IsoP formation, the fatty acid composition and PUFA pattern 
affect the levels of respective formed IsoP. Consistently, the observed high level 
of EPA derived F3-IsoP in C. elegans is in agreement with the predominant 
relative EPA content compared to ARA [48]. 
Regarding formation of epoxy-PUFA, the trans/cis-epoxy-PUFA ratio increased 
with the applied t-BOOH concentration in all cell lines and C. elegans and 
showed a distinct time dependent pattern in the different cell lines (Fig. 4.3, 
Fig. 4.4). The similar pattern in comparison with the observed IsoP levels 
suggests the contribution of related mechanisms (discussed above). Overall the 
increase in the trans/cis-epoxy-PUFA ratio was mainly caused by a favored 
formation of trans- compared to cis-isomers during t-BOOH induced oxidative 
stress. This supports previous findings demonstrating formation of epoxy-PUFA 
during autoxidation, as has been shown for ARA derived EpETrE in RBC 
incubated with t-BOOH [25, 26]. Consistently, both, free radical induced 
peroxidation in benzene and liposomes, as well as exposure of RBC to t-BOOH 
led to a favored formation of trans- over cis-epoxy-ARA [24, 26]. As double 
bonds in naturally occurring PUFA are oriented all-cis a possible mechanism 
leading to the formation of both, cis- and trans-epoxy-PUFA could involve PUFA 




carbon centered radicals with an adjacent peroxyl group. These are formed at 
the position of the double bond in the PUFA molecule during the radical chain 
reaction. These carbon radicals allow for free rotation of the σ-bond prior to 
intramolecular attack of the peroxyl bond by the reactive carbon radical which 
leads via homolytic substitution to the formation of an epoxy-moiety oriented 
either cis or trans [4, 24].  
Irrespective of the precursor PUFA the observed increase in the trans/cis-
epoxy-PUFA ratio following t-BOOH induced oxidative stress was similar for all 
regioisomers, though being slightly higher for 5(6)-EpETE. However, this has to 
be regarded with caution as 5(6)-EpETE, like 5(6)-EpETrE might rapidly 
degrade forming a six-membered δ-lacton [49]. Additionally, also high basal 
levels of cis-epoxy-PUFA derived from CYP as observed for the preferred 
formation of the ω3-epoxygenation product 17(18)-EpETE compared to its other 
regioisomers in C. elegans (Fig. 4.4) might hamper the suitability of the 
respective trans/cis-ratio reflecting the oxidative damage.  
Here, we tested for the first time if the trans/cis-epoxy-PUFA ratio can reflect 
oxidative stress. For this purpose we correlated the trans/cis-epoxy-PUFA ratio 
with the level of IsoP, which are established biomarkers of lipid peroxidation. 
Considering the consistent time and t-BOOH concentration dependent pattern, 
quite clear, positive, highly significant correlations of IsoP levels with the 
trans/cis-epoxy-PUFA ratio were observed for all epoxy-PUFA regioisomers in 
t-BOOH induced oxidative stress in all three cell lines and C. elegans (Fig. 4.6, 
Tab. 4.1). Thus, we suggest that the trans/cis-epoxy-PUFA ratio might serve as 
alternative oxidative stress marker. 
However, in the evaluated in vivo model of murine renal IRI, the moderate 
increase of IsoP was not accompanied by an increase in the trans/cis-epoxy-
PUFA ratio (Fig. 4.5, appendix Fig. 8.7). Thus, here the applicability of the 
trans/cis-epoxy-PUFA ratio as oxidative stress marker cannot be evaluated 
based on comparison with IsoP levels. Even though IRI is linked to excess ROS 





renal IRI has been observed in rat models [52, 53], there are various factors 
influencing measured IsoP levels in this model. These include clamping time, 
since longer clamping seems to lead to higher IsoP levels [52], as well as the 
time point of sampling following reperfusion, and the specimen analyzed, e.g. 
plasma, interstitial fluid, urine or tissue. Consistently to our observation of an 
increase in total 5(R,S)-5-F2t-IsoP levels in the kidney 4 h after reperfusion and 
a decrease after 24 h (Fig. 4.5), in a rat model of unilateral IRI an increase of 
oxidized phosphatidylcholine species containing IsoP was observed 6 h after 
reperfusion which decreased after 24 h [53]. A similar time course of IsoP level 
was also observed in the liver of CCl4 treated rats (see above) [7]. These 
studies show that the time point of measuring oxidative damage for the 
evaluation of oxidative stress based on IsoP and likewise probably also epoxy-
PUFA is crucial [54]. Interestingly, while showing the same time dependent 
trend, ARA and DHA derived 5(R,S)-5-F2t-IsoP and 4(R,S)-4-F4t-NeuroP, 
respectively, were modulated to a different extent in the time course of IRI in 
mice (Fig. 4.5). Also species specific differences might result in different time 
courses or extent of changes. Taken together, probably the ischemia 
reperfusion injury induced oxidative stress does not cause strong lipid oxidation 
in the investigated model and at the investigated time points. Therefore, other 
oxidative stress models, e.g. CCl4 induced liver toxicity [8, 9, 55] or paraquat 
induced lung toxicity [56, 57] should be used to evaluate the biological 
significance of the modulated trans/cis-epoxy-PUFA ratio during oxidative stress 
as seen for the t-BOOH induced oxidative stress models.  
 Conclusion 
Based on the presented results, we suggest a potential new biomarker of 
oxidative damage: the trans/cis-epoxy-PUFA ratio. In the investigated human 
cell lines from hepatic, colorectal and renal origin, as well as in the model 
organism C. elegans an increase in the trans/cis-epoxy-PUFA ratio with 
t-BOOH induced oxidative stress was observed. The trans/cis-epoxy-PUFA 




ratio correlates perfectly with common marker of oxidative stress, i.e. IsoP. 
However, in the investigated in vivo model of murine renal ischemia reperfusion 
injury an effect on the trans/cis-epoxy-PUFA ratio was absent, underlining the 
need for further investigations especially regarding different oxidative stress 
agents with different modes of inducing oxidative stress to validate its suitability. 
This analysis could also pave the way to a mechanistically understanding of 
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5 Chapter 5 
Dietary omega-3 PUFA improved tubular function after 
ischemia induced acute kidney injury in mice but did 
not attenuate impairment of renal function* 
Background: Acute kidney injury (AKI) is an important complication after major surgery 
and solid organ transplantation. Here, we present a dietary omega-3 polyunsaturated 
fatty acid (n3-PUFA) supplementation study to investigate whether pre-treatment can 
reduce ischemia induced AKI in mice. 
Methods: Male 12–14 week old C57BL/6J mice received a linoleic acid rich sunflower oil 
based standard diet containing 10% fat (STD) or the same diet enriched with n3-PUFA 
(containing 1% EPA and 1% DHA) (STD+n3). After 14 days of feeding bilateral 30 min 
renal ischemia reperfusion injury (IRI) was conducted to induce AKI and mice were 
sacrificed at 24 h. Serum creatinine and blood urea nitrogen (BUN) as well as liver 
enzyme elevation were measured. Kidney damage was analyzed by histology and 
immunohistochemistry. Furthermore, pro-inflammatory cytokines (IL-6, MCP-1) were 
determined by qPCR. FA and oxylipin pattern were quantified in blood and kidneys by 
GC-FID and LC-MS/MS, respectively. 
Results: n3-PUFA supplementation prior to renal IRI increased systemic and renal levels 
of n3-PUFA. Consistently, eicosanoids and other oxylipins derived from n3-PUFA 
including precursors of specialized pro-resolving mediators were elevated while 
n6-PUFA derived mediators such as pro-inflammatory prostaglandins were decreased. 
Feeding of n3-PUFA did not attenuate renal function impairment, morphological renal 
damage and inflammation characterized by IL-6 and MCP-1 elevation or neutrophil 
infiltration. However, the tubular transport marker alpha-1 microglobulin (A1M) was 
significantly higher expressed in proximal tubular epithelial cells of STD+n3 compared to 
STD fed mice. This indicates a better integrity of proximal tubular epithelial cells and 
thus significant protection of tubular function. In addition, heme oxygenase-1 (HO-1) 
which protects tubular function was also up-regulated in the treatment group receiving 
n3-PUFA supplemented chow. 
Discussion: We showed that n3-PUFA pre-treatment did not affect overall renal function 
or renal inflammation in a mouse model of moderate ischemia induced AKI, but tubular 
transport was improved. In conclusion, dietary n3-PUFA supplementation altered the 
oxylipin levels significantly but did not protect from renal function deterioration or 
attenuate ischemia induced renal inflammation. 
* Reprinted from Prostaglandins & Other Lipid Mediators, Vol. 146, Rund K. M., Peng S., Greite 
R., Claaßen C., Nolte F., Oger C., Galano J.-M., Balas L., Durand T., Chen R., Gueler F., 
Schebb N. H., Dietary omega-3 PUFA improved tubular function after ischemia induced acute 
kidney injury in mice but did not attenuate impairment of renal function, 106386, Copyright 
(2020), with permission from Elsevier. doi :10.1016/j.prostaglandins.2019.106386. 
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Acute kidney injury (AKI) is a frequent complication after major cardiac surgery, 
solid organ transplantation and also after trauma surgery. Onset of AKI 
increases morbidity and mortality of the patients and is characterized by an 
increase in serum creatinine and/or reduction of the glomerular filtration rate 
(GFR) [1]. In a review of 25,182 trauma patients post-traumatic AKI was as high 
as 24% and these patients had a 3.4-fold higher risk of death compared to non-
AKI patients [2]. Also, after myocardial infarction mortality was 3-fold increased 
in patients with AKI and incidence of major adverse cardiac events (MACE) was 
with 26% higher than in non-AKI patients during the three-year follow-up [3]. It 
has been shown that AKI is not only an acute event but also increases the risk 
for chronic kidney disease (CKD) [4]. Even if the serum creatinine elevation 
returns to normal levels shortly after AKI a significant proportion of patients will 
develop CKD or will even proceed to end stage renal disease with the need of 
renal replacement therapy [5]. 
Renal ischemia reperfusion injury (IRI) due to hypotension, major bleeding and 
hypoxia causes intrarenal vasoconstriction with activation of pro-oxidative 
mechanisms, release of pro-inflammatory cytokines and subsequent leukocyte 
invasion [6-9]. The severity of AKI correlates with the long-term outcome and 
progression to CKD [5]. 
Established strategies to prevent or attenuate AKI even in scheduled surgeries 
such as cardiac valve replacement are lacking. Several studies discussed a 
beneficial role of omega-3 polyunsaturated fatty acids (n3-PUFA) in the context 
of kidney diseases [10-19]. For the prevention of cardiovascular diseases the 
nutritional status of n3-PUFA is a well-established risk factor [20, 21]. The 
higher the incorporation of n3-PUFA, determined by the relative content of EPA 
and DHA in the cells, typically red blood cells [20, 22], the lower the risk for 
cardiovascular diseases and mortality [23]. It has to be noted that n3-PUFA are 
essential constituents of the human diet and that the nutritional status and not 
the intake of n3-PUFA supplements is related to their physiological effects. 




Thus, if only the intake of n3-PUFA by supplementation is correlated to the risk 
for cardiovascular diseases the outcome is less clear [24, 25].  
In the context of renal diseases effects of n3-PUFA supplementation on the 
outcome in kidney transplantation are inconsistent [26]. However, in some 
experimental AKI models the administration of n3-PUFA correlated with an 
improved kidney function [10-15].  
The molecular mechanisms underlying beneficial effects of n3-PUFA include 
direct actions, e.g. binding to ion channels or transcription factors, e.g. NFκB or 
PPARγ, thereby reducing the expression of pro-inflammatory and activating the 
expression of anti-inflammatory genes, respectively. As constituents of 
membranes, e.g. predominantly in phospholipids, n3-PUFA also impact 
membrane structure and fluidity [27]. However, it is beyond doubt that a 
relevant part of the physiological effects of n3-PUFA are mediated by their 
oxygenated products, i.e. eicosanoids and other oxylipins [27-29]. In the so-
called arachidonic acid (ARA) cascade PUFA serve as substrates for enzymatic 
and non-enzymatic conversion resulting in a multitude of lipid mediators from 
both n6- and n3-PUFA (Fig. 5.1) [27, 28, 30]. Enzymatic conversion of PUFA in 
the ARA cascade comprises three major pathways: (I) cyclooxygenases (COX) 
lead to the formation of prostanoids and thromboxanes, (II) cytochrome P450 
monooxygenases (CYP) give rise to epoxy-PUFA and terminal hydroxy-PUFA 
and (III) lipoxygenases lead via hydroperoxy-PUFA to hydroxy-PUFA and 
leukotrienes [31]. Structurally similar to these enzymatically formed products, 
oxidized PUFA also arise during non-enzymatic autoxidation, e.g. isoprostanes, 
which also have been shown to possess biological activity [32, 33]. In the 
kidney oxylipins have important functions in (patho)physiology, e.g. regulation of 
renal blood flow, glomerular filtration rate and tubular transport function [34-37]. 
As n3-PUFA compete with ARA for conversion, dietary n3-PUFA 
supplementation impacts the overall oxylipin profile resulting in a shift from 
predominantly pro-inflammatory, e.g. 2-series prostaglandins, towards n3-PUFA 





Furthermore, in recent years activity of LOX with n3-PUFA have been related to 
the formation of multiple hydroxylated PUFA, e.g. resolvins, maresins and 
protectins which have been attributed to be actively involved in the resolution of 
inflammation [38], though several studies fail to detect them in biological 
samples [39, 40].  
 
Fig. 5.1: Simplified overview of the biosynthesis of arachidonic acid (20:4 n6, ARA) from linoleic 
acid (18:2 n6, LA), and eicosapenatenoic acid (20:5 n3, EPA) and docosahexaenoic acid 
(20:6 n3, DHA) from α-linolenic acid (18:3 n3, ALA), and selected pathways for their 
oxygenation within the ARA cascade. COX – cyclooxygenase, LOX – lipoxygenase, CYP –
 cytochrome P450 monooxygenase, Tx – thromboxane; HETE – hydroxy eicosatetraenoic acid; 
HEPE – hydroxy eicosapentaenoic acid; HDHA – hydroxy docosahexaenoic acid; EpETrE –
 epoxy eicosatrienoic acid; EpETE – epoxy eicosatetraenoic acid; EpDPE – epoxy 
docosapentaenoic acid; IsoP – isoprostane; NeuroP – neuroprostane; Rv – resolvin; Lx – 
lipoxin; PD – protectin; MaR – maresin. 
Changes in the oxylipin pattern in the context of kidney function in AKI have 
been sparsely investigated. Therefore, we used a well characterized model of 
ischemia induced AKI in mice [41, 42] to study the effect of dietary n3-PUFA 
(EPA and DHA) supplementation – based on a linoleic acid rich western-like 




diet [43] for 14 days prior to surgery – on the fatty acid composition and oxylipin 
pattern in blood and tissue in comparison to renal damage and inflammation at 
24 h after reperfusion injury. 
  Experimental 
5.2.1 Chemicals and Biological Materials 
Oxylipin and deuterated oxylipin standards were purchased from Cayman 
Chemicals (local distributor: Biomol, Hamburg, Germany). Methyl 
pentacosanoate (FAME C25:0) was obtained from Santa Cruz Biotechnology 
(Heidelberg, Germany). PD1 and isoprostane standards were included in the 
method based on in-house synthesis as described [40, 44]. HPLC grade and 
LC-MS grade methanol (MeOH), LC-MS grade acetonitrile (ACN), LC-MS grade 
isopropanol, LC-MS grade acetic acid and HPLC grade methyl tert-butyl ether 
(Acros Organics) were purchased from Fisher Scientific (Schwerte, Germany). 
Sodium hydrogen phosphate and n-hexane (HPLC grade) were obtained from 
Carl Roth (Karlsruhe, Germany). Ammonium acetate (p.a.) was obtained from 
Merck (Darmstadt, Germany) and potassium hydroxide (85%) from Gruessing 
GmbH (Filsum, Germany). Ethyl acetate, acetyl chloride and potassium 
carbonate (anhydrous) were purchased from Sigma Aldrich (Schnelldorf, 
Germany). 
5.2.2 Feeding experiment and renal ischemia reperfusion injury in mice 
C57BL/6Jham-ztm male mice (12–14 weeks of age) were obtained from the 
institute of laboratory animal science (Hannover Medical School, Germany). 
Mice were cared for in accordance with the institution’s guidelines for 
experimental animal welfare and with the guidelines of the American 
Physiological Society. All experiments were approved by the animal protection 





Safety and Animal Welfare, LAVES; approval 33.19-42502-04-14/1657). Mice 
were housed under conventional conditions with a 14/10 h light/dark cycle. Mice 
were divided into two feeding groups receiving either a sunflower oil based 
standard diet (STD) or the same diet enriched with n3-PUFA containing 
1% eicosapentaenoic acid (EPA) and 1% docosahexaenoic acid (DHA) as ethyl 
esters (10% each in fat; STD+n3) based on a standard experimental diet (ssniff 
Spezialdiaeten GmbH, Soest, Germany). Both diets contained in total 10% fat. 
The fatty acid composition of the diets is shown in the appendix (Tab. 8.4). 
During the whole feeding period every 2–3 days fresh chow was provided and 
animals had free access to the food and domestic quality drinking water. 
After 14 days of feeding, renal IRI was initiated in general isoflurane anesthesia 
(5% induction, 2% maintenance) combined with iv butorphanol as analgetic 
treatment. IRI was induced by transient bilateral renal pedicle clamping for 
30 min using a non-traumatic vascular clamp [45]. Mice were sacrificed 24 h 
after reperfusion by deep general anesthesia and total body perfusion with ice 
cold PBS [45]. 
IRI experiments were conducted in three sets each with n = 7–8 animals in the 
STD and STD+n3 fed group. In one of these experiments additionally a sham 
group (n = 5) receiving STD chow was included which underwent midline 
laparotomy but without renal pedicle clamping. 
Blood was collected at baseline (before starting the feeding) and at 24 h after 
reperfusion. An aliquot of 30 µL whole blood was diluted with 150 µL deionized 
water for fatty acid analysis and EDTA-plasma was generated by centrifugation 
(10 min, 4 °C, 4000 × g) and stored at −80 °C until analysis for clinical chemistry 
and oxylipins. Kidneys were collected at endpoint, dissected and immediately 
processed as follows: one piece was fixed in paraformaldehyde for histology, 
one piece was stored in RNAlater for qPCR and one piece was shock frozen in 
liquid nitrogen and stored at −80 °C for fatty acid and oxylipin analysis. Renal 
function (serum-creatinine and BUN) and liver enzymes (aspartate 
transaminase: AST, alanine transaminase: ALT) were measured in EDTA-




plasma by an Olympus analyzer (AU400) in an automated fashion according to 
the manufacturer’s instruction. 
5.2.3 Histology and immunohistochemistry 
The middle part of the kidney was fixed in 4% paraformaldehyde (PFA) 
overnight and embedded in paraffin. Two µm paraffin sections were cut and 
PAS (Periodic Acid-Schiff) stain according to standard diagnostic protocols was 
done. For determination of AKI scores a semi-quantitative grading system was 
used: 0 = focal AKI with < 5% of tubuli of the cortex affected, 1 = mild AKI with 
5–25% of tubuli affected, 2 = moderate AKI with 26–50% of tubuli affected, 
3 = severe AKI with 51–75% of the tubuli affected, 4 = very severe AKI with 
> 75% of tubuli affected. 
Immunohistochemistry for neutrophil infiltration (Gr-1 antibody, Biorad), the 
tubular function marker alpha-1 microglobulin (A1M; gift from Magnus Gram, 
Lund University) and heme oxygenase-1 (HO-1 antibody; Enzo Life Sciences, 
Switzerland) was done on paraffin sections. Sections were incubated with 
trypsin for 15 min at 37 °C for antigen retrieval. Nonspecific binding sites were 
blocked with 10% normal donkey serum (Jackson ImmunoResearch Lab, West 
Grove, USA) for 30 min and then primary antibodies (Invitrogen, California, 
USA) were incubated for 60 min at room temperature in the dark. Afterwards 
secondary antibodies (Invitrogen, California, USA) were incubated for additional 
60 min in the dark. Analysis was performed in a blinded manner using a Leica 
imaging microscope. Gr-1 positive neutrophil infiltration was scored with a 0–4 
grading system in 10 different view fields (VF) per section in 200-fold 
magnification: 0 = no infiltrates, 1 = mild infiltrates with < 5 cells/VF, 
2 = moderate infiltrates with 6–10 cells/VF, 3 = severe infiltration with 11–
25 cells/VF, 4 = very severe infiltration with > 25 cells/VF. Semiquantitative 
analysis of the percentage of A1M or HO-1 positive proximal tubuli in the cortex 





5.2.4 Detection of pro-inflammatory cytokines by qPCR 
For mRNA work-up one part of the kidneys was fixed in RNAlater immediately. 
For total RNA extraction the RNeasy mini kit system (Qiagen, Hilden, Germany) 
was used and RNA was transcribed with Qiagen mini kits. For quantitative PCR 
(qPCR) 1 µg of DNase-treated total RNA was reverse transcribed using 
Superscript II reverse transcriptase (Invitrogen) and qPCR was performed on a 
Lightcycler 420 II (Roche Diagnostics, Penzberg, Germany) using FastStart 
SYBR Green chemistry. Gene-specific primers for MCP-1 (QT00167832) and 
IL-6 (QT00098875) were used. For normalization HPRT (QT00166768) was 
used as housekeeping gene. Quantification was carried out using qgene 
software. 
5.2.5 Extraction and quantification of fatty acids 
The fatty acid composition was analyzed in diluted whole blood (15 µL blood + 
75 µL water) and kidney tissue (15 ± 2 mg) as fatty acid methyl esters (FAME) 
using gas chromatography with flame ionization detection (GC-FID) as 
described with slight modifications [46]. Briefly, 10 µL internal standard (FAME 
C25:0, 750 µM) was added to diluted whole blood and kidney tissue samples. 
Kidney tissue was homogenized in 300 µL MeOH and 50 µL water using two 
stainless steel beads (3 mm, 5 min, 25 Hz) with a vibration ball mill (MM 400, 
Retsch, Haan, Germany). Lipids were extracted with MeOH/methyl tert-butyl 
ether and the lipid extract was trans-esterified to fatty acid methyl esters using 
methanolic hydrogen chloride. The calculation of the absolute fatty acid 
concentrations and relative pattern was based on response factors as described 
[46]. The LLOQ was 0.5 µg/mL for all FAME in the injected solution and the 
variability in quality control plasma was < 5% within batch. 




5.2.6 Extraction and quantification of oxylipins  
Oxylipins in plasma and kidney tissue were extracted using anion exchange 
Bond Elut Certify II SPE cartridges (Agilent, Waldbronn, Germany) as described 
with modifications [40, 44]. In the first step of oxylipin extraction 10 µL 
antioxidant solution and internal standards were added to each sample.  
For the determination of free oxylipins in plasma (150–200 µL) the 2.8-fold 
volume of MeOH was added and the samples were stored at −80 °C for 30 min. 
After centrifugation the supernatant was diluted with 0.1 M disodium hydrogen 
phosphate buffer yielding a MeOH content ≤ 18% (pH 6.0) and loaded on the 
preconditioned SPE cartridge. 
For analysis of free oxylipins in kidney tissue (50 ± 5 mg) samples were 
homogenized with 300 µL MeOH as described [47]. After centrifugation the 
supernatant was diluted with 2.7 mL 0.1 M disodium hydrogen phosphate buffer 
(pH 6.0) and loaded on the preconditioned SPE cartridge. 
For quantification of total, i.e. free and esterified oxylipins in kidney tissue 
(20 ± 2 mg) samples were homogenized in 400 µL isopropanol and stored for 
30 min at −80 °C. Samples were centrifuged and the supernatant was 
hydrolyzed (300 µL 1.5 M KOH (75/25, MeOH/water, v/v), immediately 
neutralized with acetic acid, diluted with 2 mL 0.1 M disodium hydrogen 
phosphate buffer (pH 5.5) and loaded on the preconditioned SPE cartridge. 
The SPE procedure was carried out as described and samples were analyzed 
by LC-MS/MS (QTRAP, Sciex, Darmstadt, Germany) in scheduled selected 
reaction monitoring mode following negative electrospray ionization as 
described [40, 44]. The lower limit of quantification [40, 44] and the analytical 
variability [48] of the representative set of quantified oxylipins are summarized 





5.2.7 Data analysis 
Data evaluation and statistical analyses were performed using GraphPad Prism 
software for Windows (version 5.0, La Jolla California USA). Data are presented 
as mean ± standard error of mean (SEM). For oxylipin and fatty acid analysis 
for the calculation of the mean ½ lower limit of quantification (LLOQ) was used if 
the concentration was below the LLOQ. The concentration was set to LLOQ if 
the analyte could not be quantified in more than 50% of the samples in one 
group. For comparison of two groups two-tailed unpaired student’s t-test was 
used. For multiple comparisons ANOVA with post hoc Tukey correction was 
applied. Differences were considered significant at a p-value < 0.05 (* p < 0.05, 
** p < 0.01, *** p < 0.001).  
 Results 
Bodyweight and food intake of both feeding groups were not different between 
the STD and the STD+n3 diet. 
5.3.1 Blood and tissue pattern of fatty acids and their oxidative 
metabolites 
After 14 days of feeding an n3-PUFA enriched sunflower oil based diet (1% 
EPA and 1% DHA in the chow, STD+n3) absolute and relative levels of 
n3-PUFA in the kidney and in the circulation were significantly increased 
predominantly at the expense of n6-PUFA compared to mice on the STD diet 
(Fig. 5.2). Considering the very low levels of EPA in tissue and in the circulation 
of mice on the STD diet, especially relative levels of EPA were massively 
increased in response to the STD+n3 diet. Interestingly, in whole blood the 
STD+n3 diet led to an overall decrease in the absolute FA level. The relative 
concentration of the sum of EPA+DHA, reflecting the endogenous n3-PUFA 
status, increased 2.5- and 3.7-fold in the kidney and whole blood, respectively 




(Fig. 5.2 B and D) indicating successful modulation of the n3-PUFA content by 
the supplementation.  
 
Fig. 5.2: Fatty acid composition in (A) kidney tissue and (C) whole blood 24 h after renal IRI in 
mice was shifted towards higher levels of n3-PUFA, while n6-PUFA decreased after 14 days of 
feeding a sunflower oil based diet enriched with EPA and DHA (STD+n3) compared to the same 
diet without EPA and DHA (STD). Consistently relative levels of EPA and DHA of all detected 
FA in (B) kidney tissue and (D) whole blood were significantly higher in mice on the STD+n3 
diet. Shown are mean ± SEM, n = 14, ** p < 0.01, *** p < 0.001. 
Consistent to the changes in the PUFA pattern, levels of eicosanoids and other 
oxylipins derived from ARA, EPA and DHA were massively altered in response 
to the STD+n3 diet, while concentrations of oxylipins in the plasma and kidney 
were almost similar in the IRI treated group compared to the sham group both 
fed with the STD diet (Fig. 5.3). Comparing levels of individual oxylipins 24 h 
after IRI a similar trend was observed for free metabolites in the plasma as well 
as for free and esterified oxylipins in kidney tissue, though levels of esterified 
oxylipins were massively higher than the respective free mediators: Overall 
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major formation pathways while EPA and DHA derived oxylipins were 
significantly elevated. Especially, regarding levels of free prostanoids in the 
kidney tissue, levels of ARA derived prostaglandins such as pro-inflammatory 
PGE2 or the prostanoid TxB2 were elevated following IRI compared to sham, 
while STD+n3 feeding caused their significant decrease and concomitant 
formation of the less potent EPA derived counterparts, i.e. PGE3 and TxB3 
(Fig. 5.3 B). Amongst others in the circulation as well as in the kidney also a 
significant increase of 17-HDHA and 18-HEPE, precursors for the formation of 
specialized pro-resolving mediators (SPM), was observed in response to 
STD+n3. However, except for DHA derived protectin D1 (PD1) and its isomer 
PDX no signals above the lower limit of quantification (LLOQ), i.e. 0.25–
2 nmol/kg in kidney tissue and 0.07–0.56 nM in plasma, were detected for all 
SPM. LC-MS/MS signals for PD1 indicated relevant apparent concentrations in 
plasma and kidney of STD+n3 fed mice (Fig. 5.6). However, the ratios between 
monitored transitions differed significantly between the authentic standard and 
the biological samples (Fig. 5.6).  
Similar to enzymatically formed oxylipins, levels of prostaglandin-like 
autoxidation products formed esterified in phospholipids were massively altered 
by n3-PUFA feeding. Total levels of ARA derived 5(R,S)-5-F2t-IsoP were 
decreased, while EPA and DHA derived 5(R,S)-5-F3t-IsoP and 4(R,S)-4-F4t-
NeuroP were elevated in response to STD+n3. Interestingly, levels of these 
peroxidation products were lower following IRI compared to sham on the same 
STD diet (Fig. 5.7).  
 
Fig. 5.3 (right, page 115): Concentration of free oxylipins in (A) plasma and (B) kidney tissue 
as well as (C) total, i.e. free and esterified oxylipins in kidney tissue. Shown are concentrations 
of selected (iso-)prostanoids, 5-LOX, 12/15-LOX, CYP2 and CYP4 products of ARA, EPA and 
DHA as well as 18-HEPE and PD1. Except for the sham group all patterns are determined in 
mice 24 h after renal IRI on a STD or STD+n3 diet. Feeding of the STD+n3 diet led to an 
increase of EPA and DHA derived lipid mediators while ARA derived oxylipins were decreased. 
Shown are mean ± SEM (sham n = 5, (A) STD: n = 19, STD+n3: n = 18; (B) STD: n = 13, 
STD+n3: n = 14; (C) STD: n = 7, STD+n3: n = 7). The lower limit of quantification (LLOQ) for 
those oxylipins is indicated by a dashed line in case it was not exceeded in > 50% of the 




















































































































































































A free oxylipins in plasma
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B free oxylipins in kidney
C total oxylipins in kidney
























































































5.3.2 Renal function, renal morphology and inflammation 
Despite successful n3-PUFA supplementation indicated by the changes in 
PUFA and oxylipin patterns renal function impairment was similar in both 
groups. IRI caused a 6-fold elevation of serum creatinine (Fig. 5.4 I). In line with 
renal function deterioration, renal damage measured by AKI score was similar 
in both groups (Fig. 5.4 A, D and G). Furthermore, Gr-1 positive neutrophil 
infiltration showed moderate to severe leukocyte infiltration in both groups 
(Fig. 5.4 B, E and H). On mRNA-level the pro-inflammatory cytokines IL-6 and 
MCP-1 were elevated in both groups. The STD+n3 group even showed a trend 
towards higher values compared to the STD group (Fig. 5.4 C and F).  
 
Fig. 5.4: Acute kidney injury and inflammation. Renal damage after IRI was comparable in STD 
and STD+n3 fed mice (A, D, G; STD: n = 18, STD+n3: n = 21). Neutrophil infiltration to the 
outer medulla was present in both groups without differences (B, E, H; STD: n = 18, STD+n3: 
n = 21). Renal function was significantly impaired after IRI in both groups (I; STD: n = 19, 
STD+n3: n = 21, sham n = 5). Relative expression of (C) IL-6 and (F) MCP-1 mRNA in kidney 
tissue was significantly up-regulated at 24 h after IRI in both groups without differences (STD: 
n = 7, STD+n3: n = 7). Shown are mean ± SEM. 




5.3.3 Tubular function and heme oxygenase-1 expression 
Alpha-1 microglobulin (A1M) is synthetized in the liver, filtered by the glomeruli 
and reabsorbed by proximal tubuli. In healthy kidneys A1M is present in 
vesicles in the cytoplasm of 60–70% of the tubuli. Upon AKI tubuli have a 
breakdown in energy metabolism and impaired transport function leading to 
lower cytoplasm concentration of A1M [49]. Due to IRI A1M expression 
decreased but was significantly higher in the STD+n3 group indicating better 
preservation of the tubular homeostasis and energy metabolism 
(Fig. 5.5 A, C and F). Heme oxygenase-1 (HO-1) is a renoprotective enzyme 
which is upregulated after AKI and mediates healing [50]. HO-1 expression was 
significantly higher in STD+n3 fed mice (Fig. 5.5 B, D and G).  
 
Fig. 5.5: Tubular transport and tubular regeneration. A1M expression was significantly higher 
after STD+n3 feeding which indicates preserved tubular transport function (A, C, F, STD: 
n = 18, STD+n3: n = 14). In addition, HO-1 expression was significantly upregulated in the 
STD+n3 fed group (B, D, G; STD: n = 7, STD+n3 n = 7) which correlates with tubular 
regeneration. Noteworthy, the elevation of the liver enzyme ALT was attenuated (E) by the 
STD+n3 diet and could point towards reduced distant organ injury (STD: n = 19, STD+n3 





Liver enzymes were elevated after IRI due to distant organ injury [51]. STD+n3 
treatment caused less elevation of liver enzymes compared to the STD diet 
(Fig. 5.5 E). Overall, we observed some protective effects by the STD+n3 diet in 
the context of renal IRI (Fig. 5.5). 
 Discussion 
Renal IRI is a common cause of AKI which is associated with high morbidity 
and mortality rates [7]. Particularly in the context of solid organ transplantations 
IRI is inevitable contributing to impaired allograft function [52]. Cardiac surgery 
in elderly patients with slightly decreased renal function has incidence rates of 
AKI of ~30% [53]. In the context of scheduled surgeries a dietary intervention 
would be possible, while the patients are waiting for the surgery. Beneficial 
effects of n3-PUFA supplementation have been reported, however in the 
context of kidney transplantation the outcome is inconsistent [26]. 
In the present study we investigated if dietary n3-PUFA supplementation 
improves renal function impairment in an ischemia induced AKI model following 
renal IRI in mice [42]. The control group received a chow, reflecting the 
omega-6 rich western diet [43] containing 10% linoleic acid rich sunflower oil 
(STD). For the investigation of potential beneficial effects of n3-PUFA 
supplementation on the base of a western diet, this chow was enriched with 
n3-PUFA (1% EPA and 1% DHA; STD+n3) as previously described [22]. In 
order to ensure a maximal modulation of the tissue fatty acid composition by the 
dietary PUFA supplementation a pre-feeding period of 14 days was included 
prior to induction of renal IRI. After 14 days of feeding the STD+n3 chow, the 
relative fatty acid pattern in the kidney, e.g. relative levels of the sum of 
saturated fatty acids, monounsaturated fatty acids, n6-PUFA and n3-PUFA 
(38.3%, 10.3%, 24.6% and 26.9% respectively), was comparable to the relative 
levels observed after 45 days of feeding the same diet to mice (38.1%, 13.0%, 
25.2% and 23.9% respectively) [22] indicating that a steady-state in the 
modulation of the kidney fatty acid composition by the feeding was reached 




after 14 days. This is also consistent with results from feeding fish oil to mice 
where a steady state of the PUFA status in heart and brain tissue was reached 
between 1 and 2 weeks [54]. Overall, feeding of the STD+n3 diet led to a 
massive elevation of absolute and relative levels of n3-PUFA (18:4 n3, 20:4 n3, 
20:5 n3, 22:5 n3, 22:6 n3) with simultaneous decrease in n6-PUFA (18:3 n6, 
20:2 n6, 20:3 n6, 20:4 n6, 22:4 n6, 22:5 n6) in the circulation and in the kidney. 
These changes are in line with previous reports showing extensive modulation 
of the PUFA composition in blood compartments and tissues by n3-PUFA 
feeding [22, 55-59] or by endogenous n3-PUFA accumulation in transgenic fat-1 
mice [22, 55, 60]. Compared to the STD chow, in response to the STD+n3 
feeding the relative content of the main long-chain PUFA ARA, EPA and DHA in 
the kidney changed from 16.4% to 8.6% (0.5-fold), 0.04% to 4.1% (99-fold) and 
10.1% to 21.0% (2-fold), respectively. Similar alterations in the renal fatty acid 
composition were also observed in mice and rats fed chow containing 1–3% 
each EPA and DHA (in each case in almost equal amount) [22, 56-58]. Relative 
levels in the kidney in response to STD+n3 are similar to earlier findings for 
n3-PUFA feeding in rodents ranging for EPA from 1–4.6% in mice and from 
5.2–9.7% in rats and for DHA from 6.7–24.6% in mice and from 5.5–7.8% in 
rats depending primarily on the diet composition (e.g. ratio of n3/n6-PUFA). The 
differences in relative renal levels of EPA and DHA between mice and rats 
mainly originate from differing PUFA compositions under basal conditions 
(steady-state without n3-PUFA supplementation) [61]. The relative renal PUFA 
composition in response to STD+n3 was similar to the relative amount in murine 
renal phospholipids, especially phosphatidylcholines (9.0–12.4% ARA, 2.3–
7.5% EPA and 10.0–18.1% DHA) observed after feeding fish oil supplemented 
chow [55, 59], reflecting that phospholipids as main membrane constituents are 
dominant lipids in the kidney [62, 63]. 
It should be noted, that the dietary supplementation by STD+n3 led to a more 
pronounced modulation of the n3-PUFA pattern compared to endogenous 
synthesis in transgenic fat-1 mice [22, 55]: The relative levels in transgenic fat-1 





of 11.3%, 0.7% and 12.9% in kidney phospholipids, respectively [55] reveal that 
relative levels reached by STD+n3 feeding are around 4.1-fold and 1.7-fold 
higher for EPA and DHA, respectively. 
The successful modulation of the endogenous n3-PUFA status by the feeding 
was also clearly indicated by the pronounced changes in %EPA+DHA levels in 
blood. In whole blood, which is dominated by the PUFA of erythrocytes, in 
response to the STD+n3 diet 3.7-fold higher levels of %EPA+DHA were 
observed compared to the STD diet (4.5 ± 0.1% in STD vs. 16.9 ± 0.3% in 
STD+n3). Extrapolating from mice to man, these concentrations reflect a very 
high endogenous n3-PUFA status, e.g. determined by the omega-3 index, i.e. 
the relative content of EPA+DHA in membranes of erythrocytes. With a value of 
16.9% the endogenous n3-PUFA levels reached in response to the STD+n3 
feeding are significantly higher than those which efficiently reduce overall 
mortality and the risk for cardiovascular diseases in men (i.e. an omega-3 index 
≥ 8) [20, 21]. In contrast, the STD diet reflects the “western-diet” causing a low 
omega-3 index, even in mice, which more efficiently convert short-chain 
n3-PUFA to long-chain n3-PUFA than men [64]. Thus, it can be concluded that 
the n3-PUFA feeding strategy used in this study reflects the maximal shift in the 
PUFA pattern which can be reached. On a side note, a well-described clinical 
effect of n3-PUFA is the reduction of serum triglyceride (TG) concentration [65, 
66]. Indeed, the total FA and thus TG concentration in whole blood was reduced 
in the animals receiving the STD+n3 compared to the STD diet (Fig. 5.2). 
It is believed that a major portion of beneficial effects of n3-PUFA are mediated 
by changes in the pattern of oxygenated PUFA, i.e. eicosanoids and other 
oxylipins [27, 29]. As eicosanoids exert important functions in renal 
(patho)physiology including regulation of renal blood flow, glomerular filtration 
rate and tubular transport function [34-37], modulation of the oxylipin pattern by 
n3-PUFA may also impact kidney function in renal IRI.  
Reflecting changes in the PUFA composition, the feeding strategy used in this 
study resulted in massive alterations of oxylipins in blood and renal tissue from 




all major formation pathways (COX, LOX, CYP as well as non-enzymatic): ARA 
derived eicosanoids were significantly decreased while EPA and DHA derived 
oxylipins were significantly elevated in response to STD+n3 feeding (Fig. 5.3). 
Reduction of ARA derived eicosanoids was similar in plasma and kidney (free 
and total) for all investigated pathways with 40–75% lower levels after STD+n3 
compared to STD feeding. Similarly, DHA derived oxylipins were 1.5–3-fold 
increased in the kidney, however a more pronounced elevation (7–12-fold) was 
observed for DHA derived products from 12/15-LOX as well as CYP in plasma. 
In contrast, EPA derived metabolites were increased to a greater extent (12–
53-fold) and in several cases were below the LLOQ in STD while clearly 
elevated in STD+n3 fed mice. These changes are overall consistent with earlier 
studies after n3-PUFA (EPA and DHA) supplementation in mice [13, 22, 55, 67-
70], rats [56, 67, 71-73] and humans [68, 74-76]. 
The strongest decrease was observed in kidney levels of ARA derived 
prostanoids, i.e. PGE2 (250 vs. 62 nmol/kg) and TxB2 (6.9 vs < 1.2 nmol/kg), 
and similar to earlier studies feeding EPA and DHA supplemented chow to mice 
[55, 67, 70]. Though respective EPA derived counterparts were simultaneously 
increased the resulting levels were considerably lower compared to their 
corresponding ARA derived prostanoids which is in line with their lower 
conversion rate by COX in addition to a simple PUFA competition [77]. 
Considering that EPA derived prostanoids are less bioactive, e.g. PGE3 
possesses less affinity towards EP receptors and exhibits lower potency 
regarding second messenger release [78] and also has been shown to cause 
less secretion of pro-inflammatory IL-6 [79] compared to PGE2, this clear shift in 
the renal prostanoid pattern suggests that STD+n3 can contribute to a lower 
inflammatory status. 
Regarding CYP derived metabolites a massive increase in levels of free 
terminal epoxy-PUFA derived from EPA and DHA, i.e. 17(18)-EpETE and 
19(20)-EpDPE, was observed especially in plasma, concomitant with a 





kidney and 1.3 vs 0.4 nM in plasma). Besides displacement of ARA by the 
n3-PUFA in response to the STD+n3 feeding this profound increase in 
n3-PUFA derived epoxy-PUFA can be explained by equal or higher conversion 
rates of DHA and EPA by several CYP isoforms in comparison to ARA [56, 80]. 
This marked elevation in n3-PUFA derived terminal epoxy-PUFA in plasma 
following STD+n3 feeding is similar to their clear increase observed in human 
plasma after fish oil supplementation [74, 81] supporting their ability to function 
as indicators for n3-PUFA supplementation as has been suggested [39]. 
Studies investigating the physiological role of epoxy-PUFA in the kidney are 
mainly focused on ARA derived EpETrE and comprise e.g. regulation of renal 
blood flow, inhibition of tubular sodium transport thereby promoting salt 
excretion, as well as anti-inflammatory effects [82]. Treatment of renal IRI in 
mice with an inhibitor of the soluble epoxide hydrolase have been shown to 
ameliorate kidney injury suggesting that epoxy-PUFA have beneficial effects on 
kidney function in renal IRI [83]. Similarly, n3-PUFA derived EpETE and EpDPE 
might impact renal physiology, e.g. owing to their higher potency regarding 
vasodilatory actions compared to EpETrE, as well as similar anti-inflammatory 
effects [82]. Regarding epoxy-PUFA, 19(20)-EpDPE reduced kidney fibrosis in 
a murine unilateral ureteral obstruction (UUO) model [84]. In contrast, in renal 
IRI administration of 19(20)-EpDPE led to aggravation of kidney damage while 
14(15)-EpETrE as well as DHA itself alleviated kidney injury in mice [85].  
In the past two decades, a class of multiple hydroxylated PUFA was proposed 
which actively terminate inflammation, so-called specialized pro-resolving 
mediators (SPM). From DHA, D-series resolvins as well as protectins and 
maresins are formed, while EPA gives rise to E-series resolvins [38]. Because 
of their low biological levels, these mediators are difficult to analyze [40]. 
Consistent with earlier reports [22, 67, 71] feeding of the n3-PUFA EPA and 
DHA led to a massive increase (2–9-fold) in the precursors of SPM, i.e. 
17-HDHA, 14-HDHA and 18-HEPE. For example, the 18-HEPE content in the 
kidney in the STD+n3 group was 9.7 nmol/kg while in the control group it was 
below the LLOQ (1 nmol/kg). However, except for PD1 all signals for SPM were 




below the LLOQ, i.e. in most cases below 2 nmol/kg kidney tissue. Thus, it has 
to be concluded that a 14-day feeding strategy with high n3-PUFA content (2%) 
does not increase the concentration of these mediators above 2 nmol/kg tissue 
or 0.56 nM blood. Either the SPM influence physiology in these picomolar, i.e. 
ppt (pg/g) concentrations or one has to conclude that they may not play a role in 
the physiological effects caused by n3-PUFA supplementation. 
The signals for free PD1 in the kidney in response to STD+n3 feeding are in a 
similar range to a previous report detecting PD1 after fish oil supplementation in 
mice undergoing renal IRI [13]. Analysis of total oxylipins in the kidney 
suggested even higher levels of PD1 (Fig. 5.6). As internationally agreed for 
LC-MS compound identification (e.g. for pesticides [86]), we evaluated two 
mass transitions, i.e. m/z 359  153 [13, 87-89] and m/z 359  206 [87, 90, 
91], which also have been previously used for PD1 detection. Particularly in the 
analysis of total PD1 in the kidney a massive divergence in the area ratio of 
these two transitions (compared to authentic PD1) was observed (Fig. 5.6). This 
clearly suggests that the signals result from isobaric interferences of the sample 
matrix and not from PD1 (Fig. 5.6). For free oxylipins in the kidney no signal 
was observed for m/z 359  206 and thus, it is even more clear that the signal 
of PD1 results from interfering matrix and not from the SPM. Isobaric 
interferences at the retention time of PD1 in reversed-phase HPLC at 
m/z 359  153 causing an apparent PD1 concentration also have been 
recently reported for plasma samples after storage [92]. By contrast, the relative 
intensities of the signals of the PD1-isomer PDX showed identical ratios for the 
authentic standard and biological samples (Fig. 5.6). Overall our data do not 
support the earlier described renal formation of PD1 in a mouse model of AKI 
following feeding a slightly lower dose of n3-PUFA (1.4% n3-PUFA in chow 






Fig. 5.6: Concentration of protectins (A) PD1 and (B) PDX quantified based on area 
analyte/area IS ratio on two different transitions for PD1 and PDX (m/z 359  153 and 
m/z 359  206) as free mediators in plasma and kidney as well as after alkaline hydrolysis in 
kidney. Shown are mean ± SEM. Means were only calculated when > 50% of the samples in the 
group were > LLOQ. The LLOQ is indicated as dashed line. For PD1 and PDX the area ratios 
resulting from both transitions were determined in authentic standard as well as in individual 
samples. Area ratios were calculated for every sample in which concentrations of both 
transitions were above LLOQ.  
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n3-PUFA are prone to oxidation and may lead to increased oxidative stress. 
Indeed, in humans receiving a very high dose of DHA (1.6 g/d) urinary 
15-F2t-IsoP, a marker of oxidative stress, was increased [93]. This could be 
even more important in ischemic injury were enhanced oxidative stress plays a 
key role in pathophysiology [6]. However, our data reveal, that the STD+n3 
group did not show elevated IsoP levels in the kidney as well as in plasma 
following IRI compared to the STD fed mice (Fig. 5.3, Fig. 5.7). Similarly, lower 
levels of the autoxidation marker malondialdehyde were observed after renal IRI 
in the kidney tissue of rats treated with n3-PUFA [11, 12]. However, to 
comprehensively investigate oxidative stress caused by IRI and its modulation 
by n3-PUFA supplementation further autoxidation parameters, such as 
8-hydroxyguanosine, glutathione, 4-hydroxy-nonenal and expression of 
(anti)oxidative stress response genes should be monitored in the future. 
 
Fig. 5.7: Concentration of (A) free isoprostanes (IsoP) in plasma and (B) total IsoP following 
alkaline hydrolysis in kidney tissue. Shown are levels of selected IsoP derived from ARA, EPA 
and DHA, i.e. 5(R,S)-5-F2t-IsoP, 5(R,S)-5-F3t-IsoP and 4(R,S)-4-F4t-NeuroP, respectively. The 
lower limit of quantification (LLOQ) is indicated by a dashed grey line in case it was not 
exceeded in > 50% of the samples per group. Statistical differences between STD and STD+n3 
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Altogether feeding of STD+n3 led to a maximal modulation of n3-PUFA and its 
lipid mediators dominated by n3-PUFA derived oxylipins. Thus, the feeding 
strategy allows to evaluate the effects of maximal dietary n3-PUFA modulation 
based on a western diet on acute kidney injury.  
Despite the clear effects on oxylipins the STD+n3 diet did not result in an 
improvement of the overall renal function or reduction of pro-inflammatory 
cytokine production or leukocyte infiltration 24 h after IRI. However, there were 
measurable effects on protective molecular mechanisms such as up-regulation 
of HO-1. It has been shown that HO-1 fosters renal regeneration and healing in 
several models of renal injury [45, 94, 95]. In addition, the tubular transport 
function which depends on intact energy metabolism of the tubuli was 
preserved as shown by A1M staining. There was a direct correlation in previous 
studies between higher A1M expression and less tissue edema measured by 
functional MRI [49]. In the current study there was also less ALT elevation 
which is a marker for impaired liver function. It is well known that AKI causes 
distant organ injury via enhanced leukocyte infiltration into other organs such as 
liver, lung, brain, gut [51, 96]. Mechanisms are multifactorial such as release of 
cytokines and inflammatory mediators, increase in oxidative stress, activation of 
various immune cells, neutrophil extravasation, generalized endothelial injury, 
increased vascular permeability and tissue edema formation [97]. In a mouse 
model of liver IRI also beneficial effects with less tissue damage have been 
attributed to n3-PUFA treatment [98]. It is conceivable that the moderate 
beneficial effects could improve patient outcome in longer follow-up by reducing 
the general inflammatory status.  
In a previous study on renal IRI beneficial effects of dietary n3-PUFA 
supplementation have been reported in mice [13]. However, the severity of AKI 
might differ between the studies. In the study by Hassan et al. creatinine 
elevation was only 2–3-fold which is less than in our study (6-fold) and might 
reflect a milder AKI model. In the clinical context interesting and relevant 
benefits from n3-PUFA diets were observed, e.g. they seemed to reduce 




cardiovascular mortality in patients with chronic kidney disease [99]. In addition, 
another study showed that n3-PUFA reduced blood pressure and triglyceride 
levels in patients with CKD stage 3–4 in a placebo-controlled intervention study 
[100]. Since AKI has a high risk of progression to CKD there might be later 
beneficial effects on clinical outcome which are missed by the nature of the 
current study design with a 24-hour follow-up. Further investigations with in-
depth analysis of oxylipin levels also at later time points of disease progression 
might be of interest and shall be addressed in the future. 
 Conclusion 
In the present study supplementation of a western-style, i.e. linoleic acid rich 
diet with the long-chain n3-PUFA EPA and DHA led to a pronounced 
modulation of the PUFA and oxylipin pattern. However, in a murine model of 
moderate AKI pre-feeding of n3-PUFA did not attenuate renal function 
impairment, morphological renal damage and inflammation characterized by 
pro-inflammatory cytokine (IL-6 and MCP-1) mRNA up-regulation and neutrophil 
infiltration. However, also beneficial effects were seen such as preservation of 
tubular transport function indicated by enhanced alpha-1 microglobulin (A1M) 
expression in cortical proximal tubular epithelial cells and enhanced up-
regulation of tubular heme oxygenase-1 (HO-1) expression which has been 
correlated to improved renal regeneration [45]. Thus n3-PUFA supplementation 
might lead to renal protection with respect to long-term damage. 
Overall it is concluded that – despite a maximal elevation of endogenous 
n3-PUFA and n3-PUFA derived oxylipin levels – n3-PUFA supplementation did 
not result in attenuation of renal function impairment or acute kidney injury 
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6 Chapter 6 
Concluding Remarks and Future Perspectives 
Within this thesis, the analytical and pre-analytical basis for a comprehensive 
analysis of oxylipins in biological samples has been established. The presented 
targeted LC-ESI(-)-MS/MS method is one of the most comprehensive methods 
for the analysis of oxylipins allowing the parallel quantification of a wide range of 
both, enzymatically and non-enzymatically formed oxylipins from the major 
biologically relevant n6- and n3-PUFA (chapter 2). However, considering their 
endogenous origin and the interaction of their formation pathways, a multitude 
of structurally distinct oxylipins can be formed of which only a part is analytically 
covered. While some oxylipins are only short-lived and rather unstable, others 
will be unveiled in the future. Continuing adaption and extension of the 
instrumental analytical method, thus allowing to monitor effects on different 
formation pathways in parallel, is therefore essential to improve our 
understanding about the physiological roles of oxylipins. Analysis of potent 
unstable oxylipins which are rapidly transformed in the organism may be 
facilitated by determining their stable metabolites such as commonly carried out 
for thromboxane (Tx)B2 used as a surrogate for the formation of unstable TxA2. 
Particularly the multitude of possible regio- and stereoisomeric IsoP formed 
during autoxidation complicates their analysis as only a few ARA derived IsoP 
are commercially available. Thus, most of the IsoP und IsoF standards covered 
by the described LC-MS/MS method are only available through tight 
collaboration with organic chemists finding new synthetic pathways to generate 
authentic oxylipin standards. Analysis of samples related to oxidative stress 
may contribute to the discovery and elucidation of the structure of new 
autoxidation products and thus enable the identification of individual compounds 





innovative techniques such as untargeted oxylipin analysis in combination with 
chemical networking may facilitate the discovery of previously unknown 
oxylipins [1]. About 20 years ago a new class of autacoids, the so-called 
specialized pro-resolving mediators (SPM) was unveiled which are today 
controversially discussed with respect to their presence in biological samples. In 
order to contribute to the understanding of their physiological role the described 
targeted LC-MS/MS method (chapter 2) was further extended during the course 
of this thesis by a comprehensive set of SPMs comprising lipoxins, resolvins, 
protectins and maresins [2].  
The multitude of stereoisomers, particularly of multiple hydroxylated PUFA, is a 
major challenge for their analysis. Parallel detection of two SRM transitions for 
the dihydroxy-DHA stereoisomers (N)PD1 and PDX (10R,17S-dihydroxy-E,E,Z-
docosahexaenoic acid and 10S,17S-dihydroxy-E,Z,E-docosahexaenoic acid, 
respectively) revealed a clear deviation of the area ratio of both transitions for 
(N)PD1 in kidney tissue compared to the authentic (N)PD1 standard, even 
though the retention time matched with the authentic standard (chapter 5). 
Determination of multiple SRM transitions, or full MS/MS spectra and the ratios 
of the fragments is therefore indispensable to recognize isobaric interferences 
and to support the identification of individual oxylipins preventing misleading 
assignments. Moreover, use of orthogonal chromatographic techniques as well 
as application of chiral chromatography may allow to support the structural 
identification and additionally to gain information about their formation route.  
Thus, the development of analytical methods in the field of oxylipins is an 
ongoing process and permanent challenge which requires on the one hand to 
constantly adapt and extend the covered analytes regarding the discovery of 
new oxylipins and on the other hand the awareness of potential isobaric 
interferences impeding reliable qualification and quantification. 
A key aspect for the oxylipin analysis in biological samples is their pre-analytical 
(in)stability. The investigation of the free and the total (i.e. sum of free and 
esterified) oxylipin profile in plasma and serum generated from stored or 




transported whole blood prior to processing provided important data for the 
characterization of the pre-analytical variability in clinical samples to evaluate 
their suitability in biomarker research (chapter 3). Levels of total oxylipins in 
plasma were almost stable and only platelet derived oxylipins were susceptible 
to changes after prolonged storage or transport of whole blood emphasizing 
that the determined concentrations of these analytes need to be interpreted with 
caution. Based on this finding within this thesis, the total oxylipin pattern in 
plasma is currently analyzed in a large prospective cohort study to assess the 
role of oxylipins in the development and progression of the metabolic syndrome. 
However, the high analytical variance observed for total oxylipin levels in 
plasma suggests that a rather high number of subjects and samples (n) is 
necessary to deduce physiological features from the determined oxylipin 
pattern. 
A central focus within this thesis is the investigation of trans-epoxy-PUFA 
formation in response to autoxidation and oxidative stress. Clear correlations of 
the trans/cis-epoxy-PUFA ratio with the autoxidatively formed IsoP in response 
to tert-butyl hydroperoxide as inducer of oxidative stress were found in multiple 
models ranging from different cell lines with various origin (colorectal, renal and 
hepatic carcinoma cells) to the model organism Caenorhabditis elegans 
(chapter 4). This suggests the use of the trans/cis-epoxy-PUFA ratio as 
promising marker for autoxidation which warrants further investigation. Based 
on their separation in reversed-phase chromatography trans-epoxy-PUFA 
isomers can be easily analyzed in parallel with their respective cis-epoxy-PUFA 
isomers allowing their facile acquisition if the respective cis-epoxy-PUFA are 
already determined.  
The absence of effects on the trans/cis-epoxy-PUFA ratio in the in vivo model of 
renal ischemia reperfusion injury might indicate that the used model is not 
associated with strong oxidative stress and lipid peroxidation. In order to obtain 
more insights in the role of epoxy-PUFA during oxidative stress further studies 





oxidative stress (e.g. CCl4, paraquat) with respect to the mechanism by which 
they elicit (aut)oxidative effects. Furthermore, parallel analysis of additional 
oxidative stress markers other than those resulting from lipid peroxidation, e.g. 
GSH/GSSG, 8-hydroxyguanosine, may be valuable to support the role of 
epoxy-PUFA in oxidative stress. Moreover, the evaluation of lipoproteins, e.g. 
VLDL, for the presence of trans-epoxy-PUFA which could indicate oxidative 
stress in the liver based on plasma analysis would be of scientific interest. 
The formation of epoxy-PUFA during autoxidative processes is also supported 
by our recent observations that apparent cis-epoxy-PUFA levels in hydrolyzed 
samples are clearly increased after SPE on silica-based material if cartridges 
are dried for longer time periods [3]. Here, massive amounts of free PUFA 
released after alkaline hydrolysis may attach on incompletely endcapped silica 
surfaces with their carboxy-terminus, thus maintaining the arrangement of their 
cis-oriented double bonds and enabling generation of cis-epoxy-isomers via 
nearby hydroperoxy-PUFA radicals particularly during drying processes [3, 4].  
A main part of this thesis focused on the anti-inflammatory properties and 
physiological effects of n3-PUFA. Based on the analysis of PUFA and oxylipins 
in combination with functional and inflammatory parameters as well as 
(immuno)histology, the efficacy of n3-PUFA in an in vivo murine model of 
oxidative stress and inflammation was investigated (chapter 5). Renal ischemia 
reperfusion injury (IRI), a common model for solid organ transplantation, is 
associated with renal function impairment. Moreover, it resembles the acute 
kidney injury which could occur during long surgeries such as cardiac surgery. 
Supplementation of long-chain n3-PUFA on a diet with a relatively high 
n6-PUFA background reflecting a typical western diet resulted only in minor 
effects on kidney function deterioration even though maximal modulation of 
n3-PUFA and their oxylipins were observed. However, n3-PUFA led to an 
improved tubular function 24 h after reperfusion. If this leads to an improved 
kidney function at later time points remains to be elucidated. Nevertheless, the 
increase of neutrophil infiltration and cytokines in spite of high n3-PUFA levels 




suggest that shifting the fatty acid and oxylipin pattern seems not be sufficient to 
reduce IRI induced inflammation and preserve kidney function. Overall, 
translating these findings to humans suggests that dietary supplementation prior 
to surgery and clamping of the renal pedicle might only be little helpful in 
preventing renal function impairment.  
Despite this on the first view disappointing finding, in cardiovascular diseases 
the dietary intake of long-chain n3-PUFA is clearly correlated with beneficial 
effects. Taken together, the results from the in vivo studies (chapter 4+5) 
indicate that the physiological effects and functions of PUFA and oxylipins in the 
organism are complex and far from being completely understood. Moreover, as 
observed for the acute formation of IsoP in the oxidative stress models 
(chapter 4), levels of oxylipins may show distinct time dependent changes. 
Thus, if only a single time point is chosen for analysis, this has to be carefully 
considered to ensure meaningful results.  
Overall, based on the comprehensive determination of oxylipins combining their 
role as indicators of oxidative stress and the n3-PUFA status with their 
functional readout regarding biological activity, this thesis contributes to a better 
understanding of the role of oxylipins in (patho)physiology. 
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Oxidative metabolites of polyunsaturated fatty acids (PUFA) – oxylipins – are 
potent lipid mediators involved in the regulation of various physiological 
functions and dysregulation of oxylipin formation has been associated with the 
pathophysiology of multiple diseases. Although the physiological impact of the 
overall oxylipin pattern is still only poorly understood, this dual role of oxylipins 
being on the one hand formed in response to (patho)physiological stimuli and 
mediating on the other hand a wide range of biological processes represents a 
promising feature for their use as functional biomarkers. Thus, the present 
thesis aims to advance the understanding of this functional role of oxylipins  
i. by improving the performance of their analysis in terms of expanding the 
analytical scope and characterizing the impact of clinical sample handling 
ii. by investigating their formation under conditions of oxidative stress and 
inflammation 
In the first part of this thesis analytical and preanalytical requirements for a 
comprehensive and reliable oxylipin quantification were established. For this 
purpose, the focus was set on the development of a reversed-phase 
LC-ESI(-)-MS/MS method for the determination of stable autoxidation products 
with prostaglandin-like structure considered as markers of oxidative stress, 
namely isoprostanes (IsoP) and isofurans (IsoF) (chapter 2). Integration of a 
broad set of products from the major n6- and n3-PUFA (27 IsoP and 8 IsoF 
from 6 biologically relevant PUFA) offers the opportunity to analyze their 
formation during oxidative stress in samples with varying PUFA composition. 
Characteristic fragment ions resulting from α-fragmentation adjacent to the 
hydroxyl-group in the side chain were chosen to guarantee the selective 





(SRM) mode. The implementation of a short isocratic step at the beginning of 
the gradient focusing the analytes at the front end of the column resulted in 
narrow peaks and thereby improved chromatographic resolution. In this way, 
the differentiation of most diastereomers, which show an identical fragmentation 
behavior, was achieved. Using mixed-mode C8 and anion-exchange solid 
phase extraction (SPE) material for sample preparation, extraction efficiency of 
internal standards from plasma, as well as intra- and inter-day accuracy and 
precision of IsoP and IsoF spiked in plasma samples were appropriate for their 
reliable quantification evaluated based on criteria for bioanalytical method 
validation. Through combination with an existing targeted oxylipin LC-MS/MS 
platform the developed method allows the sensitive and simultaneous 
quantification of a broad set of 164 enzymatically and non-enzymatically formed 
oxylipins from all formation branches and biologically relevant PUFA within 
30.5 min. This analytical approach is currently one of the most comprehensive 
targeted methods for oxylipin analysis with comparable or even higher 
sensitivity, making oxylipin quantification in biological samples in subnanomolar 
concentrations possible. 
However, (inappropriate) pre-analytical handling of biological samples could 
cause artificial alterations of endogenous oxylipin levels after sampling, thus 
affecting their reliable interpretation. In order to evaluate the suitability of clinical 
blood specimen for oxylipin analysis, the influence of typical procedures in 
clinical routine on the oxylipin profile, i.e. storage or pneumatic tube transport of 
whole blood prior to plasma or serum generation, was thoroughly characterized 
(chapter 3). Analysis of free and total (i.e. sum of free and esterified) oxylipins in 
plasma and serum revealed that platelet derived (12-LOX and COX) 
metabolites, were most susceptible to artificial formation during storage or 
transport, while dihydroxy- and epoxy-PUFA as well as IsoP were almost stable 
under the investigated storage / transport conditions. Changes in serum were 
more pronounced with particularly platelet derived oxylipins showing high inter-
individual variations. Notably, automated transport clearly increased levels of 





levels of total oxylipins were more stable than free oxylipins. Thus, for oxylipin 
analysis in clinical blood samples, the total plasma oxylipin profile, being almost 
stable after whole blood storage at 4 °C up to 24 h, seems to be most suitable. 
In the second part of this thesis oxylipin formation in the context of oxidative 
stress as well as inflammation was investigated applying the analytical 
approach developed in chapter 2. 
The presence of a second peak on the SRM transitions of epoxy-PUFA 
regioisomers – particularly in aged PUFA stocks – directed the attention 
towards the autoxidative formation of these tentatively identified trans-epoxy-
PUFA isomers. The suitability of the trans/cis-epoxy-PUFA ratio as potential 
alternative oxidative stress marker was therefore characterized based on 
correlation with IsoP applying a tiered approach using (i) tert-butyl 
hydroperoxide (t-BOOH) as inducer of oxidative stress in three human 
carcinoma cell lines (from colorectal, hepatic and renal origin) as well as in (ii) 
the in vivo model organism C. elegans and (iii) renal ischemia reperfusion injury 
in mice (chapter 4). In all investigated cell lines as well as in C. elegans, 
t-BOOH treatment led to a dose dependent increase in IsoP and trans-epoxy-
PUFA levels. Regarding incubation time, the different cell lines showed a 
distinct time dependent pattern which was consistent for these two oxylipin 
classes within each cell line. In murine kidney tissue after renal ischemia 
reperfusion injury no effects on epoxy-PUFA were observed. Nevertheless, 
clear and highly significant correlations of the trans/cis-epoxy-PUFA ratio with 
the IsoP levels in the investigated cell lines of different origin and in C. elegans 
suggest its potential use as marker of lipid peroxidation which can easily be 
assessed in parallel when enzymatically formed cis-epoxy-PUFA are already 
monitored by the RP-LC-MS/MS method and warrants further investigation.  
Considering the described anti-inflammatory properties of long-chain n3-PUFA, 
the effectivity of dietary n3-PUFA supplementation of a western-like diet on 
preserving kidney function after renal ischemia reperfusion injury was evaluated 





characterized by temporal occlusion and subsequent reperfusion of the renal 
blood flow and is a model for oxidative stress and inflammation. Moreover, this 
model also reflects processes occurring during solid organ transplantation. 
n3-PUFA pre-feeding resulted in maximal modulation of the PUFA and oxylipin 
pattern towards n3-PUFA and their oxylipins in blood and kidney, with particular 
increase in levels of terminal epoxy-PUFA and precursors of specialized pro-
resolving mediators, e.g. 18-HEPE and 17-HDHA at the dispense of n6-PUFA 
and their oxylipins. However, the overall impaired kidney function, renal 
morphological damage and inflammation was similar to mice not receiving 
n3-PUFA. Nevertheless, n3-PUFA fed mice showed beneficial effects on tubular 






Tab. 8.1: List of all internal standards used for the quantification of oxylipins with their 
LC-ESI(-)-MS/MS parameters. Shown are the mass transitions for quantification in scheduled 
SRM mode, electronical MS parameters (declustering potential (DP), entrance potential (EP), 
collision energy (CE), collision cell exit potential (CXP)), and retention time (tR). 
Analyte  Mass transition MS parameters tR 
  Q1 Q3 DP EP CE CXP [min] 
C19-17-epi-17-F1t-PhytoP 341.3 239.0 −70 −10 −35 −8 6.02 
2H4-6-keto-PGF1α 373.3 167.1 −80 −10 −36 −8 6.10 
2H4-15-F2t-IsoP 357.2 196.8 −50 −6 −33 −8 7.54 
2H4-TxB2 373.3 173.2 −65 −10 −24 −8 7.64 
2H11-5(R,S)-5-F2t-IsoP 364.3 115.2 −40 −10 −29 −10 7.97 
2H4-PGE2 355.2 275.3 −60 −10 −25 −6 8.93 
C21-15-F2t-IsoP 367.2 193.1 −60 −10 −35 −8 9.18 
2H4-PGD2 355.2 275.3 −60 −10 −25 −6 9.43 
2H4-LTB4 339.2 197.2 −65 −10 −23 −9 14.00 
2H4-9,10-DiHOME 317.2 203.4 −80 −10 −29 −8 15.13 
2H11-14,15-DiHETrE 348.2 207.1 −65 −10 −25 −10 15.83 
2H6-20-HETE 325.2 295.2 −70 −10 −24 −6 18.31 
2H4-9-HODE 299.2 172.3 −80 −10 −26 −6 19.69 
2H8-12-HETE 327.2 184.2 −65 −10 −22 −8 21.20 
2H8-5-HETE 327.2 116.1 −60 −10 −21 −8 21.75 
2H11-14(15)-EpETrE 330.2 219.3 −65 −10 −20 −4 22.48 























Tab. 8.2 (right, page 149): Parameters of the combined LC-ESI(-)-MS/MS method for the 
quantification of non-enzymatically and enzymatically formed oxylipins. Shown are the mass 
transitions for quantification in scheduled SRM mode, electronical MS parameters (declustering 
potential (DP), entrance potential (EP), collision energy (CE), collision cell exit potential (CXP)), 
the assigned internal standards (IS), retention time (tR), full peak width at half maximum 
(FWHM), limit of detection (LOD), the calibration range (lower limit of quantification (LLOQ), 


















Analyte Mass transition MS parameters Internal standard tR 1) FWHM 2) LOD 3) Calibration range r 6) 
        [min] [sec] [nM] 
[pg on 
column] 
LLOQ 4) ULOQ 5)  
 Q1 Q3 DP EP CE CXP      [nM]  
20-OH-PGE2 367.2 189.1 -30 -10 -25 -8 2H4-PGE2 3.68 3.4 0.10 0.18 0.25 500 0.9986 
ent-16(R,S)-13-epi-ST-Δ14-9- 
PhytoF 1 
343.1 200.9 -80 -10 -33 -8 C19-17-epi-17-F1t-PhytoP 4.19 3.4 0.12 0.20 0.24 235 0.9993 
ent-16(R,S)-13-epi-ST-Δ14-9- 
PhytoF 2 
343.1 200.9 -80 -10 -33 -8 C19-17-epi-17-F1t-PhytoP 4.30 3.4 0.13 0.23 0.26 265 0.9995 
ent-16-epi-16-F1t-PhytoP 327.3 225.0 -70 -10 -34 -8 C19-17-epi-17-F1t-PhytoP 4.72 3.3 0.25 0.41 0.5 500 0.9983 
ent-16-F1t-PhytoP 327.3 225.0 -70 -10 -34 -8 C19-17-epi-17-F1t-PhytoP 4.89 3.4 0.50 0.82 1.0 500 0.9997 
ent-9-F1t-PhytoP 327.3 170.9 -40 -10 -31 -8 C19-17-epi-17-F1t-PhytoP 4.81 3.3 0.10 0.16 0.25 500 0.9991 
ent-9-epi-9-F1t-PhytoP 327.3 170.9 -40 -10 -31 -8 C19-17-epi-17-F1t-PhytoP 4.98 3.3 0.25 0.41 0.5 500 0.9990 
Δ17-6-keto-PGF1α 367.2 163.2 -40 -10 -36 -10 2H4-6-keto-PGF1α 4.99 21 0.50 0.92 1.0 500 0.9938 
2,3-dinor-TxB1 343.0 142.9 -30 -10 -19 -8 2H4-TxB2 5.11 4.1 2.0 3.4 5.0 500 0.9961 
15(R,S)-2,3-dinor-15-F2t-IsoP 325.2 237.0 -40 -10 -18 -8 C19-17-epi-17-F1t-PhytoP 5.41 3.3 0.25 0.41 0.5 500 0.9995 
2,3-dinor-TxB2 341.2 167.0 -40 -10 -15 -8 2H4-TxB2 5.59 3.8 0.50 0.86 1.0 500 0.9971 
6-keto-PGF1α 369.3 163.2 -70 -10 -36 -6 2H4-6-keto-PGF1α 6.10 24 0.90 1.7 1.8 500 0.9937 
8-F3t-IsoP 351.1 155.0 -60 -10 -27 -8 C19-17-epi-17-F1t-PhytoP 6.15 3.6 0.50 0.88 1.0 500 0.9980 
8-epi-8-F3t-IsoP 351.1 155.0 -60 -10 -27 -8 C19-17-epi-17-F1t-PhytoP 6.51 3.3 0.50 0.88 1.0 500 0.9992 
RvE1 349.3 195.0 -65 -10 -22 -10 2H4-TxB2 6.21 3.5 0.60 1.1 1.2 480 0.9947 
20-COOH-LTB4 365.2 347.2 -80 -10 -25 -8 2H4-TxB2 6.25 3.8 0.50 0.92 1.0 40 0.9619 
TxB3 367.3 169.3 -70 -10 -34 -8 2H4-TxB2 6.51 3.5 0.10 0.18 0.25 100 0.9976 
20-OH-LTB4 351.2 195.2 -80 -10 -25 -8 2H4-PGD2 6.52 3.3 0.10 0.18 0.25 40 0.9984 
5(R,S)-5-F3t-IsoP 351.2 114.9 -50 -10 -27 -8 C19-17-epi-17-F1t-PhytoP 6.53 3.4 1.0 1.8 2.0 500 0.9962 






























































Analyte Mass transition MS parameters Internal standard tR 1) FWHM 2) LOD 3) Calibration range r 6) 
        [min] [sec] [nM] 
[pg on 
column] 
LLOQ 4) ULOQ 5)  
 Q1 Q3 DP EP CE CXP      [nM]  
TxB1 371.3 171.2 -70 -10 -34 -10 2H4-TxB2 7.36 3.9 0.25 0.47 0.5 100 0.9982 
15-F2t-IsoP (8-iso-PGF2α) 353.1 193.1 -70 -6 -33 -8 2H4-15-F2t-IsoP 7.56 3.7 0.25 0.44 0.5 500 0.9989 
TxB2 369.2 169.1 -60 -10 -25 -7 2H4-TxB2 7.68 3.8 0.25 0.46 1.3 500 0.9949 
11-dehydro-TxB3 365.3 161.2 -30 -10 -25 -8 2H4-TxB2 7.75 3.6 0.50 0.92 1.0 100 0.9969 
PGE3 349.3 269.2 -60 -10 -22 -6 2H4-PGE2 7.76 3.5 0.15 0.26 0.3 120 0.9995 
11β-PGF2α 353.3 193.1 -30 -12 -36 -12 2H4-PGE2 7.84 3.3 0.25 0.44 0.5 500 0.9952 
10-F4t-NeuroP 377.2 153.0 -40 -10 -25 -8 2H4-15-F2t-IsoP 8.04 3.3 0.25 0.47 0.5 500 0.9989 
10-epi-10-F4t-NeuroP 377.2 153.0 -40 -10 -25 -8 2H4-15-F2t-IsoP 8.37 3.5 0.50 0.95 1.0 500 0.9990 
5(R,S)-5-F2t-IsoP (5-iPF2α-VI) 353.2 114.8 -60 -10 -26 -8 2H11-5(R,S)-5-F2t-IsoP 8.07 3.5 0.25 0.44 0.5 500 0.9959 
PGD3 349.3 269.2 -60 -10 -22 -6 2H4-PGD2 8.15 3.4 0.50 0.88 1.0 40 0.9992 
16-B1-PhytoP 307.3 235.0 -60 -10 -27 -8 2H11-5(R,S)-5-F2t-IsoP 8.26 3.7 0.10 0.15 0.25 500 0.9994 
9-L1-PhytoP 307.3 185.1 -60 -10 -27 -8 2H11-5(R,S)-5-F2t-IsoP 8.33 3.7 0.10 0.15 0.25 500 0.9986 
PGF2α 353.2 309.2 -80 -10 -26 -7 2H4-PGE2 8.59 3.5 0.35 0.62 0.70 281 0.9991 
14(R,S)-14-F4t-NeuroP 377.2 205.1 -50 -10 -27 -8 C21-15-F2t-IsoP 8.62 6.5 10 19 20 500 0.9998 
PGF1α 355.4 293.2 -90 -12 -36 -6 2H4-PGE2 8.63 3.5 0.10 0.18 0.25 500 0.9985 
PGE2 351.2 271.3 -60 -10 -24 -6 2H4-PGE2 8.98 3.5 0.10 0.18 0.25 500 0.9982 
11-dehydro-TxB2 367.0 161.1 -50 -10 -27 -8 2H4-TxB2 9.08 3.7 0.25 0.46 0.50 100 0.9988 
PGE1 353.3 317.2 -60 -10 -20 -6 2H4-PGE2 9.27 3.6 0.13 0.23 0.33 260 0.9984 
4(R,S)-4-F4t-NeuroP 377.1 101.3 -60 -10 -26 -8 C21-15-F2t-IsoP 9.35 3.8 0.50 0.95 1.0 500 0.9982 



































































Analyte Mass transition MS parameters Internal standard tR 1) FWHM 2) LOD 3) Calibration range r 6) 
        [min] [sec] [nM] 
[pg on 
column] 
LLOQ 4) ULOQ 5)  
 Q1 Q3 DP EP CE CXP      [nM]  
PGD2 351.2 271.3 -60 -10 -24 -6 2H4-PGD2 9.46 3.6 0.50 0.88 1.0 500 0.9960 
15-keto-PGF1α 353.3 193.1 -40 -12 -38 -6 2H4-PGE2 9.54 3.7 0.10 0.18 0.25 500 0.9970 
4(R,S)-ST-Δ5-8-NeuroF 393.3 187.2 -40 -10 -29 -8 C21-15-F2t-IsoP 9.59 4.2 20 39 40 500 0.9941 
17(R,S)-17-F2t-dihomo-IsoP 1  381.3 263.2 -90 -10 -31 -8 C21-15-F2t-IsoP 9.78 3.6 0.63 1.2 1.3 314 0.9967 
17(R,S)-17-F2t-dihomo-IsoP 2 381.3 263.2 -90 -10 -31 -8 C21-15-F2t-IsoP 9.95 3.2 0.37 0.71 0.75 186 0.9980 
7(R,S)-ST-Δ8-11-dihomo-IsoF 397.3 245.1 -50 -10 -31 -8 C21-15-F2t-IsoP 9.81 3.8 1.0 2.0 2.0 500 0.9993 
ent-7(R,S)-7-F2t-dihomo-IsoP 381.3 143.0 -50 -10 -31 -8 C21-15-F2t-IsoP 9.86 5.7 0.25 0.48 0.50 500 0.9972 
11,12,15-TriHETrE 353.2 167.1 -80 -10 -28 -10 2H4-PGE2 10.20 3.4 0.25 0.44 0.50 100 0.9988 
LXA4 351.2 115.2 -60 -10 -21 -8 2H4-PGE2 10.23 3.7 0.088 0.15 0.18 70 0.9985 
RvD1 375.3 141.0 -50 -10 -20 -8 2H4-PGE2 10.35 3.6 0.10 0.19 0.25 100 0.9993 
13,14-dihydro-15-keto-PGF2α 353.3 183.3 -80 -10 -36 -10 2H4-PGE2 10.41 3.6 0.25 0.44 0.50 500 0.9990 
13,14-dihydro-15-keto-PGE1 353.3 221.2 -40 -6 -30 -6 2H4-PGE2 10.97 4.5 0.25 0.44 0.50 500 0.9989 
dihomo-PGF2α 381.4 221.1 -60 -10 -38 -10 2H4-PGE2 11.01 3.8 0.025 0.048 0.10 500 0.9977 
4(R,S)-4-F3t-NeuroPn6 379.2 273.0 -50 -10 -27 -8 C21-15-F2t-IsoP 11.03 4.1 0.50 0.95 1.0 500 0.9971 
17(R,S)-10-epi-SC-Δ15-11-dihomo-IsoF 1 397.1 221.0 -90 -10 -31 -8 C21-15-F2t-IsoP 11.26 3.7 0.52 1.0 1.0 260 0.9992 
17(R,S)-10-epi-SC-Δ15-11-dihomo-IsoF 2 397.1 221.0 -90 -10 -31 -8 C21-15-F2t-IsoP 11.44 3.7 0.48 0.96 0.96 240 0.9982 
RvE2 333.2 253.3 -60 -10 -20 -9 2H4-PGE2 11.42 3.7 1.0 1.7 2.0 100 0.9991 
PGJ2 333.3 189.2 -60 -10 -25 -8 2H4-PGE2 12.02 3.8 0.80 1.3 1.6 160 0.9957 
Δ12-PGJ2 333.1 189.0 -40 -10 -22 -8 2H4-PGE2 12.09 4.0 0.50 0.84 1.0 500 0.9986 































































Analyte Mass transition MS parameters Internal standard tR 1) FWHM 2) LOD 3) Calibration range r 6) 
        [min] [sec] [nM] 
[pg on 
column] 
LLOQ 4) ULOQ 5)  
 Q1 Q3 DP EP CE CXP      [nM]  
PGB2 333.3 175.1 -60 -10 -28 -8 2H4-PGE2 12.13 4.0 0.20 0.33 0.40 800 0.9982 
THF diol 353.2 127.1 -80 -10 -32 -8 2H4-LTB4 12.27 4.0 0.13 0.22 0.25 100 0.9987 
18(S)-RvE3 333.2 201.3 -60 -10 -20 -9 2H4-PGE2 12.78 4.1 0.50 0.84 1.0 100 0.9976 
12-OH-17(18)-EpETE 333.1 179.3 -65 -10 -20 -6 2H4-9,10-DiHOME 12.85 4.3 0.25 0.42 0.50 100 0.9992 
15,16-DiHODE 311.2 223.2 -80 -10 -29 -10 2H4-9,10-DiHOME 12.99 4.3 0.50 0.78 1.0 80 0.9992 
9,10-DiHODE 311.2 201.2 -65 -10 -27 -10 2H4-9,10-DiHOME 13.05 4.2 0.10 0.16 0.20 80 0.9998 
12,13-DiHODE 311.2 183.1 -80 -10 -30 -8 2H4-9,10-DiHOME 13.15 4.3 0.50 0.78 1.0 80 0.9990 
8,15-DiHETE 335.2 235.2 -65 -10 -22 -4 2H11-14,15-DiHETrE 13.17 4.0 0.40 0.67 0.80 80 0.9981 
10(S),17(S)-diH n3 DPA 361.3 262.9 -40 -10 -23 -8 2H4-9,10-DiHOME 13.36 4.3 0.50 0.91 1.0 500 0.9991 
18(R)-RvE3 333.2 201.3 -60 -10 -20 -9 2H4-PGE2 13.45 4.2 0.25 0.42 0.50 100 0.9960 
NPD1 359.0 153.0 -50 -10 -21 -8 2H4-9,10-DiHOME 13.49 4.2 0.25 0.45 0.50 500 0.9985 
6-trans-LTB4 335.2 195.1 -65 -10 -23 -9 2H4-LTB4 13.58 4.2 0.25 0.42 0.50 200 0.9984 
5,15-DiHETE 335.3 173.2 -60 -10 -21 -8 2H11-14,15-DiHETrE 13.60 4.0 0.13 0.21 0.25 100 0.9984 
17,18-DiHETE 335.3 247.2 -65 -10 -24 -8 2H11-14,15-DiHETrE 13.71 4.3 0.13 0.21 0.25 100 0.9978 
LTB4 335.2 195.1 -65 -10 -23 -9 2H4-LTB4 14.07 4.3 0.10 0.17 0.25 200 0.9996 
7(S),17(S)-diH n3 DPA 361.5 263.3 -65 -10 -20 -4 2H4-9,10-DiHOME 14.29 3.8 0.30 0.54 0.75 500 0.9989 
14,15-DiHETE 335.3 207.2 -65 -10 -25 -10 2H11-14,15-DiHETrE 14.34 4.5 0.13 0.21 0.25 100 0.9992 
11,12-DiHETE 335.2 167.1 -65 -10 -26 -5 2H11-14,15-DiHETrE 14.57 4.6 0.13 0.21 0.25 100 0.9977 
12,13-DiHOME 313.2 183.2 -80 -10 -30 -8 2H4-9,10-DiHOME 14.76 4.7 0.25 0.39 0.50 200 0.9986 



































































Analyte Mass transition MS parameters Internal standard tR 1) FWHM 2) LOD 3) Calibration range r 6) 
        [min] [sec] [nM] 
[pg on 
column] 
LLOQ 4) ULOQ 5)  
 Q1 Q3 DP EP CE CXP      [nM]  
10(S),17(S)-diH n6 DPA 361.2 153.1 -50 -10 -21 -8 2H11-14,15-DiHETrE 15.14 4.5 0.10 0.18 0.25 500 0.9987 
9,10-DiHOME 313.2 201.2 -80 -10 -29 -8 2H4-9,10-DiHOME 15.24 4.7 0.25 0.39 0.50 200 0.9991 
10(S),17(S)-diH AdA 363.4 263.2 -80 -10 -23 -8 2H11-14,15-DiHETrE 15.90 4.6 0.50 0.91 1.0 500 0.9993 
12(S)-HHTrE 279.1 179.0 -50 -10 -17 -8 2H11-14,15-DiHETrE 15.96 4.9 0.25 0.35 0.50 500 0.9977 
14,15-DiHETrE 337.2 207.1 -65 -10 -25 -10 2H11-14,15-DiHETrE 16.00 4.8 0.050 0.085 0.10 200 0.9985 
19,20-DiHDPE 361.2 273.2 -65 -10 -24 -6 2H11-14,15-DiHETrE 16.05 4.8 0.25 0.45 0.50 100 0.9972 
LTB3 337.2 195.2 -65 -10 -22 -8 2H4-LTB4 16.27 5.0 0.25 0.42 0.50 200 0.9995 
9,10-diH-stearic acid 315.0 170.8 -60 -10 -36 -9 2H4-9,10-DiHOME 16.61 5.1 1.0 1.6 2.0 500 0.9994 
16,17-DiHDPE 361.2 233.2 -65 -10 -24 -6 2H11-14,15-DiHETrE 16.69 4.7 0.25 0.45 0.50 100 0.9984 
11,12-DiHETrE 337.2 167.1 -65 -10 -26 -8 2H11-14,15-DiHETrE 16.82 5.0 0.10 0.17 0.25 200 0.9980 
19-HEPE 317.2 229.3 -50 -10 -18 -8 2H8-12-HETE 16.98 - 0.30 0.48 0.71  # 
13,14-DiHDPE 361.2 193.2 -65 -10 -24 -6 2H11-14,15-DiHETrE 16.99 4.8 0.13 0.23 0.25 100 0.9985 
20-HEPE 317.2 287.3 -50 -10 -20 -8 2H8-12-HETE 17.11 5.0 0.50 0.80 1.0 100 0.9985 
9-HOTrE 293.2 171.2 -65 -10 -22 -8 2H4-9-HODE 17.23 5.2 0.25 0.37 0.50 500 0.9994 
10,11-DiHDPE 361.2 153.2 -65 -10 -24 -6 2H11-14,15-DiHETrE 17.37 4.8 0.13 0.23 0.25 100 0.9987 
8,9-DiHETrE 337.2 127.1 -70 -10 -30 -8 2H11-14,15-DiHETrE 17.48 5.1 0.25 0.42 0.50 200 0.9993 
13-HOTrE 293.2 195.1 -70 -10 -24 -8 2H4-9-HODE 17.60 4.6 0.30 0.44 0.60 12 0.9961 
18-HEPE 317.2 259.2 -55 -10 -17 -7 2H8-12-HETE 17.67 4.9 0.50 0.80 1.0 500 0.9972 
15-deoxy-PGJ2 315.2 271.2 -65 -10 -20 -6 2H11-14,15-DiHETrE 18.09 6.1 0.20 0.32 0.50 400 0.9989 































































Analyte Mass transition MS parameters Internal standard tR 1) FWHM 2) LOD 3) Calibration range r 6) 
        [min] [sec] [nM] 
[pg on 
column] 
LLOQ 4) ULOQ 5)  
 Q1 Q3 DP EP CE CXP      [nM]  
7,8-DiHDPE 361.2 113.1 -65 -10 -24 -6 2H11-14,15-DiHETrE 18.22 5.3 0.50 0.91 1.0 100 0.9988 
20-HETE 319.2 289.1 -80 -10 -24 -6 2H6-20-HETE 18.40 5.1 0.50 0.80 1.0 500 0.9983 
15-HEPE 317.2 219.2 -60 -10 -20 -10 2H8-12-HETE 18.43 5.1 0.63 0.99 1.3 500 0.9991 
5,6-DiHETrE 337.2 145.1 -70 -10 -26 -10 2H11-14,15-DiHETrE 18.44 5.4 0.25 0.42 0.50 200 0.9989 
11-HEPE 317.0 167.0 -40 -10 -21 -8 2H8-12-HETE 18.52 4.5 0.25 0.40 0.50 500 0.9962 
8-HEPE 317.2 155.2 -60 -10 -20 -8 2H8-12-HETE 18.77 5.1 0.25 0.40 0.63 500 0.9986 
12-HEPE 317.2 179.2 -65 -10 -20 -8 2H8-12-HETE 18.96 5.0 0.25 0.40 0.63 500 0.9989 
9-HEPE 317.2 166.9 -40 -10 -19 -8 2H8-12-HETE 19.11 4.4 0.25 0.40 0.50 500 0.9970 
21-HDHA 343.0 255.0 -60 -10 -18 -7 2H8-12-HETE 19.38 - 1.3 2.24 1.65  # 
5-HEPE 317.2 115.1 -60 -10 -20 -6 2H8-12-HETE 19.49 5.2 0.20 0.32 0.50 500 0.9988 
22-HDHA 343.2 313.2 -65 -10 -20 -7 2H8-12-HETE 19.49 - 1.40 2.41 2.80  # 
4,5-DiHDPE 361.2 229.3 -65 -10 -24 -6 2H11-14,15-DiHETrE 19.51 4.7 1.0 1.8 2.0 100 0.9940 
13-HODE 295.2 195.2 -80 -10 -26 -9 2H4-9-HODE 19.70 5.3 2.5 3.7 5.0 400 0.9985 
9-HODE 295.2 171.1 -80 -10 -26 -7 2H4-9-HODE 19.81 5.2 2.5 3.7 5.0 400 0.9995 
20-HDHA 343.2 241.2 -55 -10 -19 -7 2H8-12-HETE 20.07 4.9 0.25 0.43 0.50 20 0.9975 
15(16)-EpODE 293.3 235.2 -65 -10 -20 -4 2H4-9(10)-EpOME 20.34 5.5 0.25 0.37 0.50 20 0.9973 
15-HETE 319.2 219.2 -60 -10 -20 -8 2H8-12-HETE 20.45 5.0 0.50 0.80 1.3 500 0.9996 
9(10)-EpODE 293.3 171.2 -65 -10 -20 -8 2H4-9(10)-EpOME 20.51 5.4 0.20 0.29 0.40 16 0.9953 
17(18)-EpETE 317.2 215.2 -65 -10 -20 -6 2H11-14(15)-EpETrE 20.58 5.2 0.50 0.80 1.0 20 0.9994 



































































Analyte Mass transition MS parameters Internal standard tR 1) FWHM 2) LOD 3) Calibration range r 6) 
        [min] [sec] [nM] 
[pg on 
column] 
LLOQ 4) ULOQ 5)  
 Q1 Q3 DP EP CE CXP      [nM]  
17-HDHA 343.2 201.2 -60 -10 -20 -6 2H8-12-HETE 20.73 4.7 1.0 1.7 2.0 500 0.9990 
13-HDHA 343.2 193.1 -55 -10 -19 -7 2H8-12-HETE 20.91 4.5 0.25 0.43 0.50 20 0.9985 
12(13)-EpODE 293.2 183.1 -65 -10 -24 -8 2H4-9(10)-EpOME 20.93 5.1 0.25 0.37 0.50 20 0.9960 
13-oxo-ODE 293.2 195.1 -75 -10 -20 -8 2H4-9-HODE 20.93 4.8 0.50 0.74 1.0 20 0.9966 
11-HETE 319.2 167.2 -60 -10 -23 -7 2H8-12-HETE 20.98 4.7 0.25 0.40 0.50 500 0.9995 
10-HDHA 343.2 153.2 -45 -10 -21 -7 2H8-12-HETE 21.14 4.4 0.25 0.43 0.50 20 0.9994 
14-HDHA 343.2 205.2 -50 -10 -19 -7 2H8-12-HETE 21.14 4.2 0.50 0.86 1.0 500 0.9979 
9-oxo-ODE 293.2 185.1 -90 -10 -28 -8 2H4-9-HODE 21.17 5.0 0.50 0.74 1.0 20 0.9934 
15-oxo-ETE 317.2 113.1 -65 -10 -25 -8 2H8-5-HETE 21.18 4.3 0.25 0.40 0.50 100 0.9981 
14(15)-EpETE 317.2 207.2 -65 -10 -20 -6 2H11-14(15)-EpETrE 21.25 4.8 0.25 0.40 0.50 20 0.9952 
8-HETE 319.2 155.2 -60 -10 -22 -6 2H8-12-HETE 21.33 4.5 0.50 0.80 1.3 500 0.9989 
12-HETE 319.2 179.2 -60 -10 -20 -8 2H8-12-HETE 21.36 4.4 0.25 0.40 0.50 500 0.9970 
11(12)-EpETE 317.2 167.2 -65 -10 -20 -6 2H11-14(15)-EpETrE 21.40 4.3 0.25 0.40 0.50 20 0.9970 
11-HDHA 343.2 121.1 -45 -10 -20 -7 2H8-5-HETE 21.41 4.0 0.10 0.17 0.25 20 0.9992 
7-HDHA 343.2 141.2 -55 -10 -19 -7 2H8-5-HETE 21.54 4.2 0.50 0.86 1.0 500 0.9984 
8(9)-EpETE 317.2 127.2 -65 -10 -20 -6 2H11-14(15)-EpETrE 21.55 4.9 0.50 0.80 1.0 20 0.9969 
9-HETE 319.2 167.2 -60 -10 -23 -7 2H8-5-HETE 21.64 4.2 1.3 2.0 2.5 1000 0.9987 
15(S)-HETrE 321.2 221.2 -70 -10 -23 -10 2H8-5-HETE 21.68 4.3 0.25 0.40 0.50 200 0.9984 
8-HDHA 343.2 189.2 -50 -10 -19 -7 2H8-5-HETE 21.73 3.8 0.50 0.86 0.50 20 0.9976 































































Analyte Mass transition MS parameters Internal standard tR 1) FWHM 2) LOD 3) Calibration range r 6) 
        [min] [sec] [nM] 
[pg on 
column] 
LLOQ 4) ULOQ 5)  
 Q1 Q3 DP EP CE CXP      [nM]  
4-HDHA 343.2 101.1 -55 -10 -19 -7 2H8-5-HETE 22.31 3.7 0.25 0.43 0.25 500 0.9986 
19(20)-EpDPE 343.2 241.2 -65 -10 -20 -7 2H11-14(15)-EpETrE 22.39 3.3 0.25 0.43 0.50 20 0.9994 
12(13)-EpOME 295.3 195.2 -80 -10 -23 -8 2H4-9(10)-EpOME 22.45 3.8 0.10 0.15 0.25 40 0.9980 
14(15)-EpETrE 319.2 219.3 -65 -10 -20 -4 2H11-14(15)-EpETrE 22.60 3.8 0.25 0.40 0.50 20 0.9985 
9(10)-EpOME 295.3 171.1 -80 -10 -23 -8 2H4-9(10)-EpOME 22.64 3.8 0.10 0.15 0.25 40 0.9949 
16(17)-EpDPE 343.2 233.2 -65 -10 -20 -7 2H11-14(15)-EpETrE 22.80 3.5 0.25 0.43 0.50 20 0.9978 
13(14)-EpDPE 343.2 193.2 -65 -10 -20 -7 2H11-14(15)-EpETrE 22.88 3.4 0.25 0.43 0.50 20 0.9961 
5-oxo-ETE 317.2 273.2 -65 -10 -22 -6 2H4-9(10)-EpOME 22.95 3.5 1.0 1.6 2.0 20 0.9998 
10(11)-EpDPE 343.2 153.2 -65 -10 -20 -7 2H11-14(15)-EpETrE 22.98 3.4 0.13 0.22 0.25 20 0.9990 
11(12)-EpETrE 319.3 167.2 -60 -10 -20 -7 2H11-14(15)-EpETrE 23.09 3.3 0.25 0.40 0.50 40 0.9965 
8(9)-EpETrE 319.2 155.2 -65 -10 -20 -6 2H11-14(15)-EpETrE 23.24 3.3 0.50 0.80 1.0 20 0.9993 
5(6)-EpETrE 319.2 191.1 -60 -10 -20 -7 2H11-14(15)-EpETrE 23.41 2.9 1.0 1.6 2.0 20 0.9974 
5(S)-HETrE 321.2 115.1 -70 -10 -19 -9 2H8-5-HETE 23.55 3.0 0.1 0.2 0.2 500 0.9991 
9(10)-ep-stearic acid 297.0 170.8 -100 -10 -28 -11 2H4-9(10)-EpOME 23.97 3.5 1.0 1.5 2.0 500 0.9953 
1) Relative standard deviation for tR within one batch was ≤ 0.18% (< 0.01 min).  
2) Full peak width at half maximum (FWHM) was determined as mean width of standards, concentration 1–200 nM. 
3) LOD was set to the lowest concentration yielding a signal to noise ratio ≥ 3. 
4) LLOQ was set to the lowest calibration standard yielding a signal to noise ratio ≥ 5 and an accuracy within the calibration curve of ± 20%. 
5) ULOQ concentration does not represent the end of the dynamic range, but is the highest calibration standard injected. 
6) Calibration was performed as weighted regression using 1/x2 weighting. 






















































A α-Linolenic acid derived PhytoP and PhytoF 
 
 
Fig. 8.1: Product ion spectra of isoprostanoids and isofurans derived from different PUFA. The 
spectra were aquired via CID of the ESI(-)-generated carboxylate-anion [M-H]- using a collision 
energy ramp from −17 to −30.  
(A) (i)-(v)  α-Linolenic acid derived PhytoP and PhytoF 
(B) (i)-(iii) Arachidonic acid derived F2t-IsoP 
(C) (i)-(ii)  Eicosapentaenoic acid derived F3t-IsoP 
(D) (i)-(iv)  Docosahexaenoic acid derived F4t-NeuroP and NeuroF 
(E) (i)-(iv)  Adrenic acid derived F2t-dihomo-IsoP and dihomo-IsoF 
(F) (i)   Docosapentaenoic acid derived F3t-NeuroPn6  











































































































































































































































































































C Eicosapentaenoic acid derived F3t-IsoP 
 
 
D Docosahexaenoic acid derived F4t-NeuroP and NeuroF 
 
Fig. 8.1: Continued. (C) (i)-(ii) Eicosapentaenoic acid derived F3t-IsoP, (D) (i)-(iv) 



















































































































































































































































































































































F Docosahexaenoic acid derived F3t-NeuroPn6 
 
G Internal Standards 
Fig. 8.1: Continued. (E) (i)-(iv) Adrenic acid derived F2t-dihomo-IsoP and dihomo-IsoF, (F) (i) 













































































































































































































































Fig. 8.2: EPA derived free oxylipins in (A) plasma and (B) serum. Shown are individual concentration 
(n = 6) of selected oxylipins from major formation pathways at t0 (immediate processing) and 
%difference vs t0 after storage for 4 hours and 24 hours at 4 °C or after pneumatic tube transport 
(PTS) before centrifugation to generate plasma or serum. The different symbols represent samples 
from different individual human subjects. The grey lines indicate acceptable change limits calculated 
based on relative standard deviation of quality control plasma (summarized in Tab. 3.1). 























Fig. 8.3: DHA derived free oxylipins in (A) plasma and (B) serum. Shown are individual 
concentration (n = 6) of selected oxylipins from major formation pathways at t0 (immediate 
processing) and %difference vs t0 after storage for 4 hours and 24 hours at 4 °C or after pneumatic 
tube transport before centrifugation to generate plasma or serum. The different symbols represent 
samples from different individual human subjects. The grey lines indicate acceptable change limits 
calculated based on relative standard deviation of quality control plasma (summarized in Tab. 3.1). 























Fig. 8.4: EPA derived total (i.e. sum of free and esterified) oxylipins in (A) plasma and (B) serum. 
Shown are individual concentration (n = 6) of selected oxylipins from major formation pathways at t0 
(immediate processing) and %difference vs t0 after storage for 4 hours and 24 hours at 4 °C or after 
pneumatic tube transport before centrifugation to generate plasma or serum. The different symbols 
represent samples from different individual human subjects. The grey lines indicate acceptable 
change limits calculated based on relative SD of quality control plasma (summarized in Tab. 3.1). 























Fig. 8.5: DHA derived total (i.e. sum of free and esterified) oxylipins in (A) plasma and (B) serum. 
Shown are individual concentration (n = 6) of selected oxylipins from major formation pathways at t0 
(immediate processing) and %difference vs t0 after storage for 4 hours and 24 hours at 4 °C or after 
pneumatic tube transport before centrifugation to generate plasma or serum. The different symbols 
represent samples from different individual human subjects. The grey lines indicate acceptable 
change limits calculated based on relative SD of quality control plasma (summarized in Tab. 3.1). 






























Fig. 8.6: Cell viability of (A) HCT-116, (B) HepG2 and (C) Caki-2 cells following treatment with 
50 µM and 200 µM tert-butyl hydroperoxide (t-BOOH) for 2 h determined by MTS-assay. 
 
Tab. 8.3: Statistical evaluation of the time dependent formation of IsoP and epoxy-PUFA in 
C. elegans following incubation with 6.5 mM tert-butyl hydroperoxide for 15, 30, 45 and 60 min. 
Statistical differences between control (C) and the different treatment time points were 
evaluated by one-way ANOVA followed by Tukey post-test (* p < 0.05, ** p < 0.01, 
*** p < 0.001). a analyte was below LLOQ in the control group. 








- - - - ns * *** ns ** ns 
EpETrE 14(15)- ns * * *** ns ns * ns ns ns 
  11(12)- ns * ** *** ns * *** ns ns ns 








ns ** *** *** ns ** *** ns ** ns 
EpETE 17(18)-  ns ns * ** ns ns * ns ns ns 
  14(15)- ns ns ** *** ns ns * ns ns ns 
  11(12)- ns * ** *** ns ns * ns ns ns 





























































































































































































































































0.20 |0.20 0.20 |0.20 0.12 |0.14 0.44 |0.45 0.45 |0.47 0.21 |0.26 0.51 |0.45 0.56 |0.46 0.30 |0.35 0.95 |0.83 1.03 |0.87 0.58 |0.71





A ARA derived EpETrE




























































































Tab. 8.4: Determined fat content and fatty acid composition of the experimental diets. Diets 
were based on a linoleic acid rich sunflower oil based standard diet from ssniff Spezialdiäten 
GmbH (product number: E15051; with 17.6% crude protein, 5.0% crude fiber, 5.3% crude ash, 
31.4% starch, 11.0% sugar and 10.1% fat as specified by the manufacturer). All results are 
shown as mean ± deviation from the mean (n = 2). 
 STD STD+n3 
Determined fat 
content in the diet 
[g/100 g] 9.7 ± 0.2 9.9 ± 0.2 
[%] Fatty Acid 
in lipid extract   
C14:0 0.15 ± 0.05 0.19 ± 0.04 
C15:0 0.07 ± 0.02 - 
C16:0 7.995 ± 0.008 6.61 ± 0.05 
C16:1n7 0.217 ± 0.008 0.24 ± 0.03 
C17:0 0.071 ± 0.007 0.058 ± 0.007 
C18:0 3.288 ± 0.001 2.64 ± 0.03 
C18:1n9 27.064 ± 0.004 21.65 ± 0.06 
C18:1n7 1.26 ± 0.04 1.047 ± 0.003 
C18:2n6 58.306 ± 0.003 46.5 ± 0.1 
C18:3n3 0.335 ± 0.005 0.287 ± 0.003 
C20:0 0.218 ± 0.003 0.184 ± 0.004 
C20:1n9 0.167 ± 0.002 0.14 ± 0.01 
C20:4n6 - 0.303 ± 0.003 
C20:5n3 - 8.91 ± 0.07 
C22:0 0.653 ± 0.008 0.95 ± 0.03 
C22:5n3 - 1.18 ± 0.05 
C24:0 0.204 ± 0.008 - 
C22:6n3 - 8.91 ± 0.09 
C24:1n9 - 0.17 ± 0.02 
For the determination of the fatty acid composition lipids were first extracted 
from the pellets according to the Weibull-Stoldt method, performed as rapid 
microextraction [1].  
The fatty acid composition was determined after derivatization to fatty acid 
methyl esters by means of gas chromatography with flame ionization detection 
using response factors [2].  
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Tab. 8.5: Lower limit of quantification (LLOQ) and analytical variability of the LC-MS method 
expressed as relative 95% standard deviation (SD). The LLOQ corresponds to the lowest 
calibration standard injected yielding a signal to noise ratio ≥ 5 and an accuracy within ± 20% in 
the calibration curve [1, 2]. The rel. 95% SD was determined for free oxylipins in quality control 
samples (plasma, n = 15) according to [3]. # Analyte was < LLOQ in quality control plasma. 
analyte 
LLOQ [nM] 
rel 95% SD 
(= 1.96 × RSD) 
PGE2 0.25 18 
TxB2 1.3 15 
PGE3 0.3 # 
TxB3 0.25 # 
5(R,S)-5-F2t-IsoP (5-iPF2α-VI) 0.5 22 
5(R,S)-5-F3t-IsoP 2.0 # 
4(R,S)-4-F4t-NeuroP 1.0 # 
5-HETE 0.50 7.7 
5-HEPE 0.50 13 
4-HDHA 0.25 9.2 
7-HDHA 1 # 
12-HETE 0.50 15 
12-HEPE 0.63 17 
14-HDHA 1.0 22 
15-HETE 1.3 10 
15-HEPE 1.3 19 
17-HDHA 2.0 17 
14(15)-EpETrE 0.50 15 
17(18)-EpETE 1.0 # 
19(20)-EpDPE 0.50 12 
20-HETE 1.0 7.7 
20-HEPE 1.0 16 
22-HDHA 2.80 8.2 
18-HEPE 1.0 9.8 
NPD1 (m/z 359 →153) 0.50 # 
NPD1 (m/z 359 → 206 0.38 # 
PDx (m/z 359 →153) 0.25 # 
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Seiwert N., Durand T. and Schebb N. H. (2018) Development of an LC-ESI(-)-MS/MS 
method for the simultaneous quantification of 35 isoprostanes and isofurans derived 
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A1M alpha-1 microglobulin 
ACL acceptable change limit 
ACN  acetonitrile 
AdA adrenic acid (C22:4 n6) 
AKI acute kidney injury 
ALA α-linolenic acid (C18:3 n3) 
ALT alanine transaminase 
ANOVA analysis of variance 
ARA  arachidonic acid (C20:4 n6) 
AST aspartate transaminase 
BHT butylated hydroxytoluene 
BUN blood urea nitrogen 
C. elegans Caenorhabditis elegans 
CE collision energy 
CID collision-induced dissociation 
CKD chronic kidney disease 
COX cyclooxygenase 
CXP collision cell exit potential 
CYP cytochrome P450 monooxygenase 
DHA docosahexaenoic acid (C22:6 n3) 
diH dihydroxy 
DiHDPE dihydroxy docosapentaenoic acid 
DiHETE dihydroxy eicosatetraenoic acid 
DiHETrE dihydroxy eicosatrienoic acid 





DiHOME dihydroxy octadecenoic acid 
dihomo-IsoF dihomo-isofuran 
dihomo-IsoP dihomo-isoprostane 
DP declustering potential 
n6-DPA docosapentaenoic acid (C22:5 n6) 
EDTA ethylenediaminetetraacetic acid 
ELISA enzyme-linked immunosorbent assay 
EP entrance potential 
EPA eicosapentaenoic acid (C20:5 n3) 
EpDPE epoxy docosapentaenoic acid 
EpETE epoxy eicosatetraenoic acid 
EpETrE epoxy eicosatrienoic acid 
EpODE epoxy octadecadienoic acid 
EpOME epoxy octadecenoic acid 
ESI electrospray ionization 
FAME fatty acid methyl ester 
FID flame ionization detector 
FWHM full width at half maximum 
GC gas chromatography 
GFR glomerular filtration rate 
GSH gluathione (reduced form) 
GSSG glutathione disulfide (oxidized form) 
HDHA hydroxy docosahexaenoic acid 
HEPE hydroxy eicosapentaenoic acid 
HETE hydroxy eicosatetraenoic acid 
HETrE hydroxy eicosatrienoic acid 
HHT/ HHTrE hydroxy heptadecatrienoic acid 
HO-1 heme oxygenase-1 
HODE hydroxy octadecadienoic acid 
HOTrE hydroxy octadecatrienoic acid 





HPLC high performance liquid chromatography 
HPRT hypoxanthine-guanine phosphoribosyltransferase 
IL interleukin 
IRI ischemia reperfusion injury 
IS internal standard 
IsoF isofuran 
IsoP isoprostane 
iv  intravenous 
KOH potassium hydroxide 
LC  liquid chromatography 
LD50 lethal dose 50% 
LLOQ lower limit of quantification 




m/z mass to charge ratio 
MACE major adverse cardiac event 
MaR maresin 
MCP monocyte chemoattractant protein 
MDA malondialdehyde 
MeOH methanol 
MRI magnetic resonance imaging 
MRM multiple reaction monitoring 
mRNA messenger ribonucleic acid 
MS  mass spectrometry 




NaClO sodium hypochlorite 







NF-κB nuclear factor κB 
NGM nematode growth medium  
(N)PD1 (neuro)protectin D1 
oxo-ETE oxo eicosatetraenoic acid 
oxo-ODE oxo octadecadienoic acid 
PAS Periodic Acid-Schiff 
PBS phosphate buffered saline 





PLA phospholipase A 
PMSF phenyl methyl sulfonyl fluoride 
PPAR peroxisome proliferator activated receptor 
PTS pneumatic tube system transport 
PUFA polyunsaturated fatty acid 
n3-PUFA omega-3 polyunsaturated fatty acid 
n6-PUFA omega-6 polyunsaturated fatty acid 
QC quality control  
qPCR quantitative polymerase chain reaction  
R resolution 
RBC red blood cells 
RONS reactive oxygen and nitrogen species  
ROS reactive oxygen species 
RP reversed-phase 
rpm rounds per minute 
RSD relative standard deviation 






S/N signal to noise ratio 
SD standard deviation 
sEH soluble epoxide hydrolase 
SEM standard error of the mean 
SIM single ion monitoring 
SPE solid phase extraction 
SPM specialized pro-resolving mediator 
SRM selected reaction monitoring 
STD standard diet (linoleic acid rich, sunflower oil based, 10% fat) 
STD+n3 
n3-PUFA enriched standard diet  
(1% EPA and 1% DHA ethyl ester in the diet) 
t-AUCB trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid 
t-BOOH tert-butyl hydroperoxide 
2-TEDC 2-(1-thienyl)ethyl 3,4-dihydroxybenzylidenecyanoacetate 
TG triglyceride 
tR retention time 
Tx thromboxane 
ULOQ upper limit of quantification 
UUO unilateral ureteral obstraction 
VF view field 
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